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Abstract  
The MACELI (Macro Cost Effectiveness corrected for Lifestyle) project studied the 
cost-effectiveness of European health systems, and the impact of differences in 
lifestyle, specifically smoking, overweight and alcohol consumption.  
Baseline analyses without standardizing for lifestyle showed on average more health 
spending was associated with better health. This effect was clearest for countries 
with lower levels of spending. Standardization towards a better lifestyle meant an 
upward shift of the health production function, but did not much alter the 
comparative efficiency of countries.  
The study covered the EU-28 Member States, Iceland, and Norway. Individual-level 
data were used to describe lifestyle across age and gender and to analyse its impact 
on health outcomes and health care use. Health outcomes and health spending were 
standardized for differences in lifestyle using a lifetable model (reference year 2010).  
Results were put into further perspective by additional qualitative research and 
through several sensitivity analyses, including an indirect disease-based approach. 
Finally, a systematic literature review was performed to investigate potential 
interventions to achieve lifestyle changes. 
Several shortcuts were taken to allow consistent estimates across a large number of 
countries, which imply that the results should be interpreted with care.  
 
Key Terms: Health system efficiency; lifestyle; lifetable modeling 
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Management Summary  
 
Introduction  
Universal access to high quality health care while ensuring fiscal sustainability requires 
efficient health systems. Consequently, European countries measure and monitor the 
performance and cost-effectiveness of their health systems, partly supported by the 
European Commission. As documented in the European Commission’s thematic summary 
report on health and health systems, various studies have suggested that health systems 
should be able to improve their efficiency (European Commission, 2014). In other words, 
better health outcomes may be in reach at current levels of resource use. However, the 
analyses need to be improved, for example by taking into account intrinsic differences in 
population conditions between countries (European Commission, 2014). The latter was the 
goal of the current study, which was conducted under the EU Health Programme. 
As described in the tender call, the main objective was to gain insight into the efficiency of 
the health system in each country ‘with the view to highlight the potential impact of 
changes in lifestyle habits’. In other words, we aimed to compare the cost-effectiveness of 
all European health systems while taking into account the variation in lifestyle behaviour 
between countries. The tender further specified a number of methodological choices. First, 
three lifestyle factors had to be studied: smoking, overweight and alcohol use. Second, a 
life-table approach was required, using public health modelling to correct for the effects of 
lifestyle factors. Third, a list of scenarios were to be included in the analyses. These 
scenarios specified changes in lifestyle prevalence to be applied to all countries for 
standardization purposes. Fourth, a literature review concerning the cost-effectiveness of 
lifestyle interventions was also required. The combining of all these elements would 
provide a better understanding of the impact of lifestyle on health outcomes and health 
spending at country level and how these healthier lifestyles might be achieved. 
 
Methods  
Conditional on data availability, the study was required to cover 31 countries: the EU-28 
Member States and the EEA countries (Iceland, Norway and Liechtenstein). Liechtenstein 
was omitted from the analyses because of its small-scale health system, which also relies 
on a lot of cross boundary use, especially of more advanced care, in combination with a 
lack of data. International data sources were used, including individual-level survey data 
and national statistics obtained from WHO, OECD, Eurohex and Eurostat. 
Previous studies have primarily used country-level summaries of lifestyle behaviour and 
included these as a confounder in their analyses of health system cost-effectiveness. In our 
analysis, we use individual-level data to describe lifestyle across age and gender and to 
analyse its impact on health outcomes and health care use. We standardized health 
outcomes and health spending for differences in lifestyle using scenarios, as specified in 
the tender requirements. In this way, we compared countries while assuming identical 
lifestyle prevalences at a detailed level. These detailed data also generated a more 
comprehensive understanding of the pathways through which lifestyle behaviour affects 
health system efficiency. 
The approach taken was as follows. First, we investigated the relationship between health 
spending and population health at country level, without adjustment for differences in 
lifestyle between countries (baseline analysis). Second, the impact of lifestyle behaviour on 
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health outcomes and health care use was estimated using individual-level survey data. We 
then estimated the impact of hypothetical changes in lifestyle behaviour using a range of 
scenarios, and a life-table approach (DYNAMO-HIA model), including the results from the 
second step. In this way, we were able to produce country-level estimates of health 
spending and population health that were standardized for lifestyle. Finally, the relationship 
between standardized health spending and standardized health outcomes at country level 
was compared with the baseline situation. The results were put into further perspective by 
additional qualitative research and through several sensitivity analyses, including an 
indirect disease-based approach. Finally, a systematic literature review was performed to 
investigate potential interventions to achieve lifestyle changes.  
 
Results of quantitative analyses 
The baseline analyses without standardization showed variation in health spending and 
health outcomes between countries. On average, more health spending was associated 
with better health. This effect was clearest for countries with lower levels of spending. The 
inclusion of confounding factors, especially Gross Domestic Product (GDP) per capita, 
substantially reduced the size of the correlation between health spending and population 
health. However, it was not possible to distinguish the impact of health spending and GDP 
with the data at hand. 
The lifestyle data showed substantial variation in lifestyle habits between countries. In 
addition, the analyses showed a positive relationship between healthy lifestyles and health 
outcomes, in particular for smoking and BMI. With regard to alcohol use, health outcomes 
were best for moderate drinkers. Furthermore, a slightly positive relationship between 
unhealthy lifestyle and health care use was found. This was strongest for BMI, but overall 
less apparent than the relationship between a healthy lifestyle and health outcomes.  
Hypothetical improvements in lifestyle behaviour, as specified in the scenarios, were 
associated with sizeable increases in healthy life expectancy across countries. For example, 
if all countries had the lifestyle prevalence of the countries with the most healthy lifestyles, 
then life expectancy would be higher, with increments varying from 0.4 to 3.1 years. In 
the extreme scenario, where all countries have a population with the most healthy lifestyle 
behaviour for overweight, smoking and alcohol use, the gain in life expectancy would vary 
from 2.5 to 5.7 years across countries. At the same time, the impact of changes in lifestyle 
on per capita health spending was limited when compared to the variation in health 
spending between countries. The strong association between health spending and GDP 
indicates that differences in wealth play an important role and may be more important 
than lifestyle in explaining cross-country health spending variation. Furthermore, cost-
savings due to more favourable lifestyle patterns and the resulting lower disability 
prevalence in the different countries were partly outweighed by the additional health 
spending that results when people live longer (higher life expectancy) as a result of those 
more healthy lifestyles.  
The overall effect of standardization towards a better lifestyle was an upward shift of the 
health production function. In other words, with a healthier lifestyle, higher healthy life 
expectancy could be achieved at country level for the same levels of health spending. A 
better outcome for approximately the same cost suggests an increase in overall efficiency. 
That is, a better lifestyle would result in a more efficient health system. However, this 
overlooks the fact that improvements in lifestyle are themselves reached at a cost and will 
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take time. In practice, better lifestyle behaviour involves costs. However, the review also 
showed that cost-effective interventions to reduce unhealthy lifestyle do exist.  
The results also suggested that the comparative efficiency of countries generally did not 
alter much by adjusting for current lifestyle differences. All countries seemed to move 
more or less in the same direction. 
These main analyses were cross-sectional and thus cannot provide insight into the 
timelines of changes in lifestyle. In additional analyses we used models with explicit 
formalization of the causal chain from a healthier lifestyle through less lifestyle-related 
disease incidence, affecting prevalence, disability and mortality over time. These scenarios 
were performed for a single country (the Netherlands) and showed that the prevalence and 
costs of lifestyle-related diseases decreased first, followed by a decrease in mortality. 
Against a long-term ‘steady-state’ time horizon, this would lead to a population that is 
larger and older on average and to an increase in all diseases related to old age, which 
would then imply an increase in lifetime health care spending. The net effect depends on 
the lifestyles at stake, and on methodological choices such as the discount factor applied 
and the time horizon considered. For smoking, which is the most mortal lifestyle factor, the 
effects of increased longevity are strongest, followed by overweight and alcohol. 
 
Results in perspective: qualitative aspects 
In a qualitative analysis we investigated the role of other health system goals that were 
not included in this study, such as the equity and responsiveness of health systems. 
Countries with a relatively low level of overall population health given their level of health 
spending may have invested more in such non-health outcomes. 
In addition, there are other confounders apart from lifestyle that affect the relationship 
between health spending and health. Income per capita is highly relevant. This implies that 
further research might be warranted, for example using more elaborate models enabling 
inclusion of the time dimension more explicitly. In particular, the recent economic crisis 
may provide new data with more variability in GDP and health spending trends, which may 
support an analysis of the role of these factors. In addition to providing insight into the 
effect of lifestyle on comparative efficiency, such research could support Member States in 
selecting the most efficient lifestyle policy for their specific circumstances.  
 
Results in perspective: findings from comparable studies  
Various previous studies used international aggregated data to analyse the relationship 
between health spending and population health across countries. Most of these studies 
focused on the average relationship between health spending and health outcomes. Some 
studies attributed part or all of the variation in health outcomes that could not be explained 
by health spending to the inefficiency of the health system. Generally, these studies aimed 
to control for confounders such as the socioeconomic characteristics of a country by 
including aggregate measures as explanatory variables in the analysis. Lifestyle 
characteristics at country level, for example the percentage of the population smoking, 
were also included as explanatory variables. Most studies showed a significant impact of 
lifestyle variables (smoking, alcohol and diet) on life expectancy, although the size of the 
impact was small in comparison to health spending, GDP and education. While previous 
studies included lifestyle behaviour as a confounder, they did not demonstrate the extent 
to which it affected the variation in health system efficiency. 
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In this study, socioeconomic characteristics, in particular GDP and education, were 
included in a similar way. The main difference between previous studies and the current 
study is the methodology used to standardize for lifestyle differences. We used a more 
sophisticated approach aiming to gain a clearer understanding of the different mechanisms 
through which lifestyle affects health system efficiency. Such a micro-level approach also 
allows for the measurement of various non-linear and interaction effects that may be at 
play in relation to lifestyle factors, in view of possible further data collection exercises. 
Measuring such effects via a macro-level regression approach would not appear 
straightforward, given unrealistic data requirements. We studied the impact of lifestyle on 
health spending and health outcomes separately, using individual-level data. These models 
included age, gender and country as confounding factors. These findings were 
subsequently included in a life-table model to investigate the impact of lifestyle changes on 
mortality and disability by age and gender. Furthermore, various standardization scenarios 
were tested in order to investigate multiple hypothetical changes in lifestyle behaviour. 
Finally, standardized measures of health spending and health were included in the 
efficiency analysis to determine whether lifestyle differences could explain efficiency 
variation among countries.  
 
Results in perspective: options for a healthy lifestyle  
To further put our results into perspective, it is relevant to compare lifestyle outcomes to 
current and potential policy efforts to achieve a healthy lifestyle across countries. Of 
course, these should be interpreted with due caution and considering the large impact of 
culture and history on each country’s lifestyle. There are policy scores for tobacco control 
and partly for alcohol policy. A similar estimate for overweight is recommended. When 
relating spending to the current prevalence of tobacco, clear differences in smoking 
prevalence can be seen between high spenders. These may reflect cultural differences or 
perhaps differences in policy choices.  
Overall, it appears rather difficult at this stage to analyse the impact of spending on 
lifestyle-related prevention across countries. Comparable spending data by lifestyle factor 
are rare. Moreover, longitudinal data would be needed to analyse the true impact of 
lifestyle-related spending.  
The results of the scenarios included in this study do provide an idea of the changes in 
mortality and disability that could be achieved if certain hypothetical changes in lifestyle 
occurred. Furthermore, the economic evaluations included in the literature review revealed 
that an effective lifestyle policy is, almost by definition, cost-effective due to the large 
potential health gains. However, by the very nature of prevention, the gains peak several 
years after initiation, as shown by the disease-specific scenarios. Policymakers need to 
have long time horizons to realize the gains from a more intensive lifestyle policy. 
Furthermore, they must realize that net health spending over the entire time horizon may 
actually increase as a result of an increased life expectancy in the population. In other 
words, a healthier lifestyle improves health outcomes but does not necessarily reduce 
costs. Most economic evaluations have traditionally been performed on individual-based 
interventions, while a number of evaluations regarding regulation, campaigns and tax 
policy have also been published.  
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Discussion of methods and results 
Several shortcuts have been taken in this project to allow consistent estimates across a 
large number of countries. The additional country-specific analyses show that more in-
depth methods can provide further insight, but also underline the large data requirements 
for such in-depth analyses. Our expert panels discussed drawbacks of our shortcuts and 
the need for further research. The options for more in-depth analyses grow as new and 
more comparable data rapidly become available. Important initiatives in this respect are 
the European Health Interview Survey (EHIS) and the System of Health Accounts (SHA). 
In addition to aggregate statistics, our methods also require individual-level data. These 
provide more in-depth insight and enable the estimation of odds ratios linking lifestyles to 
health outcomes. These results raised most concern among the expert reviewers, 
especially the findings regarding alcohol. As self-report underestimates alcohol use, this 
may have biased our findings. We suggest further epidemiological research into the 
relationship between total exposure and damage for both overweight and alcohol. 
Furthermore, better registries distinguishing lifetime abstainers from former drinkers, and 
former smokers who are long-term quitters from short-term quitters, would also assist. 
However, this is quite a challenge for self-reported questionnaires.  
The current analyses underline the fact that lifestyle is just one of a range of confounding 
factors in the relationship between total spending and health outcomes. Nevertheless, the 
analyses do reveal that lifestyle has a considerable effect on health benefits and will result 
in large gains. Hence, a fruitful direction for further research is to use the current approach 
and combine public health models with detailed information on health care spending to 
support Member States in making choices regarding prevention. The extension of the 
current additional analysis to more countries using disease-specific data would also be 
worthwhile. The methods and model structures are available, and projects such as the 
Australian ACE Prevention study and WHO CHOICE demonstrate the valuable insights that 
can be gained.  
 
Policy implications  
This project was a first attempt to provide broad insights that may assist in correcting 
health system efficiency for differences in lifestyle using individual-level data. The finding 
that a better lifestyle considerably improves health outcomes is not new, but it is 
worthwhile emphasizing once more. Both the main cross-sectional analyses and the 
additional dynamic and disease-specific analysis showed that scenarios with a healthier 
lifestyle lead to sizeable gains in the selected health outcomes; that is, healthy life 
expectancy.  
The results with respect to health care spending show that changes which lead to a 
healthier lifestyle have both downward and upward effects on the demand for health care, 
with uncertain net effects. The results of the review regarding cost-effectiveness underline 
the potential value of investing in primary prevention.  
 
Conclusions  
Compared to previous studies, the current study enabled better insight into the different 
mechanisms through which lifestyle affects health system efficiency. Individual-level data 
analysis showed an effect of self-reported lifestyle behaviour on self-reported health. 
Furthermore, unhealthy lifestyles were associated with greater mortality risk, which was 
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included in the DYNAMO-HIA simulations. Lifestyle directly affected health spending, which 
can be explained by the fact that people with unhealthier lifestyles use more care. There 
was also an indirect effect in the reverse direction: improved lifestyle behaviour generated 
a higher life expectancy, and longer lives implied greater age-related health care use. 
The results showed that factors other than differences in lifestyle explain the majority of 
the variation in health spending between countries. Also, the differences in efficiency 
between countries did not change substantially after adjustment for lifestyle. Since we 
focused on the impact of a single confounder – lifestyle – the resulting differences in 
efficiency between countries should not be taken to constitute a definitive ranking of health 
systems.  
Differences between countries in traditional lifestyle patterns could further complicate the 
picture. While the relationship between smoking history and current risk is well 
established, relatively little is known about the history of exposure and current risks for 
alcohol and BMI. This demands further epidemiological research and more extensive 
simulation modelling. Given the rather small effect of lifestyle standardization on the 
countries’ relative efficiency in the current analysis, it does not seem very likely that an 
extensive analysis including all time lags in the proper way would reach different 
conclusions regarding the countries’ comparative efficiency. 
The scenarios ignored the costs and difficulties of achieving an improved lifestyle and this 
precludes any definitive statement of policy implications. However, our literature review 
underlines the fact that potentially cost-effective policy options are available and there is a 
clear potential for efficient prevention policy to improve health outcomes. 
The study showed that hypothetical lifestyle changes generated higher healthy life 
expectancy at country level. At the same time, these changes had a limited impact on 
differences in health spending between countries. These outcomes were the result of a 
cross-sectional analysis without consideration of time lags, which should be kept in mind 
when interpreting them. Disease-specific scenarios for the Netherlands further clarified the 
mechanisms at stake, demonstrating that prevention does not necessarily result in lower 
acute care spending for all lifestyle factors, as a result of costs in life years gained. A 
healthier lifestyle in all scenarios improves health outcomes.  
To conclude: the current cross-sectional results do not support the notion that the selected 
lifestyle factors of smoking, BMI and alcohol use are important confounders when 
establishing the comparative efficiency of the health systems of countries in Europe. No 
definite conclusions regarding the effects of more prevention on curative care spending can 
be drawn. However, the results support the view that substantial health gains can be 
achieved from a healthier lifestyle. As a result, the ‘health production function’ moves 
upward in hypothetical scenarios when all countries have a healthier lifestyle.  
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Résumé du rapport  
Introduction  
L’accès universel à des soins de grande qualité tout en assurant une viabilité budgétaire 
nécessite des systèmes de santé efficaces. C’est pourquoi les pays européens mesurent et 
surveillent les résultats et l’efficacité des coûts des systèmes de santé européens, soutenus 
en partie dans cette tâche par la Commission européenne. Ainsi qu’il en ressort des 
résumés thématiques de la Commission européenne portant sur la santé et les systèmes 
de santé, diverses études semblent indiquer que les systèmes de santé devraient être en 
mesure d’améliorer leur efficacité (Commission européenne, 2014). Autrement dit, de 
meilleurs résultats en matière de santé sont à portée de main avec les niveaux actuels 
d’utilisation de ressources. Cependant, les analyses doivent être améliorées en tenant par 
exemple compte des différences de conditions démographiques selon les 
pays (Commission européenne, 2014). Ce dernier point constituait l’objectif de la présente 
étude, qui fut menée dans le cadre du programme de santé de l’Union européenne. 
Comme décrit dans l’appel d’offre, l’objectif principal consiste à mieux nous faire 
comprendre l’efficacité des coûts « afin de souligner l’impact potentiel des changements 
dans les mode de vie ». En d’autres mots, nous avions pour but de comparer l’efficacité 
des coûts de tous les systèmes de santé des pays européens en tenant compte des 
différences au niveau des modes de vie des différents pays. L’appel d’offre précisait ensuite 
plusieurs choix de méthodologie. Trois facteurs de risque devaient être étudiés : le 
tabagisme, le surpoids et la consommation d’alcool. Ensuite, il exigeait une analyse des 
tables de survie  à l’aide des modélisations de santé de la population  pour corriger les 
effets des facteurs de mode de vie. Troisièmement, l’appel incluait une liste de scénarios à 
inclure dans les analyses. Ces scénarios précisaient des changements au niveau de la 
prévalence de mode de vie à appliquer à tous les pays dans un souci de standardisation. 
Quatrièmement, il nécessitait une analyse documentaire de l’efficacité des coûts des 
interventions axées sur le mode de vie. Tous ces aspects contribuent conjointement à une 
meilleure compréhension de l’impact du mode de vie sur la santé et les dépenses de santé 
par pays et sur les méthodes à adopter pour parvenir à des modes de vie plus sains. 
 
Méthodes  
Sous réserve de la disponibilité de données, l’étude devait couvrir 31 pays ; les 28 États 
membres ainsi que les pays de l’EEE (Islande, Norvège et Liechtenstein). Le Liechtenstein 
n’a pas été pris en compte dans les analyses parce que son système de santé à petite 
échelle présente de nombreuses utilisations transfrontalières de soins médicaux, 
notamment des soins plus avancés, ainsi qu’en raison d’un manque de données. Des 
sources de données internationales disponibles ont été utilisées, y compris des données 
d’enquête au niveau individuel ainsi que des statistiques nationales provenant de l’OMS, de 
l’OCDE, d’Eurohex et d’Eurostat.  
Les études précédentes utilisaient principalement des résumés à échelon national portant 
sur des modes de vie en les incluant comme facteur de confusion au sein des analyses de 
l’efficacité des coûts du système de santé. Dans notre analyse, nous avons utilisé des 
données au niveau individuel afin de décrire le mode de vie selon l’âge et le sexe et 
analyser son impact sur l’état de santé et l’utilisation de soins de santé. Nous avons 
standardisé les états de santé et les dépenses de santé pour les différents modes de vie à 
l’aide des scénarios spécifiés dans l’appel d’offre. Cela nous a permis de comparer les pays 
tout en assumant des prévalences identiques de modes de vie à un niveau détaillé. Ces 
données détaillées génèrent également une plus grande compréhension des mécanismes 
par lesquels les modes de vie influent sur l’efficacité du système de santé. 
L’approche adoptée est la suivante. Nous avons tout d’abord étudié le lien entre les 
dépenses de santé et la santé de la population au niveau du pays sans procéder à aucun 
ajustement pour des différences de modes de vie entre pays (analyse préliminaire). Nous 
avons ensuite procédé à l’estimation de l’impact du mode de vie sur l’état de santé et 
l’utilisation des soins de santé à l’aide de données d’enquête au niveau individuel. Nous 
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avons ensuite estimé l’impact de variations hypothétiques au niveau des modes de vie à 
l’aide d’une palette de scénarios. Pour cela, nous avons employé une approche par table de 
mortalité (modèle DYNAMO-EIS) en y incluant les résultats de la seconde étape. Cela nous 
a ainsi permis de produire, à l’échelon des pays, des estimations des dépenses de santé et 
de la santé de la population standardisées par mode de vie. Pour finir, nous avons comparé 
le lien entre les dépenses de santé standardisées et les états de santé standardisés à 
l’échelon du pays avec la situation de l’analyse préliminaire. Nous avons approfondi 
l’interprétation des résultats à l’aide d’une recherche qualitative supplémentaire et de 
plusieurs analyses de sensibilité, notamment une approche indirecte, basée sur la maladie. 
Pour finir, nous avons conduit une analyse documentaire systématique pour examiner les 
interventions susceptibles de parvenir à des changements de modes de vie.  
Résultats d’analyses quantitatives 
Les analyses préliminaires sans standardisation ont montré des différences au niveau des 
dépenses de santé et des états de santé selon les pays. En général, plus les dépenses de 
santé sont élevées, plus la santé est bonne. Cet effet est le plus évident dans le cas des 
pays présentant les plus bas niveaux de dépenses. La prise en compte de facteurs de 
confusion, notamment le produit intérieur brut (PIB) par habitant, a permis de réduire de 
manière substantielle l’ampleur de la corrélation entre les dépenses de santé et la santé de 
la population. Il n’a pas été possible de séparer clairement l’impact des dépenses de santé 
et le PIB sur la base des données disponibles. 
  
Les données relatives au mode de vie ont montré d’importantes différences d’habitudes de 
vie entre les pays. Les analyses ont en outre montré l’effet positif d’un mode de vie sain 
sur l’état de santé, notamment pour ce qui est du tabagisme et de l’IMC. Pour ce qui est de 
l’alcool, les consommateurs modérés présentaient de meilleurs états de santé. En outre, un 
lien plutôt positif a été établi entre un mode de vie malsain et l’utilisation des soins de 
santé. Ce lien était le plus fort pour l’IMC mais, en général, moins prononcé que celui entre 
un mode de vie sain et un bon état de santé.  
 
Les améliorations hypothétiques en matière de mode de vie spécifiées dans les scénarios 
étaient associées à une augmentation sensible de l’espérance de vie en bonne santé pour 
l’ensemble des pays. Par exemple, si tous les pays avaient eu la prévalence des modes de 
vie des pays ayant le mode de vie le plus sain, l’espérance de vie aurait été plus élevée 
avec des hausses entre 0,4 et 3,1 années. Dans le scénario extrême où tous les pays 
auraient eu une population présentant le mode de vie le plus sain en matière de surpoids, 
de tabagisme et de consommation d’alcool, l’augmentation de l’espérance de vie aurait pu 
varier de 2,5 à 5,7 ans dans tous les pays. En même temps, l’impact des changements au 
niveau du mode de vie sur les dépenses de santé par habitant était limité par rapport aux 
différences des dépenses de santé selon les pays. La forte corrélation entre les dépenses 
de santé et le PIB indique que les différences de richesse jouent un rôle important, peut-
être même plus important que le mode de vie, pour expliquer les différences de dépenses 
de santé des pays. De plus, les économies générées par des styles de vie plus favorables 
et résultant en une prévalence moindre de l’incapacité dans les différents pays ont en 
partie été contrebalancées par les dépenses de santé supplémentaires liées à la plus 
grande espérance de vie des personne adoptant des modes de vie plus sains.  
 
L’effet général de la standardisation vers un meilleur mode de vie fut synonyme de hausse 
de la valeur du capital-santé. En d’autres mots, avec un mode de vie plus sain et des 
dépenses de santé identiques, il serait possible de parvenir à une espérance de vie (en 
bonne santé) plus élevée. Un meilleur résultat pour un montant de dépenses semblables 
suggère une efficacité générale accrue. Cela signifie qu’un mode de vie meilleur résulterait 
en un système de santé plus efficace. Cependant, une telle conclusion revient à ignorer 
que les améliorations au niveau du mode de vie ont un coût et ne se font pas 
instantanément. Dans la pratique, un mode de vie meilleur implique des coûts. L’analyse a 
montré que des interventions rentables pour réduire les modes de vie malsains sont 
possibles.  
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Les résultats ont également suggéré que l’efficacité comparée de certains pays par rapport 
à d’autres ne variait en général pas beaucoup par l’ajustement des différents de mode de 
vie actuels. Tous les pays semblaient évoluer de manière plus ou moins similaire. 
 
Ces principales analyses étant transversales, elles n’ont pas fourni d’explications quant aux 
délais des changements de modes de vie. Dans les analyses supplémentaires, nous avons 
utilisé des modèles avec modélisation explicite de causalité entre un mode de vie plus sain 
par le biais d’une incidence moindre de maladies liées au style de vie, affectant la 
prévalence, l’incapacité et la mortalité sur les changements dans le temps. Ces scénarios 
ont été appliqués pour un seul pays (les Pays-Bas) et ont illustré que ce sont d’abord la 
prévalence et les coûts de maladies liées au mode de vie qui baissent, suivie de la 
mortalité. En cas de modèle d’état stable, cela engendrerait une population plus 
importante et plus âgée en moyenne, ainsi qu’une hausse de toutes les maladies liées à 
l’âge, ce qui impliquerait par la suite une hausse des dépenses de santé sur une vie 
entière. Le résultat net dépend des modes de vie en jeu et des choix méthodologiques 
comme le facteur d’actualisation appliqué et la période prise en compte. C’est pour le 
tabagisme, facteur de mode de vie le plus mortel, que les effets sur une longévité accrue 
sont les plus tangibles, suivi par le surpoids et la consommation d’alcool. 
Résultats en contexte, aspects qualitatifs 
Dans une analyse qualitative, nous avons examiné le rôle d’autres objectifs de systèmes de 
santé qui ne faisaient pas partie de l’étude, comme l’équité et la réactivité des systèmes de 
santé. Les pays affichant une santé de population relativement faible malgré le niveau de 
leurs dépenses de santé ont peut-être investi davantage dans de tels objectifs non 
médicaux. 
 
En outre, des facteurs de confusion additionnels existent au-delà du mode de vie et jouent 
sur l’efficacité des coûts sur la santé. Les revenus par habitant sont un facteur très 
important. Cela implique que des recherches supplémentaires pourraient s’avérer 
nécessaires, par exemple en utilisant des modèles plus élaborés permettant d’inclure plus 
explicitement la dimension temporelle. En particulier, la récente crise économique peut 
fournir de nouvelles données montrant des PIB plus variables et des tendances en matière 
de dépenses de santé justifiant l’analyse du rôle de ces facteurs. En plus d’améliorer la 
compréhension des effets du mode de vie sur l’efficacité comparée, de telles recherches 
pourraient aider les États membres à sélectionner la politique la plus efficace en matière de 
mode de vie dans leur contexte particulier.  
Résultats en contexte, constatations issues d’études semblables  
Plusieurs études précédentes se sont basées sur des données internationales agrégées afin 
d’analyser le lien entre les dépenses de santé et la santé des populations des différents 
pays. La plupart de ces études se sont intéressées au rapport moyen entre les dépenses de 
santé et les états de santé. Certaines études ont attribué la variation (ou une partie de 
celle-ci) des résultats de santé qui ne pouvant pas s’expliquer par les dépenses de santé à 
l’inefficacité des systèmes de santé. De façon générale, ces études avaient pour objectif de 
contrôler les facteurs de confusion comme les caractéristiques socio-économiques propres 
au pays en incluant dans l’analyse des mesures agrégées comme variable explicative. Les 
caractéristiques de mode de vie à l’échelon du pays, par exemple le taux de fumeur de la 
population, ont également été incluses comme variable explicative. La plupart des études 
ont montré un impact significatif des variables de mode de vie (tabagisme, consommation 
d’alcool et alimentation) sur l’espérance de vie, tout en soulignant que cet impact était 
faible comparé à celui des dépenses de santé, du PIB et du niveau de formation. Alors que 
les études précédentes incluaient les modes  de vie en tant que facteur de confusion, elles 
n’ont pas permis de démontrer à quel degré celles-ci affectaient la variation au niveau de 
l’efficacité du système de santé. 
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Cette étude comprend de manière similaire des caractéristiques socio-économiques, 
notamment le PIB et le niveau de formation. La plus grande différence entre les études 
précédentes et l’étude actuelle est la méthodologie employée, qui consiste à standardiser 
les différences de mode de vie. Nous avons adopté une approche plus sophistiquée avec 
pour objectif une meilleure compréhension des différents mécanismes permettant au mode 
de vie d’influer sur l’efficacité du système de santé. En outre, une telle micro-approche 
permet de mesurer divers effets non linéaires et effets d’interaction entrant en jeu dans les 
facteurs de mode de vie, en prévision de collectes de données à venir. La mesure de tels 
effets par le biais d’une macro-approche de la régression semble compliquée, compte tenu 
d’exigences excessives relatives aux données. Nous avons étudié l’impact du mode de vie 
sur les dépenses de santé et les états de santé séparément à l’aide des données au niveau 
individuel. Ces modèles incluaient l’âge, le sexe et le pays comme facteurs de confusion. 
Ensuite, nous avons inclus ces constatations dans une table de survie pour étudier l’impact 
des changements de mode de vie sur la mortalité et l’incapacité selon l’âge et le sexe. En 
outre, plusieurs scénarios de standardisation ont été testés afin d’étudier des changements 
hypothétiques multiples au niveau des modes de vie. Pour finir, nous avons inclus les 
mesures standardisées des dépenses de santé et des états de santé dans l’analyse 
d’efficacité pour examiner si les différences au niveau des modes de vie pouvaient 
expliquer les variations selon les pays.  
Résultats en contexte, options pour un mode de vie sain  
Pour relativiser les résultats de notre étude, il convient de comparer les résultats de mode 
de vie aux efforts actuels et à venir des différents pays visant un mode de vie sain. Bien 
évidemment, il convient de faire preuve de prudence pour interpréter ces résultats et de 
prendre en compte l’impact important de la culture et de l’histoire sur le mode de vie des 
différents pays. Des chiffres sont disponibles pour les politiques de lutte contre le 
tabagisme et, dans une moindre mesure, pour les politiques de lutte contre l’alcoolisme. Il 
est recommandé de procéder à une estimation semblable pour le surpoids. Si l’on examine 
le lien entre les dépenses et la prévalence actuelle du tabagisme, on observe de nettes 
différences au niveau de la prévalence du tabagisme entre les pays où les dépenses sont 
élevées. Ces différences peuvent être le reflet de différences culturelles ou résultent 
probablement de différences de choix stratégiques. 
  
Globalement, il s’avère difficile à ce stade d’analyser l’impact des dépenses en matière de 
prévention au niveau du mode de vie pour les différents pays. Il y a peu de données de 
dépenses comparables par facteur de mode de vie. En outre, il faudrait des données 
longitudinales pour analyser l’impact réel des dépenses liées au mode de vie.  
 
Les résultats des scénarios inclus dans cette étude nous dévoilent les changements au 
niveau de la mortalité et de l’incapacité qui pourraient être réalisés si certains 
changements (hypothétiques) intervenaient au niveau du mode de vie. En outre, les 
évaluations économiques incluses dans la documentation montrent qu’une politique 
efficace en matière de mode de vie est presque par définition rentable en raison des 
importants gains sanitaires potentiels. Cependant, par la nature même de la prévention, 
les gains atteignent leur sommet au bout de quelques années, comme le montrent les 
scénarios spécifiques par maladie. Les décideurs politiques en la matière doivent penser 
sur le long terme pour réaliser des gains en adoptant une politique plus intensive en 
matière de mode de vie. En outre, ils doivent se rendre compte que les dépenses nettes de 
santé sur toute la période risquent d’augmenter en raison de la hausse de l’espérance de 
vie de la population. En effet, un mode de vie plus sain permet une amélioration des états 
de santé, mais ne signifie pas forcément des économies d’argent. La plupart des 
évaluations économiques ont généralement été effectuées sur des interventions 
individuelles ; plusieurs évaluations des politiques en matière de régulation, de campagnes 
et de taxation ont été publiées.  
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Discussion sur les méthodes et les résultats 
Plusieurs raccourcis ont été pris au sein de ce projet pour nous permettre d’obtenir des 
estimations cohérentes pour un grand nombre de pays. Les analyses supplémentaires par 
pays montrent que des méthodes plus approfondies permettent une compréhension plus 
poussée, mais soulignent également la nécessité de données importantes pour mener à 
bien de telles analyses approfondies. Nos comités d’experts ont souligné ces raccourcis et 
formulé la nécessité de poursuivre les recherches. Les options possibles pour des analyses 
plus approfondies se multiplient au fur et à mesure que des données comparables plus 
nombreuses deviennent rapidement disponibles. Dans ce cadre, il convient de signaler des 
initiatives importantes, comme l’Enquête européenne de santé (European Health Interview 
Survey, EHIS) et le Système de comptes sur la santé (System of Health Accounts, SHA).  
 
Nos méthodes nécessitent, en plus des statistiques agrégées, des données à un niveau 
individuel. Celles-ci nous fournissent une compréhension plus approfondie et permettent 
une estimation des odds ratios reliant modes de vie et états de santé. Cette partie de nos 
résultats, en particulier les constatations concernant l’alcool, a suscité des interrogations 
parmi les experts. Les déclarations volontaires entraînent une sous-estimation de la 
consommation d’alcool, ce qui a peut-être faussé nos constatations. Nous suggérons de 
poursuivre les recherches épidémiologiques pour ce qui est du surpoids et de la 
consommation d’alcool en examinant le lien entre exposition totale et dommages sur la 
santé. En outre, il convient de mieux distinguer les personnes n’ayant jamais bu d’alcool et 
les personnes ayant arrêté ainsi que les anciens fumeurs ayant arrêté de longue date et 
ceux ayant récemment arrêté. Sur la base de déclarations volontaires, cela constitue un 
défi certain !  
 
Les analyses actuelles soulignent que le mode de vie est simplement un type 
de facteurs de confusion sur le lien  entre les dépenses totales et les états de santé. Les 
analyses précisent que le mode de vie joue un rôle crucial sur les bienfaits sur la santé et 
entraînera des améliorations notables. Pour des recherches fructueuses à venir, il est donc 
conseillé d’adopter l’approche actuelle en l’associant à des modèles de santé des 
populations comprenant des informations détaillées sur les dépenses de santé afin d’aider 
les États membres à faire des choix en matière de prévention. Il serait très pertinent 
d’étendre l’analyse supplémentaire actuelle à plus de pays en utilisant des données 
relatives aux maladies. Les méthodes et les structures de modèles sont disponibles et les 
projets tels que « Australian ACE » et le projet OMS CHOICE nous offrent des perspectives 
précieuses.  
Conséquences au niveau politique  
Il s’agissait d’une première tentative visant à fournir des connaissances larges sur le lien 
entre l’efficacité du système de santé et les différences de mode de vie sur la base de 
données au niveau individuel. Constater qu’un meilleur mode de vie contribue à améliorer 
les états de santé n’a rien de nouveau. Il convient cependant de souligner une nouvelle fois 
cette constatation. Les deux types d’analyses, transversales d’une part et dynamiques et 
spécifiques à la maladie d’autre part, montrent qu’un mode de vie plus sain contribue à des 
améliorations considérables dans les états de santé sélectionnés : espérance de vie (en 
bonne santé).  
Les résultats concernant les dépenses de santé montrent que les changements visant un 
mode de vie plus sain ont des effets positifs et négatifs sur la demande de soins de santé, 
engendrant des effets nets incertains. Les résultats de l’analyse de la rentabilité des 
coûts soulignent la valeur potentielle de l’investissement dans la prévention primaire.  
Conclusions  
Par rapport aux études précédentes, la présente étude nous a permis de mieux 
comprendre les différents mécanismes par lesquels le mode de vie influe sur l’efficacité du 
système de santé. L’analyse des données au niveau individuel a montré l’effet du mode de 
vie sur la santé, le tout basé sur des données de mode de vie et de santé autodéclararées. 
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En outre, les modes de vie malsains étaient associés à un risque de mortalité plus élevé 
qui a été inclus dans les simulations DYNAMO-EIS. Le mode de vie influait directement sur 
les dépenses de santé parce les gens ayant un mode de vie malsain utilisent plus de soins. 
Nous avons également noté un effet indirect allant dans la direction opposée. Un meilleur 
mode de vie engendre une espérance de vie plus longue, ce qui implique une 
augmentation de l’utilisation de soins de santé liés à l’âge. 
 
Les résultats ont montré que des facteurs autres que les différences de mode de vie 
expliquaient la plupart des différences de dépenses de santé entre les pays. En outre, les 
différences d’efficacité entre les pays ne changeaient pas de manière significative après 
avoir modifié le mode de vie. Puisque nous nous sommes concentrés sur l’impact d’un seul 
facteur de confusion, le mode de vie, les différences d’efficacité entre les pays ne 
doivent pas être utilisées pour établir un classement définitif des différents systèmes de 
santé.  
 
Les différences historiques entre pays au niveau des modes de vie risqueraient 
de compliquer encore plus le tableau. Alors que le lien entre les antécédents de 
tabagisme et le risque actuel est bien défini, on sait peu de chose sur les antécédents et le 
risque actuel en ce qui concerne l’alcool et le surpoids. Cela nécessiterait des recherches 
supplémentaires au niveau de l’épidémiologie ainsi qu’un modèle de simulation plus 
approfondi. Compte tenu de l’effet plutôt limité de la standardisation du mode de vie sur 
l’efficacité relative des pays dans la présente analyse, il semble cependant très peu 
probable qu’une analyse plus poussée, avec les périodes et délais voulus, pourrait mener à 
des conclusions différentes sur l’efficacité relative des pays. 
 
Les scénarios ne tenaient pas compte des frais engagés et des difficultés rencontrées pour 
parvenir à un mode de vie amélioré. Cela empêche actuellement toute implication politique 
ferme. Notre analyse documentaire souligne que des options stratégiques rentables 
existent et souligne également le potentiel évident d’une politique efficace en matière de 
prévention pour améliorer la santé.  
 
L’étude a montré que les changements hypothétiques en matière de mode de vie 
pouvaient générer une espérance de vie en bonne santé plus élevée à l’échelon du pays. 
En même temps, ces changements avaient un impact limité sur les différences en matière 
de dépenses de santé selon les pays. Ce sont des résultats découlant d’une analyse 
transversale qui ne tient pas compte de délais, ce qui convient de garder à l’esprit dans 
l’interprétation des résultats. Les scénarios de maladie pour les Pays-Bas ont permis de 
mieux expliquer les mécanismes en jeu en soulignant que la prévention n’implique pas 
forcément des dépenses de soins aigus plus faibles pour tous les facteurs de mode de vie ; 
en effet les frais peuvent augmenter en raison d’une augmentation des années vécues  
Dans tous les scénarios, un mode de vie plus sain améliorait les états de santé.  
 
En conclusion : les résultats actuels (transversaux) ne corroborent pas l’idée selon laquelle 
les facteurs de mode de vie que sont le tabagisme, l’IMC et la consommation d’alcool sont 
un facteur de confusion  important lorsqu’il s’agit de comparer l’efficacité des systèmes de 
santé en Europe. Aucune conclusion définitive ne saurait être tirée quant aux effets de 
dépenses accrues en matière de soins curatifs. Les résultats soulignent par contre que des 
améliorations sensibles de la santé peuvent être obtenues grâce à un mode de vie plus 
sain. Par conséquent, le « capital santé » augmente dans les scénarios hypothétiques selon 
lesquels tous les pays présenteraient un mode de vie plus sain. 
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1. Introduction  
 
Health expenditures have risen continuously in the past decades across all European 
countries. Health spending growth rates even outpaced national income growth and, 
consequently, comprise an increasing part of government and household budgets. On 
a European level, healthcare systems account for 8% of the workforce and 10% of 
GDP. Since a large part of its funding is from either general taxation or mandatory 
contributions to public insurance, the efficiency of the sector and its financial 
sustainability are relevant issues. Moreover, it has become increasingly important to 
improve the efficiency of European health systems in order to be able to ensure 
universal access to high quality care. 
 
Against this backdrop, there is a need to improve the understanding of the efficiency 
of national health systems for European Union Member states and the European 
Commission, in cooperation with the Directorate-General for Health and Consumers 
(DG SANCO) (Council of the European Union, 2011; European Commission, 2014). 
Besides, DG Sanco aims to inform and support policy makers, stakeholders and 
citizens of European countries through information and knowledge about health 
system performance. Such empirical evidence should assist policy makers in 
analyzing, benchmarking and learning from best-practices in order to improve the 
cost-effectiveness of national health systems.  
 
Measuring the efficiency of health systems is not easy for several reasons. Its output 
(health) is both multifactorial and hard to value in monetary terms. The inputs (health 
care spending) are but one factor that affects the output, next to a range of 
confounding factors, of which the most important are the general wealth of the 
population, environmental factors, lifestyle, and demographics. Additionally, the 
definitions and boundaries of health care systems may vary between countries (Arah 
et al., 2006). Finally, time plays an important role. Health outcomes may be affected 
both by current health care, but also by care in the past. Current spending will affect 
future health as well as current health. Similarly, past lifestyle behaviour may affect 
current levels of health and health spending. Hence, analyzing cross-country variation 
in health spending and the relationship between health spending and health outcomes 
(efficiency) is a complex undertaking. 
 
Previous studies mostly used so-called health production functions representing the 
relationship between health outcomes and several input variables (determinants of 
health). These input variables included health spending, but also socioeconomic 
characteristics or lifestyle variables (see e.g. Nixon and Ulmann, 2006; Joumard et al., 
2008 and Van Baal et al., 2013). Commonly, aggregate input measures and health 
outcome measures at country level were used. First, the production function 
determines the average relation between health spending and health while controlling 
for potential confounders. Second, it can be used to estimate the efficiency of 
individual countries. To that purpose, (part of) the variation in health outcomes that 
cannot be explained by input variables, is attributed to inefficiency. Though authors 
have aimed to tackle the issues mentioned in the previous paragraph, no study using 
country level data was able to address all methodological issues (Van Baal et al., 
2013). 
 
In this research project, the aim was to elaborate upon the impact of one particular 
input variable on health system efficiency, i.e. lifestyle behaviour. As stated in the Call 
for tender EAHC/2013/Health/05, ‘Life Table Analysis: health system cost-
effectiveness assessments across Europe’, the main aim of this study is “… to provide 
a more complex analysis of cost-effectiveness of health systems that can allow the 
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European decision-makers to choose the correct strategic alternatives for the future of 
its health care systems, particularly regarding risks associated to lifestyle”. More 
specifically the objective was to “carry out a health-system cost-effectiveness 
assessment in the EU-27 Member States, Croatia and the EEA countries (Iceland, 
Norway and Liechtenstein) with the view to highlight the potential impact of changes 
in lifestyle habits”. 
 
In particular, it focused on the impact of smoking, alcohol and overweight/obesity, 
which account for almost 15% of the burden of disease worldwide, 23% for the 
Western European region, or 29% for the Central European region (Lim et al., 2012, 
IHME 2014). The main objective was to compare the cost-effectiveness of European 
health systems while taking into account the variation in lifestyle conditions between 
countries. We used a more elaborate approach compared to previous studies, using 
individual level data to create better insight into the different mechanisms through 
which lifestyle affects health system efficiency. We studied the impact of lifestyle on 
health spending and health outcomes separately. Next, these findings were included in 
a life table model to investigate the impact of lifestyle changes by age and gender. 
Furthermore, various standardization scenarios were tested in order to investigate 
multiple hypothetical changes in lifestyle behaviour. In additional analyses, the effects 
of time lags were studied in more detail.  
 
The report is structured as follows. Chapter 2 presents the study design and the main 
analytical steps that were taken. Chapter 3 presents intermediate results concerning 
the link between risk factors and health outcomes as well as health spending. 
Following, we present the main results in chapter 4. Chapters 5 and 6 provide 
additional results from a qualitative and lifestyle policy perspective. Chapter 7 contains 
discussion and conclusions.   
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2. Methods  
 
The main objective of the study was to assess the average cost-effectiveness of 31 
European health systems, while correcting for the impact of three lifestyle factors 
(tobacco, alcohol, and overweight) on both health spending and population health. 
This chapter gives a detailed overview of the methods used to reach this objective. 
Readers interested in the results could proceed directly to chapters 4 and further after 
having read the outline below describing the nine main steps of the study: 
 
Step 1: Draft study design and review by experts.  
A panel of experts received a detailed study design and a questionnaire asking for 
structured feedback. Their feedback was used in finalizing the study design. 
 
Step 2: Health care efficiency without correction. 
In the first part of the analysis, we analysed the relationship between health spending 
and population health at country level using scatter plots and regression analysis. We 
assessed countries’ efficiency both parametrically by considering their distance from 
the regression line and non-parametrically by use of data envelopment analysis (DEA). 
In this step, we did not take into account differences in lifestyle behaviour between 
countries. Both cross-sectional and panel-data models were estimated. 
 
Step 3: Information on lifestyle prevalence.  
In the third step, we analysed the variation in lifestyle behaviour across the 31 
countries, by age and sex, using individual level survey data. We focused on smoking, 
BMI and alcohol consumption. We collected cross-sectional lifestyle data for the most 
recent year available. 
 
Step 4: impact of lifestyle on health and health spending. 
We estimated the impact of each lifestyle variable on health outcomes and health 
spending. International individual-level survey data were used containing information 
on lifestyle, health outcomes and health care use. Odds ratios were estimated, 
representing the probability of higher/lower health spending or better/worse health 
outcomes for different categories of each lifestyle variable.  
 
Step 5: standardizing health and health spending for lifestyle using scenarios. 
In step 5, we analysed several scenarios representing hypothetical changes in the 
prevalence of lifestyle factors across countries. These lifestyle changes cause changes 
in health outcomes at country level and in health spending (defined as either total 
spending, or spending on curative care only). The DYNAMO-HIA (DYNamic MOdeling 
for Health Impact Assessment) lifetable model was used to estimate the impact of 
these hypothetical scenarios, in terms of the three measures of population health and 
the two health spending measures. The outcomes of step 3 and step 4 are used as 
input into the DYNAMO model, together with the observed mortality and health 
outcomes by country, age and sex. 
 
Step 6: health care efficiency with correction. 
Next, we used the results from step 5, i.e. the adjusted levels of health spending and 
population health at country level, to re-analyse the relationship between health 
spending and population health. Again, scatter plots and regression models were used 
to investigate the relationship between these two (adjusted) variables. 
 
Step 7: inventory of policy options. 
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Additionally, we performed a literature review to gain insight into the (cost)-
effectiveness of interventions aimed at lifestyle improvement. This review can provide 
lessons how to achieve lifestyle changes as hypothesized in the scenario analyses.  
 
Step 8: Qualitative analyses and expert workshop.  
To put our results into perspective we organised an expert workshop and consulted 
literature on definitions of health and health care systems. The results of this are 
described in the discussion sections 
 
Step 9: Additional quantitative analyses. 
For sensitivity analyses and to further understand the timing of the effects of lifestyle 
on health care spending and health outcomes, a full disease model was applied for the 
Netherlands.  
 
Variables and countries 
Health spending was defined in two ways: 1) including all health care and 2) including 
curative (health) care only. For the main results, the latter restricted definition was 
used, for three reasons. First, the objective of certain health services such as long-
term care may not be to improve length of life. In that case, they will have a weaker 
relation to the summary measures of population health used. Second, definitions of 
long-term care show high variability across countries and their inclusion could result in 
less consistent estimates. Third, by restricting ourselves to curative care we ensure 
that costs of preventive care are excluded which makes it easier to interpret the 
results in the lifestyle scenarios. Throughout the study, 2010 was the main reference 
year. If necessary, costs were adjusted to the 2010 level using price indices. Three 
population health measures were used: life expectancy (LE), healthy life years (HLY, 
which refers to life expectancy without activity limitations) and life expectancy in good 
perceived health (LEGPH, which refers to life expectancy in at least good self-
perceived health). 
The study includes the EU-28 Member States and the EEA countries (Iceland, Norway 
and Liechtenstein). Table 2.1 shows the countries and their corresponding 
abbreviations. For most analyses, Liechtenstein and Luxembourg have been excluded, 
due to their small-scale health care systems, which include a limited set of health 
services only. Appendix 29.5 contains selected results for the EU-28 Member States.   
2.1 Study design and expert consultation 
A study design was drafted and summarized in a 10 pages document. This was sent to 
10 experts, selected from a wide variety of expertise along with a structured comment 
sheet. The results were combined in an overview table, and used to summarize the 
main comments to SG Sanco. In consultation with DG Sanco, the design was finalized. 
The Appendix (Chapter 9.6, page 113 onwards) contains the design as provided to the 
reviewers, the questionnaire and a summary of their comments, as well as the list of 
experts consulted and their responses. 
2.2 Health care efficiency without correction 
Data and variables 
 
Health spending 
Data on health spending at macro-level were obtained from Eurostat, OECD and WHO, 
for the years 2004-2011. All three sources use the System of Health Accounts (SHA) 
definition of health expenditures (OECD, Eurostat, WHO, 2011). The SHA has been 
created to enhance the comparability of health spending data over time and across 
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countries. In case these sources reported different health expenditures for a specific 
country and year, we used the identical value reported by two of these sources. 
We computed per capita health expenditures in Euros. The harmonized index of 
consumer prices (2005=100; Eurostat) was used to correct for inflation and calculate 
spending expressed at price level 2005 for all countries. Purchasing Power Parities for 
2005 (EU28=1; Eurostat) were then used to correct for differences in price levels 
across countries.  
 
Table 2.1: List of countries and abbreviations 
Country Eurostat abbreviation 
Austria AT 
Belgium BE 
Bulgaria BG 
Croatia HR 
Cyprus CY 
Czech Republic CZ 
Denmark DK 
Estonia EE 
Finland FI 
France FR 
Germany DE 
Greece EL 
Hungary HU 
Iceland IS 
Ireland IE 
Italy IT 
Latvia LV 
Liechtenstein LI 
Lithuania LT 
Luxembourg LU 
Malta MT 
Netherlands NL 
Norway NO 
Poland PL 
Portugal PT 
Romania RO 
Slovakia SK 
Slovenia SI 
Spain ES 
Sweden SE 
United Kingdom UK 
 
Two different health spending measures were used: (1) total health expenditures and 
(2) expenditures on curative care. According to the SHA, total health expenditure is 
equal to “the sum of expenditure on activities that - through application of medical, 
paramedical, and nursing knowledge and technology – has the goals of:  
- promoting health and preventing disease;  
- curing illness and reducing premature mortality;  
- caring for persons affected by chronic illness who require nursing care;  
- caring for persons with health-related impairments, disability, and handicaps who 
require nursing care;  
- assisting patients to die with dignity;  
- providing and administering public health; 
- providing and administering health programmes, health insurance and other funding 
arrangements” (OECD, Eurostat, WHO, 2011).  
Curative care is defined as the sum of the SHA categories hospital care (HP.1), 
ambulatory care (HP.3) and outpatient medication (HP.4). These provider groups 
constitute around 80% of total health spending (on average across countries). Only 
the OECD and Eurostat provide detailed information on health spending by type of 
provider. 
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Table 2.2 presents the availability of data by country for both health expenditures 
measures between 2004 and 2011. For our base year (2010), data on total health 
spending were unavailable for Cyprus and Liechtenstein. In addition, information on 
curative care spending was also unavailable for Bulgaria, Croatia, Greece, Ireland, 
Italy, Latvia, Malta, and the UK. Proxy-values were estimated for these countries. 
Liechtenstein and Luxembourg have quite open health care systems, with a lot of 
cross boundary use of especially more advanced care. Furthermore, these two 
countries are quite small. For these reasons, they were excluded from the main 
analyses. Such exclusion criteria are necessarily arbitrary. One might e.g. argue that 
Malta and Cyprus would also qualify for exclusion. However, their isolated geography 
will reduce the amount of cross border care and hence we decided to keep them in.   
 
Table 2.2: Data availability health spending per country over the period 2004-2011 (shaded 
cells indicate availability of data for entire period) 
 
Total health spending  Curative care spending  Source useda 
Austria 2004-2011 2004-2011 Eurostat, OECD 
Belgium 2004-2011 2004-2011 Eurostat, OECD 
Bulgaria 2004-2011 2004-2008 Eurostat, WHO 
Croatia 2004-2011  N.A. WHO 
Cyprus 2004-2010 2004-2008 Eurostat, WHO 
Czech Republic 2004-2011 2004-2010  Eurostat, OECD, WHO 
Denmark 2004-2011 2004-2010  Eurostat, OECD, WHO 
Estonia 2004-2011 2004-2011 Eurostat, OECD, WHO 
Finland 2004-2011 2004-2011 Eurostat,OECD 
France 2004-2011 2004-2011 Eurostat,OECD 
Germany 2004-2011 2004-2011 Eurostat, OECD, WHO 
Greece 2004, 2009-2011  N.A. OECD 
Hungary 2004-2011 2004-2011  Eurostat,OECD 
Iceland 2004-2011 2004-2010  Eurostat,OECD 
Ireland 2004-2011  N.A. OECD 
Italy 2004-2011  N.A. OECD 
Lithuania 2004-2011 2004-2011 Eurostat, WHO 
Latvia 2004-2011 2004-2009 Eurostat, WHO 
Luxembourg 2004-2011 2004-2011 Eurostat, OECD, WHO 
Malta 2004-2011  N.A. WHO 
Netherlands 2004-2011 2004-2011  Eurostat, OECD 
Norway 2004-2011 2004-2010 Eurostat, OECD 
Poland 2004-2011 2004-2011 Eurostat, OECD 
Portugal 2004-2011 2004-2011 Eurostat, OECD 
Romania 2004-2011 2004-2011 Eurostat, WHO 
Slovenia 2004-2011 2004-2011 Eurostat, OECD 
Slovakia 2004-2011 2005-2011  OECD, WHO 
Spain 2004-2011 2004-2011 Eurostat,OECD 
Sweden 2004-2011 2004-2011 Eurostat, OECD 
United Kingdom 2004-2011  N.A. OECD 
a In case more than one source is reported, sources reported similar amounts of health spending (millions of 
National Currency Units). 
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Health outcome measures 
In the macro-analysis without correction for lifestyle, we used three health outcome 
measures from the Eurostat databases: life expectancy at birth (LE), healthy life years 
at birth (HLY) and life expectancy in good perceived health at birth (LEGPH). We chose 
these outcomes since they are well defined and available in a consistent way in 
several questionnaires. The two quality of life outcomes rely on self-report and direct 
valuations of quality of life. QALYs and DALYs, two other well-known measures to 
include morbidity next to mortality in health outcomes do this slightly different. They 
value morbidity in terms of a 5 item questionnaire on daily activities or prevalent 
conditions respectively which are weighted using tariffs. The latter are based on 
population surveys and expert opinion. Since we knew that consistent information on 
disease prevalence or a dataset with both QALY values and lifestyle information would 
not be available, we preferred the self-reported outcomes. HLY is based on the GALI 
(General Activity Limitation Indicator) included in the EU-SILC survey (Statistics on 
Income and Living Conditions) and LEGPH is based on the variable good perceived 
health from the EU-SILC survey). The SILC data are published on the Eurohex 
website. Both health measures were available in the SHARE dataset, a large European 
dataset with lifestyle information.  
 
Other variables used in the country-level regression models  
While a whole range of potential confounders have been investigated, we decided to 
focus on a few important ones, for reasons of availability of consistent estimates for all 
countries and to keep the models as parsimonious as possible.  
Thus, health outcomes were modelled as a function of health spending, adding 
national income and education to account for confounding. National income is 
measured by gross domestic product per capita (in 2005 international Euro’s corrected 
using PPPs). Education is defined as the percentage of the population aged 25 years or 
older that has attained at least a higher secondary education degree. Information on 
both GDP per capita and education was obtained from the Eurostat website. 
 
Analysis: health spending – health relationship 
 
All analyses in this section were performed using Stata 13.  
 
Cross-sectional models  
First, we estimated the cross-sectional relationship between health spending and 
health for the reference year 2010, using the following ordinary least squares (OLS) 
model: 
 
𝑌𝑖 = 𝛼 + 𝑋𝑖𝛽 + 𝜀𝑖     (1) 
 
with Yi and Xi being a measure of population health and  a matrix of explanatory 
variables in country i, respectively. Three measures of population health were 
distinguished: life expectancy at birth, healthy life expectancy at birth and life 
expectancy in good perceived health at birth. Xi consists of a measure of health 
spending (either total health spending or curative care spending), income and 
education. Using all combinations of the three population health measures and the two 
health spending measures resulted in six regression models.  
All variables are logarithmically transformed to capture the diminishing marginal 
returns of health expenditures. As a result, the coefficients can be interpreted as 
elasticities. 
 
Panel data models 
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Second, in line with the literature, we also estimated a panel model. Since data on 
health outcomes information in its current form (i.e. as estimated by the EU-SILC 
surveys) is only collected from 2004, regressions on a panel of countries over the 
period 2004-2011 have been used to measure the effect of health spending on health 
outcomes. Unlike the cross-sectional regression, the panel data regression can exploit 
variation over time t and between countries i:  
 
𝑌𝑖,𝑡 = 𝛼𝑡 + 𝑋𝑖,𝑡𝛽 + 𝜀𝑖,𝑡 
    
Xi,t includes a measure for health spending, GDP per capita and education. Country 
dummies (αi) have been included representing time-invariant factors (e.g. institutional 
factors) that may influence the performance of health systems. At the same time, 
these fixed effects comprise all time-invariant or structural efficiency of health 
systems. As OLS residuals of the above equation were both heteroskedastic and 
serially correlated, the equation has instead been estimated by generalized least 
squares (GLS) with first order autoregressive and heteroskedastic error structure.   
Note that this model cannot serve to compare health system cost-effectiveness before 
and after standardizing for lifestyle, because the standardization could be performed 
for one year of data only. Therefore, it was used as a robustness check to explore the   
extent to which the elasticity of health spending in the unadjusted model is sensitive 
to cross-sectional or panel data modelling. 
 
Analysis: health system efficiency 
 
To compare health system cost-effectiveness between countries, output-oriented 
technical efficiency scores were calculated. Output-oriented measures assess the 
possible improvement in population health that could be achieved by a country using 
the same amount of health spending with a similar socio-economic environment (the 
efficiency analyses also control for GDP per capita and education). Parametric and 
non-parametric approaches have been selected to assess relative efficiency of health 
systems in reaching the level of highest population health. As mentioned before, 
relative efficiency was analysed using cross-sectional data only. 
 
Parametric method 
Regression analyses can be used to assess relative performance by assuming that 
unexplained cross-country variation in population health reflects efficiency differences 
in the use of existing inputs.  
First, A GLM regression with log link and gamma family has been used to assess the 
health production function. Population health is modelled as a function of health 
spending, GDP per capita and education (as in equation (1) above). A GLM regression 
has been selected to avoid the retransformation problem (see e.g. Manning and 
Mullahy, 2001). Second, efficiency (TEi) is computed by 
 
𝑇𝐸𝑖 = 𝑌𝑖 − ?̂?𝑖  
 
where Yi is actual population health and ?̂?𝑖  is predicted population health using the GLM 
estimates. Hence, countries with a positive score perform on average better. 
 
Non-Parametric method 
The shape of the efficiency frontier constructed in the data envelopment analysis 
(DEA) depends on the choice regarding returns to scale. A variable returns to scale 
has been selected, allowing both increasing and decreasing returns to scale. Health 
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spending, GDP per capita and education were included as inputs. Separate DEA were 
performed to assess efficiency in achieving each of the three health outcomes. 
  
2.3 Information on lifestyle prevalence 
Lifestyle 
Our main data source was the Eurobarometer survey containing consistent questions 
on lifestyles across EU countries. The Eurobarometer data were available at the 
individual level. The lifestyle questions were not systematically included in all waves of 
the Eurobarometer survey. Therefore, reference years differed. For each of the 
lifestyle variables we used the most recent Eurobarometer data available: 2005 for 
BMI, 2009 for alcohol consumption and 2012 for smoking. For countries outside the 
EU before 2012, we had to rely on data from alternative (inter)national sources. Table 
2.3 shows data availability for each of the three lifestyle variables used in this study, 
EB indicating available data from the Eurobarometer, “NS” indicating data were 
obtained from national sources and “GB” indicating only aggregate data from the WHO 
Global Burden of disease study were available.  
For Iceland and Norway, alcohol data had to be imputed, based on summary data 
from the CAMH2012 report (Rehm et al. 2012), while overweight data could be 
obtained in more detail from the Global Burden of Disease Study. For smoking, data 
from the Norwegian Survey of Living Conditions held by Statistics Norway (aggregated 
data by age and sex) were used for Norway and Danish estimates were used as proxy 
for Iceland because national data were unavailable. Global Burden of Disease data 
were less suitable since these did not contain former smokers as a separate category. 
For Croatia, data for all lifestyle factors were available from the Croatian Adult Health 
Survey (individual level data could be used). Use of these different data sources 
implies that results for Iceland, Norway and Croatia may be less well comparable to 
the EU countries as regards lifestyle prevalence. Table 2.4 shows the categories we 
used for each of the three lifestyle variables.  
The Eurobarometer data contained relatively few observations per country, while we 
needed estimates for each category, age and gender. Hence, data were pooled across 
all countries using country dummies to obtain prevalence estimates by country, 
gender and age using maximal power. In order to predict smoothed estimates, a 
multinomial ‘vector generalized additive model’ was applied, using the R package 
‘VGAM’. Several country specific dummies were included to allow flexibility in the 
location and shape of the relation between age and lifestyle. Likelihood ratio tests 
were applied to find the best smoothing parameter. However, these tests revealed a 
rather high value for smoothing, around 10 or 11. Upon visual inspection, a lower 
value of 6 was applied in all analyses to avoid too “bumpy” curves. Appendix 9.4 
provides further details about the surveys and lifestyle data analysis.  
Finally, the smoothed data were combined into a single dataset with age, gender and 
country specific percentages for a combined lifestyle variable containing 36 categories 
ranging from “never-smoker, healthy weight, not drinking” to “current smoker, obese, 
heavy drinker”. This was done assuming independence between lifestyles.  
Figure 2.1 to Figure 2.3: smoking in all countries show lifestyle prevalence at the 
aggregate level for each country as resulting from the smoothed data. The EU average 
was calculated by averaging over the smoothed data using country age and gender 
specific population sizes as weights.  
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Table 2.3: Data availability lifestyle variables per country 
 
Smoking  BMI  Alcohol 
Austria EB EB EB 
Belgium EB EB EB 
Bulgaria EB EB EB 
Croatia NS NS NS 
Cyprus EB EB EB 
Czech Republic EB EB EB 
Denmark EB EB EB 
Estonia EB EB EB 
Finland EB EB EB 
France EB EB EB 
Germany EB EB EB 
Greece EB EB EB 
Hungary EB EB EB 
Iceland GB GB CAMH 
Ireland EB EB EB 
Italy EB EB EB 
Lithuania EB EB EB 
Latvia EB EB EB 
Malta EB EB EB 
Netherlands EB EB EB 
Norway NS NS NS+GB 
Poland EB EB EB 
Portugal EB EB EB 
Romania EB EB EB 
Slovenia EB EB EB 
Slovakia EB EB EB 
Spain EB EB EB 
Sweden EB EB EB 
United Kingdom EB EB EB 
 
Table 2.4: Lifestyle categories used in the study 
Lifestyle Categories 
Smoking 1) Current smoker 
2) Ex-smoker 
3) Never smoked 
Alcohol use (average daily 
consumption between 
brackets) 
1) Current abstainer (0-0.025 gr/day) 
2) Minor drinker (Males: 0.025-40 gr/day; Females: 0.025-20 gr/day) 
3) Moderate drinker (Males: 40-60 gr/day; Females: 20-40 gr/day) 
4) Heavy drinker (Males: >60 gr/day; Females: >40 gr/day) 
BMI 1) Obese (BMI>30) 
2) Overweight (BMI=>25 & BMI<=30) 
3) Normal weight (BMI<25) 
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Figure 2.1: overweight in all countries 
Figure 2.2: alcohol use in all countries 
Figure 2.3: smoking in all countries 
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2.4 Impact of lifestyle on health outcomes and health care spending 
 
The analyses in this section were performed in SPSS and Stata. 
Odds Ratios ’lifestyle – health outcomes’ 
Odds ratios linking risk factor exposure to health outcomes (GALI and self-perceived 
health) were estimated using the European Survey of Health and Retirement (SHARE, 
www.share-project.org) for BMI and smoking behaviour, and the Enquête ‘d’handicap 
et Santé” (HSM, www.insee.fr) data for drinking behavior. SHARE is an international 
longitudinal survey that covers a variety of European countries, including both 
Western and Eastern European countries. SHARE has collected detailed information on 
lifestyle, health, and health care use of individuals aged 50+ and their spouses. The 
odds ratios were calculated using wave 4 of the SHARE survey including the country 
samples listed in Table 2.5. We used the most recent wave 4, because certain lifestyle 
questions had been changed over time, creating incomparability between the different 
waves. The HSM is a French survey conducted between March and July 2008. The 
response rate was 76.6% corresponding to 29931 subjects. The questionnaire 
included questions on GALI limitations and self-perceived health, age and gender. 
14,798 respondents aged 15 years and over also participated in the “auto 
questionnaire” which included detailed questions life style factors, including alcohol 
consumption, weight, lengths, and tobacco use. 
 
Table 2.5: Countries included in odds ratio ‘lifestyle - health outcomes’ calculation 
Country Sample size 
Austria 5,091 
Belgium 5,098 
Czech Republic 5,867 
Denmark 2,203 
Estonia 6,683 
France 5,596 
Germany 1,556 
Hungary 2,987 
Italy 3,510 
Netherlands 2,716 
Poland 1,708 
Portugal 1,999 
Spain 3,486 
Slovenia 2,699 
Sweden 1,943 
Total 56,757 
 
Odds ratios were estimated using logistic regression models. The two outcome 
measures, GALI and SPH, were split into two categories. For GALI we distinguished 
disabled (including both “limited” and “severely limited”) and non-disabled. For SPH, 
we distinguished “good health (at least a good perceived health) and “no good 
perceived health” (remaining categories). Odds ratios were adjusted for age, sex, 
country and the other two lifestyle behaviours and were assumed constant over all 
countries and regions. For alcohol, only French data were used. The odds ratios for 
smoking behaviour and BMI were stratified by sex and age (50-65 and 65+), since 
both were a significant covariate. For alcohol, the models contained age as a 
continuous variable if the relation to age was significant.   
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For the age group <15 years, odds ratios were set to 1 and for the age group 15-50 
years the odds ratios were assumed to be equal to those of the 50-65 years age group 
for smoking and overweight. Finally, all resulting odds ratios were checked for 
consistency and face validity by discussing results with project group members. They 
have also been presented as part of the interim report to the participants of the expert 
workshop. For alcohol, the initial SHARE analyses yielded very little contrast in odds 
ratios and hence the French data set was analysed in addition. The results from this 
dataset showed more consistency and face validity and were hence preferred over the 
SHARE results.  
The odds ratios for all three lifestyle variables and categories were combined into 36 
values representing all possible combinations of risk factor prevalences. To find odds 
ratios for these combined categories, the single category odds ratios were multiplied 
with each other.  
We are aware that this is a simplifying assumption. However, it suits well to the way 
the odds ratios have been estimated (correcting for the remaining lifestyle factors). It 
is also the only way to use the currently available data, with separate sources for each 
of the lifestyle factors. Only when sufficiently consistent estimates of lifestyle 
prevalence at the individual level would be available for all countries and for each 
lifestyle simultaneously, other approaches would be suitable. 
Odds Ratios ’lifestyle-health spending’  
This section describes the data and methods used to estimate odds ratios for lifestyle 
and health variables. We used data from the SHARE survey to estimate these odds 
ratios. Here we included wave 1, 2 and 4 of the SHARE, to have maximal power. 
Respondents aged below 50 years (n=3395), permanent residents of LTC institutions 
(n=426) and respondents with incomplete information on variables of interest were 
excluded (n=5366). Table 2.6 presents the countries that are included in SHARE along 
with their sample size stratified by wave.  
 
Table 2.6: Countries included in odds ratio ‘lifestyle - health spending’ calculation 
Country Wave 1 Wave 2 Wave 4 Total sample 
Austria 1,494 1,128 4,852 7,474  
Belgium 3,534 2,949 4,840 11,323  
Czech Republic 0 2,592 5,608 8,200  
Denmark 1,528 2,403 2,107 6,038  
Estonia 0 0 6,416 6,416  
France 2,852 2,689 5,264 10,805  
Greece 2,608 2,944 0 5,552  
Germany 2,863 2,417 1,475 6,755  
Hungary 0 0 2,889 2,889  
Ireland 0 1,062 0 1,062  
Italy 2,402 2,833 3,378 8,613  
Netherlands 2,716 2,452 2,538 7,706  
Poland 0 2,358 1,488 3,846  
Portugal 0 0 1,865 1,865  
Spain 2,114 1,924 3,081 7,119  
Slovenia 0 0 2,578 2,578  
Sweden 2,904 2,596 1,829 7,329  
Total 25,015 30,347 50,208 105,570  
 
SHARE collects data on health care use, and not health spending. The following health 
care use variables were selected: hospital use, medical doctor (MD) visits, and 
medication use. These are exactly the three types of care that are represented in the 
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curative care spending variable of the SHA (i.e. hospital care, ambulatory care and 
medication, see 2.2). Hospital care use is defined as being hospitalized in the 12 
months preceding the interview. MD visits measures whether someone has visited a 
medical doctor in the 12 months preceding the interview. Medication use is defined by 
weekly medication use for at least one of the following conditions: high blood 
cholesterol, high blood pressure, coronary diseases, other heart disease, asthma, 
diabetes, joint pain, sleep problems, anxiety or depression, osteoporosis, stomach 
burns, chronic bronchitis. 
  
2.5 Standardization 
Standardization procedure 
The DYNAMO-HIA model produced mortality probabilities, prevalence of self-rated 
health/disability by age, gender and country, as well as life expectancy and health 
expectancy (HLY, LEGHP) in various scenarios in which risk factor levels were varied. 
Health outcomes at population level were adjusted using the relative risks (for 
mortality) and odds ratios (for self-reported health and disability) that were associated 
with changes in lifestyle. 
Lifetable model (DYNAMO-HIA) 
We used the DYNAMO-HIA (DYNamic MOdeling for Health Impact Assessment) Model 
to calculate lifestyle standardized outcomes (www.dynamo-hia.eu; Boshuizen et al. 
2012). DYNAMO-HIA is a modelling tool to quantify the health impact of lifestyle 
changes. The range of countries and many scenarios involved in our study make it 
more practical and less error-prone to use this dedicated software. DYNAMO-HIA 
includes checks of the input data (e.g. total prevalence of risk factor equals 100%) 
and has data storage capacities. The model was extended to allow for multiple risk 
factors so that in the scenario analyses all three risk factors could be changed 
simultaneously.  
 
We ran DYNAMO-HIA with lifestyle risk factors directly linked to general health 
outcomes, in terms of mortality (relative risks) and disability (odds ratios). This avoids 
the use of less comparable and often unavailable country specific disease prevalence, 
incidence and mortality data, as well as disease and country specific cost data that will 
be impossible to obtain for all countries included.  
 
The reference or baseline scenario was filled with data for 29 countries (excluding 
Liechtenstein and Luxembourg). This scenario reflects the current situation, that is, it 
represents countries’ current lifestyle prevalence in relation to current health 
outcomes in terms of mortality and quality of life. Using odds ratios and relative risks, 
total mortality and quality of life were attributed to in total 36 different lifestyle 
categories, specific for age and gender.     
Population 
Data on population size by country, age and sex was obtained from the Eurohex 
website (www.eurohex.eu). In case the Eurohex population data were incomplete, 
data from the Human Mortality Database were added. In addition, for Croatia and 
Romania the highest age group was 85+ years. For these two countries, we estimated 
the age distribution of the 85+ population using the distribution of similar countries 
with regard to geographical location and life-expectancy, i.e. Slovenia (Croatia) and 
Hungary (Romania).  
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We averaged the population estimates of 2010 and 2011 for the mid-year population 
size of 2010. For countries with a population size lower than 2,000,000 (Cyprus, 
Malta, Estonia and Slovenia) the years 2009, 2010, 2011 and 2012 were averaged. 
Mortality 
Data on death counts were obtained from the Eurohex website, complemented with 
data from the Human Mortality Database (www.mortality.org) where necessary. 
Mortality by age and sex was calculated by dividing the death counts by mid-year 
population size of 2010. For the four small countries the death counts of 2010 and 
2011 were averaged and divided by the average population sizes of 2009, 2010, 2011 
and 2012. 
Health status  
For GALI, both “limited” and “severely limited” people were considered disabled and 
for self-perceived health we distinguished the groups “good health (at least a good 
perceived health) and “no good perceived health” (remaining categories). The Eurohex 
website published these data in 5-year age categories (from 16-19 years to 85+ 
years).  The data were interpolated and smoothed by regression in combination with a 
smoothing spline, using the R package VGAM for categorical data analysis. The 
prevalence for 0 to 19 and 85 to 95 were set constant at their 19 and 85 year values.  
Scenarios used in the standardization 
Health outcomes were standardized using different scenarios. These scenarios 
describe hypothetical changes in the prevalence of lifestyle factors causing changes in 
health outcomes and health spending. In each of the scenarios, the prevalence of a 
certain lifestyle variable (e.g. BMI) is set to a certain value for each country, gender 
and age stratum. We used the following scenarios: 
 
Scenario 0, “reference” 
In the reference scenario, lifestyle prevalences were the smoothed observed data.  
 
Scenario 1, “best of all” 
In the first scenario, we apply the prevalence of the best-performing country to all 
other countries. A separate adjustment is made for each age group and gender. In 
other words, in each age-gender stratum a different country may be the best-
performing country. ‘Best-performing’ in this case is equal to the highest prevalence in 
the most favorable category from a health perspective, i.e. the lowest prevalence of 
current-smokers, the highest prevalence of moderate drinkers and the highest 
prevalence of no overweight. By using a different reference category in each age-
gender stratum, we assume that health behaviour and health policy can vary within 
countries. 
 
Scenario 2 
The second scenario consists of four variants. In the first variant, “positive all”, we set 
the prevalence of the most favorable category to 100% for all three lifestyle variables. 
In the other three variants, we applied the most favorable category of one of the three 
lifestyle variables to the entire population and used the observed prevalence for the 
other two lifestyle variables. This means that in the scenario 2a we set all the 
prevalence of moderate drinking to 100% and used the observed prevalence for each 
BMI-category and smoking-category. In scenario 2b we set BMI<25 to 100% for all 
countries and used the observed prevalence for each smoking-category and each 
alcohol use-category. In scenario 2c we set the prevalence of never-smokers to 100% 
and used the observed prevalence for alcohol use and BMI. These scenarios are called 
positive alcohol, positive weight and positive smoking, respectively. 
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Scenario 3 
The third set of scenarios consisted of ‘negative’ changes in lifestyle behavior. In 
scenario 3, we set the prevalence of current smoking, obesity and no drinking to 
100% for all populations. The other three variants showed one of the three lifestyle 
variables set to 100% in the most unhealthy category. This means that in the first 
scenario 3a we set all the prevalence of no drinking to 100% and used the observed 
prevalences for each BMI-category and smoking-category. In scenario 3b we set 
BMI>30 to 100% for all populations and used the observed prevalences for each 
smoking-category and each alcohol use-category. In scenario 3c we set the 
prevalence of current smokers to 100% and used the observed prevalences for alcohol 
use and BMI. 
 
Scenario 4, “equal percentages” 
In scenario 4, we set: 1) the prevalence of each smoking category (current smokers, 
never smokers and former smoker) to 1/3 of the population, 2) the prevalence of each 
BMI category (BMI<25, 25<BMI<30, BMI>30) to 1/3 of the population, and 3) the 
prevalence of each alcohol use category (abstainer, minor drinker, moderate drinker 
and heavy drinker) to 25% for all populations.  
 
Scenario 5, “median health outcomes” 
In scenario 5, we used health outcomes to adjust lifestyle prevalences. We selected 
the country with the median life expectancy at birth when averaging over men and 
women, i.e. Finland. The Finnish prevalences for each lifestyle variable were applied to 
all other countries. 
 
Scenario 6 “median spending” 
In the final scenario, we used health expenditure data to select a new reference 
country. Lifestyle prevalences of the country with median levels of health 
expenditures, Portugal, were chosen and applied to all other countries. 
 
The table underneath summarizes the scenarios. 
 
Table 2.7:  Overview of scenarios. Assumptions regarding lifestyle prevalence  
Scenario Short name Smoking BMI Alcohol 
 0 Reference As observed As observed As observed 
 1 Best of all Best performing 
country 
Best performing 
country 
Best performing 
country 
 2a Positive all 100% healthy category 100% healthy category 100% healthy category 
 2b Positive smoking 100% healthy category As observed As observed 
 2c Positive bmi As observed 100% healthy category As observed 
 2d Positive alcohol As observed As observed 100% healthy category 
 3a Negative all 100% unhealthy 
category 
100% unhealthy 
category 
100% unhealthy 
category 
 3b Negative 
smoking 
100% healthy category As observed As observed 
 3c Negative bmi As observed 100% healthy category As observed 
 3d Negative alcohol As observed As observed 100% healthy category 
 4 Equal 
percentages 
Equal division Equal division Equal division 
 5 Median health Finnish prevalence Finnish prevalence Finnish prevalence 
 6 Median spending Portuguese prevalence Portuguese prevalence Portuguese prevalence 
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Adjusting health spending 
We first estimated health care use as a function of demographic, lifestyle and health 
variables and then used this function to estimate health care utilization in each of the 
hypothetical scenario’s (see previous section for a description of the scenarios). The 
data contained three types of healthcare use: MD visits, medication and 
hospitalizations. The function for MD visits was used to adjust spending on ambulatory 
care; the function of medication to adjust spending on medical goods; the function of 
hospitalizations to adjust hospital spending. 
 
Model specification 
A pooled logistic regression model with standard errors clustered at the individual level 
has been used to estimate the association between demographics, lifestyle and health 
with health care use. 
 
𝑌𝑖𝑡 = 𝛼 + 𝛽1𝐴𝑔𝑒𝑖𝑡+𝛽2𝐹𝑒𝑚𝑎𝑙𝑒𝑖 + 𝛽3𝐴𝑔𝑒𝑖𝑡 ∗ 𝐹𝑒𝑚𝑎𝑙𝑒𝑖 + 𝛽4𝐺𝐴𝐿𝐼𝑖𝑡 + 𝛽5𝐴𝑔𝑒𝑖𝑡 ∗ 𝐺𝐴𝐿𝐼𝑖𝑡
+ 𝛽6𝑆𝑃𝐻𝑖𝑡+ 𝛽7𝐴𝑔𝑒𝑖𝑡 ∗  𝑆𝑃𝐻𝑖𝑡 + 𝛽8𝐶𝑜𝑢𝑛𝑡𝑟𝑦𝑖 + 𝛽9𝐶𝑜𝑢𝑛𝑡𝑟𝑦𝑖 ∗ 𝐺𝐴𝐿𝐼𝑖𝑡 + 𝛽10𝐶𝑜𝑢𝑛𝑡𝑟𝑦𝑖
∗ 𝑆𝑃𝐻𝑖𝑡 + 𝛽11𝑆𝑚𝑜𝑘𝑖𝑛𝑔𝑖𝑡 + 𝛽12𝐵𝑀𝐼𝑖𝑡 + 𝜖𝑖𝑡 
 
Yit is a measure of health care use (hospitalization, MD visits or medication use) for 
individual i at time t, using the SHARE data.  
 
Given that health care use largely depends on the way the health care system is 
organized in a country, country dummies and an interaction between country and both 
health measures (GALI and SPH) were included as explanatory variables. This enables 
estimating country-specific OR’s for GALI and SPH. Because alcohol consumption was 
not associated with health care use (only indirectly through health), it was not 
included as an explanatory variable. Lifestyle and health variables were defined as 
described in 2.3.    
Several countries were not included in the SHARE survey. Therefore, it was impossible 
to obtain OR’s for lifestyle/disability on health care use for all 29 countries with 
information on health spending in 2010. We therefore assumed that the OR’s for the 
countries not represented in the SHARE survey are similar to those of neighbouring 
countries. Table 2.7 shows how the OR’s of these countries have been approximated.  
 
Using the above model specification, we computed an adjustment factor for each 
scenario and for each of the three types of care included in the SHARE survey. This 
adjustment factor consisted of two components. First, we calculated the probability of 
health care use for each country by multiplying: 1) the observed values at country 
level for the variables in the above model; with 2) the coefficients of the model as 
estimated from the SHARE data. Second, we computed the adjusted probability of 
health care use for each country by multiplying: 1) the adjusted values at country 
level for the variables in the above model; with 2) the coefficients of the model as 
estimated from the SHARE data. So for each scenario, country and type of care the 
adjustment factor was equal to the ratio of these two probabilities, i.e. one estimated 
using observed values and one estimated using adjusted values: 
 
𝐴𝑑𝑗𝑢𝑠𝑡𝑚𝑒𝑛𝑡 𝑓𝑎𝑐𝑡𝑜𝑟 =
Probability using care (covariates as in scenarios)
Probability using care (covariates as observed)
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Table 2.8:  Approximate countries used 
Country OR based on: 
Bulgaria Hungary 
Finland Sweden 
Croatia Slovenia 
Iceland Sweden 
Lithuania Estonia 
Luxembourg Belgium 
Latvia Estonia 
Malta Italy 
Norway Sweden 
Romania Hungary 
Slovakia Czech Republic 
United Kingdom Ireland 
 
The values of the lifestyle covariates in each scenario follow from the scenario 
definitions (e.g. positive all indicates that there are no smokers and no overweight and 
obese individuals). Furthermore, the percentage of disabled (GALI) and the 
percentage of individuals in less than good SPH (SPH) are taken from the DYNAMO 
output produced in each scenario (see 2.5). Hence, changes in lifestyle will both 
directly and indirectly (through disability and health) affect the level of health 
spending. Finally, DYNAMO’s output for life expectancy was used to estimate the 
impact of age on healthcare use. As such, although improvements in lifestyle will 
improve overall health and disability they do not necessarily decrease health spending 
as older people use more health care. To compute the probabilities, female was set to 
0.5.  
The adjustment factors were multiplied with the actual spending for that type of 
service in 2010 (as registered in OECD and/or Eurostat). In other words, the 
adjustment factor for MD visits was used to adjust total expenditure on ambulatory 
care, the adjustment factor for medication was used to adjust total expenditure on 
medical goods, and the adjustment factor hospitalizations was used to adjust total 
expenditure on hospital care. Following the sum of the adjusted spending on 
ambulatory care, medical goods and hospital care generated total adjusted curative 
spending.  
 
We assumed that changes in lifestyle would affect curative care spending only. For the 
9 countries that did not have data on curative spending for 2010, we estimated these 
using data from other countries or earlier years. We found a strong association 
between GDP and the percentage of total spending allocated to curative care. As a 
result, the percentage of total spending allocated to curative care was estimated from 
countries with similar GDP levels in 2010. This approach was used for 6 countries; 
Croatia, Greece, Ireland, Italy, Malta and the UK. For Bulgaria, Cyprus and Latvia, 
data on curative care were available until 2008. We estimated the cost of curative care 
using the trend in total spending, which commonly follows a similar trend.  
 
Table 2.9: Approximate countries used 
Country Reference country 
Croatia Estonia and Hungary (average) 
Greece Iceland and Portugal (average) 
Ireland Netherlands and Denmark 
Italy Spain 
Malta Iceland and Portugal (average) 
UK France and Spain (average) 
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2.6 Health care efficiency after correction for lifestyle  
The model used to estimate standardized health system cost-effectiveness is similar to 
the models described in 2.2, but Yi and Xi now include a standardized measure for 
population health and health spending, respectively. Standardization methods were 
explained in section 2.5. The analyses were performed in Stata 13. 
 
2.7 Review of policy options 
The existing RIVM database on cost-effectiveness studies in prevention was extended 
with dedicated searches on tobacco, overweight and alcohol interventions in the TUFT 
database and the York database. In addition, the standard search strategy that is 
applied for the RIVM database was updated to 2013 to obtain the most recent studies. 
Studies were then selected on title and abstract on the following criteria: presenting a 
cost-effectiveness study for an intervention aiming at a healthy lifestyle concerning 
smoking, alcohol or overweight; being performed in a European country, to assure 
comparability regarding health care system and insurance habits; Original study, not a 
review or abstract only. Finally, the studies were classified according to the type of 
lifestyle intervention(s) evaluated. 
 
Selection was performed by two independent researchers. Appendix 9.5 contains three 
tables with an overview of studies selected. The studies were then categorized 
regarding type of outcome measure (QALYs, LYG or another effect measure), setting, 
especially which country (EU or elsewhere) and type of intervention evaluated. A 
distinction was made between interventions targeting individuals, e.g. counselling to 
support weight reduction and policy interventions targeting groups of people, e.g. tax 
policy or smoking restrictions. Finally, for a selection of studies the results were 
extracted in more detail. 
 
2.8 Qualitative analyses 
An expert workshop was organized around the interim results, as resulting from steps 
1 to 6. Care was taken to invite experts from a broad field of expertise, as well as an 
invited speaker applying an alternative approach to the issue of lifestyle and its effect 
on health system efficiency. The program of the workshop, a list of participants and 
summary of discussion points brought forward are given in the appendix (chapter 
9.6). In addition, literature was consulted regarding health, health systems and the 
influence of lifestyle on health outcomes.  
2.9 Understanding the dynamics resulting from lifestyle changes  
To obtain better insight into how changes in lifestyle affect health outcomes over time, 
a number of scenarios was analysed in a dynamic lifetable model with explicit 
modelling of chronic diseases and their link to lifestyle factors. This was done using 
data from the Netherlands. The reference scenario, the “best of all” scenario and the 
“all positive scenario” were analysed in this disease specific model. Comparing the 
“best of all” or “all positive” scenario to the reference scenario shows how much is 
gained over time when all persons in a country change their lifestyle at baseline. 
Health care costs were calculated by multiplying disease prevalences with the annual 
costs per disease per patient (age and gender specific). Costs of all diseases not 
explicitly modelled were assumed to depend on age and gender while accounting for 
the fact that health care use is concentrated in the last year of life (van Baal et al. 
2011a and 2011b).  
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Furthermore, for smoking, two extreme variants were compared in the “best of all 
scenario”. One variant assumed that all former smokers in the country had quitted 
smoking long ago, and thus had risks on disability and mortality equal to that of never 
smokers (former smoker is never smoker). The other variant assumed that former 
smokers had quitted only recently, and thus had the same relative risks as current 
smokers (former smoker is smoker). Both situations were standardized to the best-of-
all country scenario, where -as before - former smokers have a relative risk that 
applies to a mixture of quitting durations. As such, the results give the maximum 
range of the impact of differences in time-effects from smoking. In all countries, 
however, the majority of former smokers are long-term quitters, so especially the 
former smoker is smoker scenario is rather unrealistic.  
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3 Intermediate results  
Results regarding the effects of lifestyle on health 
outcomes and health care spending 
3.1 Results analysis lifestyle – health outcomes 
The relationship between lifestyle and health outcomes was estimated using data from 
the SHARE survey for BMI and smoking, and data from the Enquête ‘d’handicap et 
Santé” (HSM) for alcohol consumption (see 5.1.4). Table 4.1 and Table 4.2 provide 
the odds ratios for different lifestyle categories and two health outcomes: the General 
Activity Limitation Indicator (GALI) and self-perceived health.  
 
Table 3.1 shows that the probability of having activity limitations was higher for 
smokers and ex-smokers compared to non-smokers. Also, this probability was higher 
for those with overweight and obesity compared to respondents with normal weight. 
For females older than 65 years, we found a non-significant odds ratio for smoking of 
0.92, implying a protective effect of smoking on disability (GALI). Since this finding is 
conflicting with literature and it was not significant we set this value to 1 in further 
analyses. The absence of increased risk of disability among smokers may reflect a 
“healthy smoker” effect, that is, smokers with smoking related diseases will be more 
inclined to quit smoking than smokers without such diseases. It may however also be 
a matter of data, with relatively low numbers of female older smokers and former 
smokers.  
 
Table 3.1: Odds ratio’s for GALI (limited or severely limited in activities) by gender and age 
group (95% CI between brackets) 
Sex/ age Male 
50-64 
(n=11693) 
Male 
65+ 
(n=11761) 
Female 
50-64 
(n=14754) 
Female 
65+ 
(n=14696) 
Smoker 1.80 
(1.63-1.99) 
1.28  
(1.13-1.45) 
1.14  
(1.04-1.25) 
0.92* 
(0.80-1.06) 
Ex-smoker 1.56  
(1.42-1.71) 
1.07  
(0.98-1.17) 
1.07  
(0.97-1.17) 
1.09 
(0.99-1.20) 
Obesity 2.03 
(1.82-2.26) 
1.64 
(1.46-1.85) 
2.56 
(2.32-2.82) 
2.29 
(2.07-2.54) 
Overweight 1.33 
(1.21-1.45) 
1.11  
(1.01-1.21) 
1.33 
(1.22-1.44) 
1.24 
(1.14-1.34) 
* Set to 1 
 
Table 3.2 demonstrates a more complex outcome for alcohol. The odds ratios do vary 
significantly with age for females, but not for men. For alcohol, “no consumption” is 
the reference category. No consumption, that is less than 0.25 g/day, appears as the 
unhealthiest category for men and older women. For young women, high consumption 
has large health risks. For men, the same trend was present but not significant. Part 
of the results will be due to a selection issue, because the category of no consumption 
probably contained a mixture of lifetime abstainers and former heavy drinkers.   
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Table 3.2: Odds ratio’s for GALI (limited or severely limited in activities) by gender and for 
selected ages. ORs are available as a function of age. 
Sex/ age Male 
20 
 
Male 
40 
 
Male 
60 
 
Male 
80 
 
Female 
20 
 
Female 
40 
 
Female 
60 
 
Female 
80 
 
High alcohol 
consumption1  
0.91 0.91 0.91 0.91 11.91* 1.32 0.63 1.31 
Medium alcohol 
consumption2 
0.55 0.55 0.55 0.55 0.26 0.48 0.71 0.83 
Low alcohol 
consumption3 
0.60 0.60 0.60 0.60 0.65 0.65 0.64 0. 64 
* In the analyses this value was capped at 3 to avoid computational difficulties. Given the small size of the group and low prevalence 
of health problems that will only to a minor degree affect the results. 1 Male: >60g/day, Female: >40g/day; 2 Male: 40-60g/day, 
Female: 20-40g/day; 3 Male: 0.25-40 g/day, Female: 0.25-20 g/day 
 
Table 3.13 and Table 3.14 show the results for self-perceived health. The table shows 
that for smoking and overweight, unhealthy lifestyles have larger odds ratios for “less 
than good” self-perceived health. These results are a bit more outspoken and 
consistent than for the GALI as a measure of health benefit. Age trends in odds ratios 
of alcohol are now significant in men and not in women. For alcohol, “no consumption” 
is the reference category. Hence ORs below one imply that the indicated category is 
more healthy than “no consumption”.  
 
Table 3.13: Odds ratio’s for “Less than good” self-perceived health, by gender and age group 
(95% CI between brackets) 
Sex/ age Male 
50-64 
(n=11692) 
Male 
65+ 
(n=11758) 
Female 
50-64 
(n=14756) 
Female 
65+ 
(n=14690) 
Smoker 2.54 
(2.29-2.81) 
1.48 
(1.30-1.68) 
1.60 
(1.45-1.76) 
1.22  
(1.06-1.40) 
Ex-smoker 1.58 
(1.44-1.74) 
1.10 
(1.00-1.08) 
1.04 
(0.94-1.15) 
1.09 
(0.99-1.07) 
Obesity 2.06 
(1.85-2.31) 
2.33  
(2.07-2.63) 
3.17 
(2.86-3.50) 
2.27 
(2.05-2.51) 
Overweight 1.18 
(1.07-1.29) 
1.32 
(1.20-1.44) 
1.61 
(1.47-1.76) 
1.37 
(1.26-1.48) 
 
Table 3.14: Odds ratio’s for “Less than good” self-perceived health by gender and for selected 
ages 
Sex/ age Male 
20 
 
Male 
40 
 
Male 
60 
 
Male 
80 
 
Female 
20 
 
Female 
40 
 
Female 
60 
 
Female 
80 
 
Heavy drinking1  1.26 0.83 0.54 0.35 0.95 0.95 0.95 0.95 
Moderate alcohol 
consumption2 
1.04 0.78 0.59 0.45 0.63 0.63 0.63 0.63 
Minor alcohol 
consumption3 
0.35 0.44 0.56 0.70 0.49 0.49 0.49 0.49 
1 Male: >60g/day, Female: >40g/day; 2 Male: 40-60g/day, Female: 20-40g/day; Male: 0.25-40 g/day, Female: 0.25-20 g/day 
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3.2 Results analysis lifestyle – health spending  
 
Table 3.25 presents the association between demographic, lifestyle and health 
variables and three types of health care use, i.e. visiting a medical doctor (MD) 
(column 2), taking weekly medication (column 3), or being hospitalized (column 4). 
These three groups (doctor visits, medication use and hospital care) represent a large 
part (around 80%) of total curative care spending.  
The columns present the odds ratios (and corresponding confidence intervals) 
estimated with the regression model. The odds ratios represent the probability of 
health care use for the category shown, in relation to the probability of health care use 
for a reference group. For example, the odds ratio for MD visits was 1.04 for females, 
meaning that the odds of visiting a MD was 1.04 times higher for females than for 
males. The reference groups are mentioned in the table. For age, the interpretation is 
a bit different, each additional year implies a higher odds at the given size of using the 
specific type of care. 
Most results are as expected. The probability of health care use was higher for older 
people and females. Regardless of the country, having a limitation or being in less 
than good self-perceived health increases the odds of an MD visit, medication use and 
a hospitalization. The ORs for both GALI and self-perceived health (SPH) are country-
dependent as shown by the country-specific odds ratios. 
 
Section 3.1 showed that lifestyle affects the probability of having activity limitations 
and self-perceived health. As a result, lifestyle will affect health care use and health 
spending through these two variables. On top of this, some risk factors also have an 
independent effect on health care use even after controlling for health status, as Table 
3.25 shows. Individuals with overweight and in particular obese individuals, have a 
higher probability to visit the MD or use medication weekly. BMI does not have an 
independent effect on hospital care use. It turns out that ex-smokers have a higher 
probability of health care use compared to never smokers. At the same time, the 
probability of health care use was (surprisingly) lower for daily smokers compared to 
never smokers. Again, this might reflect the “healthy smoker” effect that was 
explained on page 39. 
 
Table 3.25: Odds ratio’s (95% CI) for health care use by self-reported health status 
Variable OR MD visit  OR medication OR hospital 
Age 1.04 (1.04-1.04) 1.07 (1.07-1.08) 1.03 (1.03-1.04) 
Female 5.94 (4.42-7.98) 2.37 (1.81-3.09) 1.04 (0.81-1.34) 
Female*Age 0.98 (0.97-0.98) 0.99 (0.99-1.00)  1.00 (0.99-1.00) 
Smoking†  
   ex-smoker 1.18 (1.12-1.24) 1.28 (1.23-1.34) 1.27 (1.22-1.33) 
   Smoker 0.66 (0.63-0.70) 0.96 (0.91-1.00) 0.98 (0.93-1.03) 
BMI†    
     Overweight 1.27 (1.21-1.32) 1.56 (1.50-1.62) 0.92 (0.88- 0.96) 
     Obese 1.33 (1.25-1.41) 2.42 (2.29-2.55) 1.00 (0.96-1.06) 
GALI*Age 0.98 (0.98-0.99) 0.99 (0.99-0.99)  0.99 (0.98-0.99) 
SPH*Age 0.99 (0.98-0.99) 0.99 (0.98-0.99)  0.99 (0.98-0.99) 
GALI†  
   Austria 5.36 (3.59-7.99) 5.73 (4.17-7.87) 4.80 (3.44-6.72) 
   Germany 9.08 (4.45-18.55) 4.74 (2.83-7.96) 5.72 (3.29-9.95) 
   Sweden 7.32 (3.89-13.77) 5.21 (3.14-8.66) 6.83 (3.96-11.80) 
   Netherlands 7.35 (3.90-13.83) 3.92 (2.37-6.46) 5.32 (2.98-9.47) 
   Spain 6.69 (3.35-13.38) 6.47 (3.72-11.25) 6.04 (3.43-10.64) 
   Italy 6.92 (3.56-13.46) 4.67 (2.78-7.82) 6.95 (4.02-12.02) 
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   France 6.50 (3.25-13.00) 4.05 (2.44-6.72) 4.85 (2.88-8.18) 
   Denmark 6.03 (3.09-11.73) 4.49 (2.65-7.60) 6.06 (3.40-10.81) 
   Greece 6.92 (3.44-13.94) 6.20 (3.41-11.28) 7.38 (3.97-13.71) 
   Belgium 7.50 (3.81-14.74) 4.23 (2.56-6.98) 6.00 (3.57-10.08) 
   Czech Republic 8.14 (4.14-16.00) 7.96 (4.78-13.27) 5.33 (3.09-9.19) 
   Poland 7.37 (3.71-14.61)  6.66 (3.82-11.63) 5.49 (3.01-10.01) 
   Ireland 20.59 (6.21-68.32) 6.38 (3.08-13.21) 8.83 (4.08-19.13) 
   Hungary 6.76 (3.26-14.02) 9.20 (5.03-16.81) 6.19 (3.28-11.69) 
   Portugal 6.36 (2.80-14.44)  5.97 (3.09-11.53) 7.13 (3.39-15.03) 
   Slovenia 6.17 (3.00-12.70) 5.29 (2.97-9.45) 6.13 (3.22-11.68) 
   Estonia 7.09 (3.75-13.40) 6.44 (3.85-10.76) 6.90 (3.88-12.27) 
SPH† 
   Austria 3.32 (2.13-5.17) 7.63 (5.22-11.15) 4.57 (3.35-6.25) 
   Germany 4.94 (2.16-11.29) 8.58 (4.54-16.21) 5.26 (3.14-8.82) 
   Sweden 4.18 (2.00-8.73) 7.25 (3.79-13.86) 4.48 (2.68-7.49) 
   Netherlands 5.34 (2.53-11.26) 9.97 (5.29-18.79) 6.67 (3.92-11.35) 
   Spain 5.37 (2.52- 11.45) 8.60 (4.54-16.29) 5.01 (2.90-8.64) 
   Italy 4.74 (2.28-9.88) 6.01 (3.24-11.14) 4.55 (2.71-7.64) 
   France 4.71 (2.16-10.25) 7.77 (4.16-14.51) 5.02 (3.06-8.23) 
   Denmark 3.86 (1.78-8.34) 7.34 (3.78-14.26) )4.82 (2.79-8.36) 
   Greece 4.72 (2.18-10.21) 7.19 (3.63-14.27) 5.08 (2.81-9.18) 
   Belgium 6.09 (2.70-13.75) 7.34 (3.88-13.88) 4.13 (2.53-6.74) 
   Czech Republic 3.67 (1.71-7.87) 5.38 (2.88-10.07) 4.32 (2.62-7.13) 
   Poland 3.81 (1.79-8.08) 5.95 (3.11-11.37) 4.49 (2.52-7.99) 
   Ireland 7.31 (1.93-27.67) 7.45 (2.97-18.67) 3.98 (1.86-8.50) 
   Hungary 3.16 (1.43-6.95)  5.79 (2.94-11.41) 4.50 (2.43-8.34) 
   Portugal 4.07 (1.74-9.52) 6.20 (3.04-12.66) 3.39 (1.62-7.12) 
   Slovenia 3.37 (1.53-7.41) 4.80 (2.45-9.43) 3.41 (1.87-6.24) 
   Estonia 3.25 (1.60-6.62) 6.73 (3.64-12.44) 4.18 (2.34-7.44) 
Country†  
     Germany 1.34 (1.15-1.56) 0.91 (0.81-1.02) 0.53 (0.45-0.62) 
     Sweden 0.46 (0.40-0.52) 0.90 (0.81-1.01) 0.42 (0.36-0.49) 
     Netherlands 0.51 (0.45-0.58) 0.75 (0.67-0.84) 0.29 (0.25-0.35) 
     Spain 0.96 (0.84-1.10) 1.18 (1.06-1.31) 0.33 (0.27-0.39) 
   Italy 0.81 (0.71-0.92) 1.23 (1.11-1.36) 0.39 (0.33-0.46) 
   France 2.05 (1.79-2.35) 1.65 (1.50-1.82) 0.57 (0.49-0.65) 
   Denmark 0.75 (0.66-0.85) 0.95 (0.85-1.06) 0.45 (0.38-0.53) 
   Greece 0.58 (0.51-0.66) 1.49 (1.33-1.66) 0.26 (0.21-0.32) 
   Belgium 1.58 (1.39-1.80) 1.85 (1.67-2.04) 0.61 (0.54-0.70) 
   Czech Republic 1.24 (1.08-1.42) 1.09 (0.98-1.21) 0.56 (0.47-0.66) 
   Poland 0.42 (0.36-0.49) 0.72 (0.62-0.84) 0.51 (0.40-0.65) 
   Ireland 0.68 (0.55-0.83) 0.86 (0.73-1.03) 0.52 (0.39-0.70) 
   Hungary 0.67 (0.56-0.81) 0.91 (0.78-1.06) 0.47 (0.36-0.61) 
   Portugal 0.81 (0.65-1.01) 1.23 (1.03-1.47) 0.30 (0.21-0.44) 
   Slovenia 0.60 (0.51-0.71) 0.91 (0.79-1.05) 0.45 (0.35-0.58) 
   Estonia 0.42 (0.36-0.48) 0.49 (0.43-0.56) 0.31 (0.24-0.39) 
Constant 0.33 (0.26-0.44) 0.01 (0.01-0.01) 0.02 (0.01-0.03) 
†Smoking: reference category = never smoker; 
BMI: reference category = BMI<25; 
GALI odds ratio: numerator = activity limitations, denominator/references=not limited; 
SPH odds ratio: numerator = less than good perceived health; denominator/reference= 
good SPH; 
Country: reference category = Austria.  
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4 Results of quantitative analyses 
4.1 Health system cost-effectiveness unadjusted for lifestyle 
This section presents the cost-effectiveness of health systems before filtering out the 
variation in lifestyles between countries. Therefore, estimating the relationship 
between health spending and health outcomes is at the core of this section. This 
section presents the findings for curative care spending only. The conclusions from the 
analysis with total health spending are virtually identical (see Appendix 9.1). Appendix 
9.7 contains the results for the EU-28 member states.  
 
The analyses in this paragraph are based on country-level data obtained from OECD, 
Eurostat and WHO. These include health spending and population health variables as 
explained in the previous chapters. Furthermore, variables on education (percentage 
of population 25 years and older with at least secondary education) and national 
income (GDP per capita) were added to the analyses. All figures present per capita 
health expenditures in Euros, price level 2011. Purchasing Power Parities (EU28=1; 
Eurostat) were used to correct for differences in price levels across countries. More 
details on data and methods can be found in Chapter 2.  
Graphical presentation of the association between health spending and 
population health 
Figure 4.1 to Figure 4.3 presents the association between curative care spending and 
population health for the year 2010. The level of curative care spending ranged 
between around € 400 per capita in Romania and around € 2800 per capita in Norway. 
Population health varied as well. Life expectancy at birth ranged between almost 73 
years in Lithuania and over 82 years in Spain, for both sexes combined.  
Regardless of the population health measure, curative care spending and population 
health were positively associated. A comparison of goodness of fit measures (i.e. R-
squared) between an OLS model with raw variables and logarithmically transformed 
variables, revealed that the association could best be described as one with 
diminishing marginal returns of curative care spending on population health. The 
variation in curative care spending could explain over 50 percent of the variation in life 
expectancy or life expectancy in good perceived health, but only 19 percent of the 
variation in healthy life years. 
 
The figure also presents the elasticity1 of curative care spending obtained from an OLS 
model with all variables logarithmically transformed, showing a significantly positive 
association between curative care spending and population health (the elasticity is 
equal to coefficient of health spending in the regression model). The association is 
stronger for the two population health measures that take into account quality of life 
next to length of life. A 1 percent increase of curative care spending is associated with 
a 0.057, 0.066, and 0.094 percent increase in life expectancy, healthy life years and 
life expectancy in good perceived health, respectively. 
Total health spending also has a clear, but weaker, relationship with all three 
population health measures (see Chapter 9.1). This is not surprising given that total 
health spending also includes spending categories that do not directly aim to improve 
life expectancy (i.e. administrative costs, long-term care spending).  
 
                                           
1 Elasticity = the percentage change in population health (LE, HLY, LEGPH) associated 
with a 1% change in health spending. 
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Figure 4.1: The association between curative care spending and life expectancy 
 
 
Figure 4.2: The association between curative care spending and healthy life years 
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Figure 4.3: The association between curative care spending and life expectancy in good 
perceived health 
  
The effect of health spending on population health 
This subsection provides a more thorough analysis of the relationship between 
curative care spending and population health. 
 
Table 4.1 below shows that after controlling for additional variables, i.e. GDP per 
capita and education, curative care spending is only positively associated with life 
expectancy. The absence of a significant and positive effect of curative care spending 
on HLY and LEGPH is related to the high correlation between curative care spending 
and GDP per capita (ρ=0.93). Figure 4.1 already showed that richer western European 
countries have higher levels of health spending and population health. It means that it 
is difficult to separate out and estimate the true effects of GDP per capita and curative 
care spending on population health. Moreover, both curative care spending and GDP 
per capita may also be affected by population health (issue of endogeneity) (Gravelle 
and Backhouse, 1987). The results of the basic model in Table 4.1 are robust for the 
selection of the year (2004-2011).  
Table 4.1 also presents the effect of health spending, GDP per capita and education as 
estimated by a panel data model. Note that the panel analyses were used to increase 
the reliability of the estimates of the basic model and not to investigate the lagged 
impact of health spending on health. The direction of the effect of health spending is 
similar to the one estimated by the basic model. However, health spending now has a 
significant effect on all three population health outcomes. Curative care spending 
positively affects LE(GPH), but has a negative effect on HLY. Overall, it appears that 
using HLY as outcome measure gives different results in comparison to LE and LEGPH. 
Figure 4.1 also showed a much lower R-squared for the HLY-variable. These 
differences require further exploration before reaching conclusions. The same holds 
true for the negative impact of GDP per capita on health as estimated in the panel 
data model. A major problem in all these analyses is the large correlation between the 
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different explanatory variables. Education and curative care spending both rise with an 
increasing GDP and show relatively little variation among the European countries, if 
compared to the variance observed worldwide. More advanced data analyses would be 
advisable, applied to a larger dataset. A longer period of panel data would allow to 
include lagged variables.    
 
Table 4.1: Elasticity of population health to curative care spending, GDP per capita and 
education 
 LE HLY LEGPH 
Basic model (2010)    
   Curative care spending 0.055*** -0.076 0.053 
   GDP per capita 0.000 0.180 0.055 
   Education -0.022 -0.031 0.018 
   N 21 21 21 
   R-squared 0.76 0.30 0.58 
    
Panel data model (2004-2011)    
   Curative care spending 0.031*** -0.174*** 0.103*** 
   GDP per capita -0.022** 0.097** -0.059*** 
   Education 0.131*** 0.311** 0.252*** 
   N 179 164 164 
P-value of null hypothesis of no effect. *p<0.10; **p<0.05; ***p<0.01 
Technical efficiency of health systems   
A simple way of measuring the efficiency of health systems is to first estimate the 
relationship between health spending and population health (using the basic model in 
Table 4.1) and then to compare the actual absolute values of population health with 
their fitted (predicted) values. The log-transformation is chosen as health care is most 
likely subject to diminishing returns, i.e. it could be quite costly to further improve 
population health if population health of a country is already quite high. Hence, a 
country’s relative performance is measured as the distance between the actual and 
fitted values of population health in comparison to that distance for the other 
countries. 
 
Figure 4.4 presents the efficiency measures described above for each country for all 
three population health measures, for the year 2010. That is, it shows the differences 
between the observed and predicted levels of population health. The figure clearly 
shows that a country’s performance depends on the health measure chosen. However, 
a few countries performed above average on all three health measures (Iceland, 
Sweden, Spain, Czech Republic and France). In other words, these countries attained 
a higher level of population health than expected, given their level of health spending, 
education and GDP. At the same time, some countries performed consistently worse 
than average, such as Denmark, Hungary, Slovakia, Portugal, Luxembourg, Germany, 
and Austria. Note that a zero distance means this country has actual performance as 
predicted and hence is at the average level. 
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Figure 4.4: Health system efficiency estimated by parametric analyses (actual – predicted 
population health in years) 
 
Figure 4.5 presents the relative efficiency of health systems in achieving population 
health as estimated by a non-parametric method, the Data Envelopment Analysis 
(DEA). Similar to the parametric model above, the DEA was based on cross-sectional 
2010 data including GDP and education as additional inputs. The higher the score, the 
more efficient a country is. A country with a score of 1 is regarded efficient. The 
majority of countries that are relatively efficient according to the parametric approach 
(e.g. Iceland and Sweden) also score high on technical efficiency obtained by a DEA. 
Again, Denmark, Lithuania and Slovakia are among the worst performing countries, as 
are Slovenia, Germany, and Austria for HLY and LEGPH. However, some obvious 
differences also arise. Probably, most notable is the result that Portugal and Romania 
do very well according to a DEA, but not according to the parametric approach. For 
Romania, this could be explained by very few countries having comparable low levels 
of spending per capita, and hence being an outlier that will be placed artificially on the 
frontier by DEA. For Portugal however that explanation cannot be used, its level of 
spending is quite modal.  
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Figure 4.5: Health system efficiency estimated by DEA (efficiency score between 0 and 1) 
 
 
4.2 Health system cost-effectiveness adjusted for lifestyle - Results 
scenario 1 
Changes in health outcomes and health spending 
Table 4.2 presents results after standardization for differences in life style, for the 
outcome measures life expectancy (LE), healthy life expectancy (LEGPH, HLY) and 
total curative health expenditures (TCHE) in scenario 1(“best of all”) as compared to 
the reference scenario. In this scenario, we applied the prevalence of the best-
performing country (with respect to the specific lifestyle behaviour at that specific age 
and gender category) to all other countries. Thus, we took the most healthy behaviour 
actually observed for a certain age and gender and assumed all countries would have 
this behaviour at this age and gender. The scenarios specified smoking, alcohol and 
BMI. Risk factors were assumed to be independent, in line with the corrected ORs. The 
results of the other scenarios are presented in section 4.3. The baseline (absolute) 
values can be found in Appendix 9.2.   
 
The table illustrates that lifestyle has quite a big impact on (healthy) life expectancy 
and that the increases in healthy life expectancy are bigger than on life expectancy. 
Life expectancy increases between 0.36 years (Italy) and 2.3 years (Latvia), while HLY 
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lifestyle on per capita health expenditures is rather modest as the additional costs of 
living longer are more or less outweighed by the cost-savings induced by more 
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On balance, health care expenditures per capita increase a bit (up to 95 euros per 
capita in Norway). 
 
Table 4.2: Changes in health and health expenditures in scenario 1 compared to the base case 
scenario 
 
Difference between scenario 1 and base case scenario 
Country LE (years) LEGPH (years) HLY (years) TCHE* (€) 
Austria 0.95 2.98 2.18 38 
Belgium 1.11 3.21 2.21 31 
Bulgaria 1.31 2.77 2.19 10 
Croatia 1.65 3.77 4.91 30 
Cyprus 1.21 3.90 2.90 23 
Czech Republic 1.21 3.90 2.90 21 
Denmark 1.41 2.67 2.00 60 
Estonia 1.66 3.79 2.99 19 
Finland 0.85 3.16 2.86 15 
France 1.05 2.73 1.69 39 
Germany 1.15 3.46 2.34 35 
Greece 1.80 3.73 2.71 33 
Hungary 1.67 4.14 3.26 19 
Iceland 2.06 3.95 3.25 47 
Ireland 0.63 2.93 2.15 21 
Italy 0.36 2.59 1.58 14 
Latvia 2.25 4.87 3.99 13 
Lithuania 1.89 3.58 3.23 21 
Luxembourg TBA TBA TBA TBA 
Malta 1.26 4.95 3.00 13 
Netherlands 1.38 2.68 2.14 52 
Norway 2.14 3.66 3.07 95 
Poland 1.86 3.74 3.36 22 
Portugal 0.65 3.75 2.73 12 
Romania 1.38 2.75 2.46 11 
Slovakia 1.30 2.79 2.30 20 
Slovenia 1.20 3.42 2.79 24 
Spain 1.21 4.38 3.25 29 
Sweden 0.66 1.25 0.92 26 
United Kingdom 0.99 3.22 2.42 21 
*Total curative care spending (€ per capita, price level 2010) 
 
Figure 4.6 illustrates that – on average - the hypothetical lifestyle improvements 
according to scenario 1 had a larger impact on life expectancy in unhealthier countries 
compared to healthier countries (in terms of life expectancy). This is related to the 
unhealthier lifestyle behaviour in countries with low life expectancy at baseline (there 
is more to be gained). 
 
    Final report MACELI 
 
 
December, 2014  
 50 
 
Figure 4.6: Relative change in life expectancy across all levels of life expectancy per country in 
scenario 1  
 
Changes in health system efficiency 
After adjustment for lifestyle, the relation between spending and health was weaker 
and the elasticities were reduced to some extent. For instance, the elasticity of 
curative care spending with respect to life expectancy decreased from 0.057 to 0.053.  
Figure 4.7 to Figure 4.9 show the relationship between health spending and population 
health before (unadjusted) and after (adjusted) standardization for lifestyle in scenario 
1 (“best of all”). This scenario was defined by a hypothetical shift for each age and 
gender category to the best observed lifestyle among all countries and thus presents a 
potential, but hypothetical, most healthy ideal situation. As mentioned above, the 
impact of standardization on population health differences was much larger compared 
to its impact on differences in health spending between countries. As a result, the 
relationship between health spending and population health remained similar and was 
just shifted upward a bit. 
 
  
AT
BE
BG
CY
CZ DE
DK
EE
EL
ES
FI
FR
HU
IE
IS
IT
LT
LV
MT
NL
NO
PL
PT
RO
SE
SI
SK
UK
.5
1
1
.5
2
2
.5
3
c
h
a
n
g
e
 l
if
e
 e
x
p
e
c
ta
n
c
y
(%
)
72 74 76 78 80 82
life expectancy unadjusted
    Final report MACELI 
 
 
December, 2014  
 51 
 
Figure 4.7: The association between curative care spending and life expectancy, unadjusted and 
adjusted for lifestyle behaviour (scenario 1)  
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Figure 4.8: The association between curative care spending and healthy life years, unadjusted 
and adjusted for lifestyle behaviour (scenario 1) 
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Figure 4.9: The association between curative care spending and life expectancy in good 
perceived health, unadjusted and adjusted for lifestyle behaviour (scenario 1) 
 
The technical efficiency, as presented in section 4.1, was affected to some extent 
through standardization as population health changed differently across the countries 
(see Figure 4.7 to Figure 4.9). Nevertheless, the general pattern remained similar. In 
order to illustrate the impact of standardisation on country-specific efficiency scores 
(using life expectancy as outcome measure), Figure 4.10 shows the correlation 
between the unadjusted and adjusted efficiency scores (based on the parametric 
method). It demonstrates a high correlation between the unadjusted and adjusted 
efficiency measure (r=0.84). 
Concluding, we can say that while current lifestyle is important for health it is less 
important for health spending, in particular regarding the variation in health spending 
between countries. Consequently, also the influence on cross-country differences in 
health system cost-effectiveness was limited. Please note that these adjusted cost-
effectiveness estimates should not be interpreted as policy scenarios. They reflect 
hypothetical immediate changes in lifestyle and ignore intervention costs. They are an 
indication as to how lifestyle confounds the observed relation between health care 
spending and health outcomes.  
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Figure 4.10: The association between country-specific efficiency scores, using life expectancy as 
outcome, unadjusted and adjusted for lifestyle behaviour (scenario 1) 
  
4.3 Health system cost-effectiveness adjusted for lifestyle - Results 
scenarios 2 to 6 
 
The figures and tables in this paragraph show the results of the other standardization 
scenarios 2 to 6 (see 2.5), i.e.: 
 2a: 100% in healthiest category for all lifestyle variables 
 2b: 100% in healthiest category for smoking 
 2c: 100% in healthiest category for BMI 
 2d: 100% in healthiest category for alcohol consumption  
 3a: 100% in most unhealthy category for all lifestyle variables 
 3b: 100% in most unhealthy category for smoking 
 3c: 100% in most unhealthy category for BMI 
 3d: 100% in most unhealthy category for alcohol consumption 
 4: equal division across lifestyle categories 
 5: lifestyle prevalence of country with median population health 
 6: lifestyle prevalence of country with median health spending 
 
Changes in health outcomes and health spending 
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gain in life expectancy, i.e. between 2.4 years in Italy (+3%) and 5.1 years in Latvia 
(+7%).  
As shown in Table 4.4 and Table 4.5, the changes in healthy life expectancy were even 
larger than the gains in life expectancy for scenario 2a. Gains in terms of Healthy Life 
Years varied between 4.8 years (+7%) in Sweden and 8.1 years (+19%) in Latvia; 
and in terms of Life Expectancy in Good Perceived Health between 6.6 years (+9.8%) 
in Sweden and 9.9 years (+18%) in Latvia. 
The results differed between the lifestyle variables. Changing current smoking 
prevalence (scenario 2b and 3b) showed a greater impact in terms of (healthy) life 
expectancy, compared to BMI (scenario 2c and 3c). Changes in current alcohol 
consumption (scenario 2d and 3d) produced a rather small change in (healthy) life 
expectancy. This reflects the values of odds ratios and relative risks for the different 
lifestyle factors. 
In all scenarios, and for all health measures, differences between countries were 
reduced a bit, because the countries with lower (healthy) life expectancy had more 
unhealthy lifestyle behaviours as well. Nevertheless, differences remained substantial 
and countries with high (healthy) life expectancy at baseline remained high after 
standardization. This finding holds for all scenarios. In other words, standardizing for 
differences in lifestyle cannot explain all cross-country variation in population health. 
Finally, similar to the results for scenario 1, changes in health spending at country 
level were small in all scenarios (Table 4. 6). We also re-estimated the regression 
models using adjusted curative care spending and adjusted population health. Table 
4.7 shows the elasticity of health outcomes with respect to changes in health 
spending. The table shows that elasticity is rather stable across the standardization 
scenarios, except for scenario 3a (100% in most unhealthy category for all lifestyles).     
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Table 4.3: Changes in Life Expectancy (years) by country and scenario 
 Scenario no2 2a 2b 2c 2d 3a 3b 3c 3d 4 5 6 
Austria 3.09 1.79 1.24 0.07 -6.27 -3.75 -3.13 -0.04 -2.48 0.14 0.35 
Belgium 3.30 1.95 1.27 0.09 -6.29 -3.78 -3.15 0.01 -2.42 0.26 0.49 
Bulgaria 3.74 2.16 1.57 0.02 -6.07 -3.67 -3.19 0.01 -2.24 0.33 0.65 
Croatia 4.03 2.11 1.79 0.06 -5.64 -3.70 -2.60 0.07 -1.86 0.75 1.00 
Cyprus 3.18 1.80 1.32 0.03 -5.44 -3.38 -2.58 -0.01 -1.98 0.51 0.67 
Czech Republic 3.42 1.77 1.59 0.04 -6.26 -3.96 -2.97 -0.02 -2.41 0.20 0.46 
Denmark 3.65 2.37 1.20 0.12 -6.08 -3.51 -3.34 0.02 -2.15 0.54 0.79 
Estonia 4.31 2.43 1.77 0.03 -6.35 -3.82 -3.42 0.03 -2.32 0.61 0.90 
Finland 3.07 1.62 1.41 0.04 -6.52 -4.10 -3.12 0.00 -2.69 0.00 0.22 
France 3.34 1.94 1.32 0.09 -6.66 -3.99 -3.37 0.00 -2.60 0.18 0.39 
Germany 3.83 2.33 1.32 0.07 -6.51 -3.95 -3.33 -0.06 -2.59 0.28 0.49 
Greece 3.95 2.26 1.63 0.05 -5.34 -3.29 -2.69 0.03 -1.64 1.03 1.20 
Hungary 4.43 2.37 1.97 0.00 -6.36 -4.07 -2.99 0.03 -2.16 0.59 0.92 
Iceland 3.98 2.02 1.77 0.15 -4.82 -3.21 -2.26 0.18 -1.23 1.34 1.51 
Ireland 2.73 1.44 1.19 0.09 -6.55 -4.14 -3.03 0.01 -2.84 -0.19 0.03 
Italy 2.42 1.33 0.99 0.10 -6.65 -4.07 -3.02 -0.08 -2.96 -0.39 -0.21 
Latvia 5.05 2.97 1.98 -0.01 -6.04 -3.55 -3.30 0.06 -1.84 1.09 1.46 
Lithuania 4.70 2.51 2.11 0.00 -6.50 -4.04 -3.45 0.12 -2.30 0.69 1.06 
Malta 3.29 1.38 1.79 0.02 -5.62 -3.95 -2.16 0.05 -2.04 0.52 0.70 
Netherlands 3.47 2.12 1.21 0.15 -5.79 -3.43 -3.00 0.04 -2.01 0.59 0.81 
Norway 4.23 2.25 1.75 0.17 -5.14 -3.31 -2.55 0.19 -1.35 1.36 1.55 
Poland 4.46 2.71 1.67 0.03 -6.12 -3.59 -3.23 0.00 -1.99 0.84 1.13 
Portugal 2.89 1.40 1.38 0.07 -6.78 -4.32 -2.99 0.00 -2.89 -0.22 0.00 
Romania 4.19 2.27 1.71 0.10 -6.60 -4.09 -3.36 0.07 -2.53 0.29 0.63 
Slovakia 3.83 2.09 1.64 0.03 -6.29 -3.91 -3.03 -0.02 -2.34 0.32 0.61 
Slovenia 3.47 1.62 1.77 0.05 -6.13 -4.06 -2.67 0.02 -2.27 0.36 0.58 
Spain 3.34 1.78 1.45 0.07 -5.97 -3.79 -2.65 0.00 -2.17 0.45 0.62 
Sweden 2.71 1.63 1.02 0.05 -6.43 -3.83 -3.14 -0.07 -2.71 -0.12 0.09 
UK 3.16 1.79 1.26 0.13 -6.38 -3.96 -3.09 0.04 -2.53 0.15 0.38 
 
  
                                           
2 Scenario definitions were 2a: 100% healthy; 2b: 100% no smoking; 2c: 100% best BMI; 2d: 100% in 
healthiest category for alcohol consumption; 3a: 100% unhealthy; 3b: 100% smoking; 3c: 100% worst 
BMI; 3d: 100% most unhealthy category for alcohol consumption; 4: equal division; 5: country with median 
population health; 6: country with median health spending 
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Table 4.4: Changes in Healthy Life Years (years) by country and scenario3 
  2a 2b 2c 2d 3a 3b 3c 3d 4 5 6 
Austria 6.57 2.30 2.49 1.78 -14.78 -2.79 -7.53 -3.63 -3.96 -0.34 -0.72 
Belgium 6.48 2.20 2.66 1.74 -14.84 -3.18 -7.37 -3.39 -4.05 -0.28 -0.62 
Bulgaria 5.60 2.13 2.36 1.15 -9.82 -2.73 -5.23 -1.78 -2.44 0.38 0.33 
Croatia 7.84 2.36 3.43 2.12 -10.61 -2.49 -5.58 -2.43 -1.40 1.59 1.35 
Cyprus 6.55 2.01 2.82 1.80 -11.42 -2.44 -5.63 -2.67 -2.15 0.84 0.55 
Czech Republic 6.23 1.95 2.83 1.40 -12.96 -3.05 -6.15 -2.90 -3.33 -0.02 -0.26 
Denmark 7.02 3.20 2.81 1.18 -19.27 -4.02 -8.90 -4.89 -5.93 -1.04 -1.47 
Estonia 7.20 2.39 2.82 1.84 -12.66 -2.41 -6.37 -2.93 -2.80 0.60 0.32 
Finland 7.62 2.23 3.33 2.12 -16.37 -3.55 -7.85 -3.98 -4.25 0.00 -0.46 
France 5.95 2.16 2.42 1.47 -15.35 -2.97 -7.70 -3.85 -4.53 -0.84 -1.21 
Germany 6.68 2.31 2.57 1.82 -14.43 -2.94 -7.28 -3.34 -3.78 -0.12 -0.47 
Greece 5.81 1.81 2.53 1.39 -8.19 -1.77 -4.39 -1.97 -1.24 1.04 0.84 
Hungary 7.21 2.09 3.03 2.02 -10.69 -2.56 -5.66 -2.16 -1.85 1.08 0.88 
Iceland 7.31 2.49 3.94 0.97 -14.99 -3.32 -6.12 -3.94 -3.57 0.76 0.39 
Ireland 6.26 1.78 2.46 2.09 -14.05 -3.59 -6.83 -2.61 -3.85 -0.14 -0.42 
Italy 5.22 1.37 1.76 2.13 -12.34 -2.99 -6.71 -2.08 -3.45 -0.47 -0.74 
Latvia 8.06 2.73 3.21 1.96 -11.27 -2.06 -5.92 -2.43 -1.77 1.61 1.38 
Lithuania 7.00 2.21 3.01 1.62 -9.88 -2.45 -5.30 -1.82 -1.86 1.14 1.01 
Malta 6.20 1.44 3.16 1.55 -8.78 -2.96 -4.10 -1.55 -1.45 1.30 1.13 
Netherlands 6.70 2.50 2.77 1.48 -16.39 -3.07 -7.82 -4.34 -4.60 -0.57 -1.00 
Norway 7.28 2.91 3.70 0.75 -15.62 -3.53 -6.34 -4.00 -3.98 0.58 0.28 
Poland 7.45 2.48 2.75 2.07 -11.62 -2.47 -6.23 -2.23 -2.21 1.07 0.83 
Portugal 6.81 1.71 2.68 2.44 -13.12 -2.90 -7.07 -2.61 -2.99 0.36 0.00 
Romania 6.35 1.95 2.43 1.82 -10.51 -2.46 -5.81 -2.10 -2.38 0.42 0.23 
Slovakia 5.99 1.88 2.40 1.68 -11.92 -2.19 -5.75 -2.90 -2.76 0.19 -0.10 
Slovenia 7.65 2.20 3.42 1.96 -16.07 -3.36 -7.53 -4.24 -4.17 -0.08 -0.57 
Spain 7.33 2.08 2.91 2.29 -12.72 -2.65 -6.56 -2.62 -2.55 0.91 0.55 
Sweden 4.83 1.82 2.08 1.01 -15.88 -4.06 -7.27 -3.13 -5.41 -1.38 -1.64 
UK 6.68 2.16 2.74 1.96 -14.72 -3.48 -7.22 -3.22 -3.94 -0.04 -0.35 
 
  
                                           
3 Scenario definitions were 2a: 100% healthy; 2b: 100% no smoking; 2c: 100% best BMI; 2d: 100% in 
healthiest category for alcohol consumption; 3a: 100% unhealthy; 3b: 100% smoking; 3c: 100% worst 
BMI; 3d: 100% most unhealthy category for alcohol consumption; 4: equal division; 5: country with median 
population health; 6: country with median health spending 
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Table 4.5 Changes in Life Expectancy in Good Perceived Health (years) by country and 
scenario4 
 
2a 2b 2c 2d 3a 3b 3c 3d 4 5 6 
Austria 8.40 3.04 2.90 2.52 -19.31 -4.54 -11.16 -3.59 -4.65 -0.43 -0.89 
Belgium 8.69 3.04 3.44 2.40 -19.94 -5.22 -10.64 -1.89 -4.66 -0.25 -0.69 
Bulgaria 6.51 2.37 2.51 1.70 -11.96 -2.82 -6.86 7.66 -2.11 0.56 0.38 
Croatia 9.80 3.11 4.14 2.73 -14.14 -4.22 -7.59 -2.95 -1.50 2.03 1.75 
Cyprus 8.29 2.56 3.42 2.38 -14.12 -3.68 -7.37 2.00 -1.84 1.23 0.91 
Czech Republic 7.17 2.36 2.79 1.89 -15.91 -3.86 -8.92 5.41 -3.89 -0.35 -0.71 
Denmark 9.03 3.90 3.63 1.73 -24.53 -6.19 -13.52 -3.99 -7.25 -1.46 -2.09 
Estonia 9.14 3.11 3.07 2.55 -16.92 -4.17 -10.34 5.65 -4.20 0.44 -0.09 
Finland 8.19 2.50 3.49 2.29 -17.77 -4.76 -9.44 -6.19 -3.96 0.00 -0.41 
France 8.39 3.09 3.17 2.28 -20.86 -5.03 -11.88 0.30 -5.53 -0.93 -1.46 
Germany 9.31 3.21 3.38 2.68 -19.81 -5.12 -11.23 1.42 -4.75 -0.16 -0.68 
Greece 7.53 2.51 3.20 1.91 -11.49 -2.78 -6.05 1.67 -1.03 1.42 1.18 
Hungary 8.56 2.64 2.97 2.74 -13.05 -3.48 -7.77 6.94 -2.10 1.42 1.09 
Iceland 8.79 3.12 4.81 1.21 -20.34 -5.30 -9.09 -5.07 -4.23 0.63 0.16 
Ireland 7.77 2.39 3.08 2.66 -19.12 -5.67 -9.73 -4.45 -4.40 -0.12 -0.43 
Italy 7.41 2.05 2.20 3.20 -17.49 -4.60 -9.79 6.58 -4.06 -0.44 -0.84 
Latvia 9.94 3.59 3.12 2.69 -14.54 -3.31 -9.41 9.35 -2.86 1.66 1.14 
Lithuania 7.82 2.68 2.82 2.04 -13.30 -3.11 -8.15 12.10 -2.82 0.90 0.55 
Malta 9.83 2.39 4.46 2.92 -15.62 -4.53 9.41 12.58 -1.86 1.88 1.46 
Netherlands 7.98 3.08 3.31 1.80 -21.23 -5.22 -15.83 -9.66 -5.32 -0.77 -1.22 
Norway 8.70 3.44 4.55 0.98 -21.20 -5.54 -9.59 -5.14 -4.84 0.33 -0.05 
Poland 8.36 2.88 2.57 2.56 -14.48 -3.39 2.52 8.57 -2.90 0.89 0.50 
Portugal 8.81 2.59 2.57 3.53 -16.27 -4.65 3.54 10.04 -3.94 0.56 0.00 
Romania 6.79 2.18 2.48 2.03 -11.65 -3.22 -6.64 -0.62 -2.21 0.46 0.29 
Slovakia 7.22 2.30 2.67 2.07 -14.57 -3.76 -8.19 -2.73 -3.36 0.10 -0.22 
Slovenia 9.20 2.83 3.73 2.46 -19.03 -5.07 -9.74 -3.26 -4.93 -0.20 -0.78 
Spain 9.47 2.79 3.54 3.15 -16.67 -4.28 -5.69 0.35 -2.55 1.16 0.74 
Sweden 6.56 2.13 2.84 1.70 -23.57 -6.42 -6.14 -0.01 -7.19 -2.29 -2.77 
UK 8.22 2.80 3.47 2.35 -19.22 -5.45 -10.47 -4.63 -4.25 0.03 -0.32 
 
  
                                           
 
4 Scenario definitions were 2a: 100% healthy; 2b: 100% no smoking; 2c: 100% best BMI; 2d: 100% in 
healthiest category for alcohol consumption; 3a: 100% unhealthy; 3b: 100% smoking; 3c: 100% worst 
BMI; 3d: 100% most unhealthy category for alcohol consumption; 4: equal division; 5: country with median 
population health; 6: country with median health spending 
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Table 4.6: Changes in curative care spending per capita (€) by country and scenario4 
Country 2a 2b 2c 2d 3a 3b 3c 3d 4 5 6 
Austria 112 74 33 3 47 -6 24 -2 -54 15 19 
Belgium 89 67 16 3 38 -19 30 0 -41 14 17 
Bulgaria 28 26 1 0 28 -7 25 0 -8 4 6 
Croatia 51 41 5 1 37 -12 34 1 -27 0 5 
Cyprus 57 39 15 1 39 2 24 0 -20 13 14 
Czech Republic 57 38 16 1 24 -10 17 0 -30 4 6 
Denmark 156 107 40 5 38 12 -10 1 -58 29 35 
Estonia 51 35 13 0 19 -5 11 0 -16 9 12 
Finland 296 152 145 1 -226 -120 -124 0 -47 0 3 
France 116 80 29 4 44 -19 31 0 -52 17 21 
Germany 111 89 10 3 45 -32 42 -2 -47 15 18 
Greece 74 55 15 1 44 2 25 1 -18 22 23 
Hungary 54 49 1 0 41 -28 53 1 -13 9 13 
Iceland 82 49 25 4 47 8 21 4 -13 24 28 
Ireland 99 55 37 3 14 -10 -2 1 -75 -3 1 
Italy 70 39 26 3 18 -2 5 -2 -56 -4 -2 
Latvia 30 24 5 0 14 -3 10 1 -5 8 9 
Lithuania 55 38 13 0 16 -14 13 2 -17 9 12 
Malta 47 30 13 0 30 -12 28 1 -28 4 6 
Netherlands 133 81 42 6 42 26 -10 2 -49 26 30 
Norway 172 102 54 8 71 18 17 9 -32 49 59 
Poland 50 39 8 0 27 -7 22 0 -7 14 16 
Portugal 59 40 14 2 24 -31 34 0 -45 -3 0 
Romania 34 22 8 1 15 -6 12 1 -11 4 6 
Slovakia 55 53 -3 1 64 -35 78 -1 -9 13 16 
Slovenia 72 48 19 1 39 -27 45 1 -32 10 12 
Spain 80 52 21 2 40 -7 30 0 -33 15 16 
Sweden 103 64 34 2 25 6 -4 -3 -70 2 5 
UK 73 55 12 4 33 -17 26 1 -42 6 9 
 
Table 4.7 Elasticity of population health to curative care spending in different scenarios (health 
spending coefficients from regression analyses) 
 
LE HLY LEGPH 
Baseline 0.059 0.055 0.138 
2a 0.047 0.045 0.129 
2b 0.054 0.055 0.139 
2c 0.053 0.051 0.139 
2d 0.060 0.051 0.133 
3a 0.066 -0.010 0.050 
3b 0.064 0.048 0.122 
3c 0.064 0.033 0.094 
3d 0.059 0.036 0.030 
4 0.060 0.027 0.109 
5 0.056 0.038 0.118 
6 0.055 0.036 0.117 
 
Changes in health system efficiency 
First, Figure 4.11 to Figure 4.13 present scatter plots following the adjustment 
scenarios 2b-2d.  The figures present similar pictures as in Figure 4.1 (unadjusted) 
and Figure 4.7 to Figure 4.9 (adjusted using scenario 1). The figures show that the 
effect of a hypothetical change in lifestyle may differ between lifestyle factors. 
Scenario 2b, i.e. 100% of the population in the healthiest category for smoking, has 
the largest effect on population health (i.e. upward shift in the health production 
function). At the same time, changing all populations towards 100% in the healthiest 
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category for alcohol consumption generates a limited shift only (Figure 4.13). It shows 
that the impact of changing alcohol prevalences was limited in terms of both health 
spending and health outcomes. This partly reflects the relatively small odds ratios for 
alcohol, as they were estimated from the individual level data, which were self-
reported. The total changes are affected by the combined result of morbidity and 
mortality risks for alcohol. While the self-reported data suit well to the prevalence 
numbers (also self-reported), they do have their drawback and some caution in the 
interpretation is warranted.  
The figures also show that those countries under the curve in the unadjusted scenario 
(e.g. LT, HU, SK, BE, AT, DE, DK in Figure 4.11) all remain under the curve in the 
adjusted scenario. The same holds true for most countries above the curve. Which 
implies that standardization according to the scenarios has a small impact on 
countries’ relative efficiency.  
 
 
 
Figure 4.11 The association between curative care spending and life expectancy in good 
perceived health, unadjusted and adjusted for lifestyle behaviour (scenario 2b - 100% in 
healthiest category for smoking) 
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Figure 4.12 The association between curative care spending and life expectancy in good 
perceived health, unadjusted and adjusted for lifestyle behaviour (scenario 2c - 100% in 
healthiest category for BMI) 
AT
BE
BG
CY
CZ
DE
DK
EE
EL
ES
FI
FR
HR
HU
IE
IS IT
LTLV
MT NL
NO
PL
PT
RO
SE
SI
SK
UK
AT
BE
BG
CY
CZ
DE
DK
EE
EL
ES
FI
FR
HR
HU
IE
IS
IT
LT
LV
MT
NL
NO
PL
PT
RO
SE
SI
SK
UK
7
0
7
5
8
0
8
5
lif
e
 e
x
p
e
c
ta
n
c
y
500 1000 1500 2000 2500 3000
curative care spending per capita
Unadjusted Adjusted
Unadjusted Adjusted
    Final report MACELI 
 
 
December, 2014  
 62 
 
Figure 4.13 The association between curative care spending and life expectancy in good 
perceived health, unadjusted and adjusted for lifestyle behaviour (scenario 2d - 100% in 
healthiest category for alcohol). 
 
4.4 Additional scenarios  
Additional scenarios with disease modelling 
In the additional scenarios, as described in section 2.9, we used dynamic models to 
investigate the impact of changes in lifestyle on disease prevalence, health outcomes 
and health spending over time. The analyses were performed using Dutch data. The 
analyses can only change one lifestyle factor at a time. Hence, the main analysis 
covers scenario 1 in three versions (each lifestyles shifts to its best observed value at 
all ages). They also include scenarios 2b-2d, in which the entire population moves for 
100% to the most healthy lifestyle category at baseline, for smoking, BMI and alcohol 
use respectively. These two scenarios are then compared to the reference scenario. 
Below the mechanisms at stake are explained for the case of smoking for scenario 1b 
and scenario 2b. That is, at the start of the simulation period, the entire population 
shifts to a more healthy smoking behaviour, one that reflects best practice at each age 
throughout the set of countries considered (1b), or one that reflects the most healthy 
solution with only never smokers. Similar figures for BMI scenarios and alcohol 
scenarios are presented.  
  
Reducing the prevalence of smoking has a clear impact on the prevalence of smoking-
related diseases. Figure 4.14 illustrates this effect for lung cancer. The blue line refers 
to the reference scenario. The other two lines show a decline in the prevalence of lung 
cancer for scenario 1 and scenario 2, demonstrating a bigger effect for scenario 2. 
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Figure 4.14: The number of persons with lung cancer in the reference scenario (lifestyle 
prevalence as observed), scenario 1 (“best of all for smoking”), and scenario 2 (100% in 
healthiest smoking category) 
 
These prevalence figures differ between diseases as the impact of smoking varies from 
one disease to another. Figure 4.15 shows what happens with the prevalence of 
Chronic Obstructive Pulmonary Disease (COPD) over time where the decrease in 
smoking prevalence leads to an apparent decrease in the prevalence of COPD across 
all years. Similar results are obtained for other smoking related diseases such as 
ischaemic heart disease (IHD). (Figure 4.16).  
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Figure 4.15 The number of persons with COPD in the reference scenario (lifestyle prevalence as 
observed), scenario 1 (“best of all for smoking”), and scenario 2 (100% in healthiest smoking 
category) 
 
As mortality and morbidity from smoking-related diseases decline, the population lives 
longer. Figure 4.17 illustrates this, showing an increase in the size of the population 
over time in scenario 1 and 2. As a result the number of persons with chronic diseases 
not related to smoking will rise slightly.(Figure 4.18)   
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Figure 4.16: The number of persons with IHD in the reference scenario (lifestyle prevalence as 
observed), scenario 1 (“best of all for smoking”), and scenario 2 (100% in healthiest smoking 
category), for the Netherlands, base year 2010. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.17 The total population in the reference scenario (lifestyle prevalence as observed), 
scenario 1 (“best of all for smoking”), and scenario 2 (100% in healthiest smoking category) 
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Figure 4.18: The number of persons with Diabetes in the reference scenario (lifestyle prevalence 
as observed), scenario 1 (“best of all for smoking”), and scenario 2 (100% in healthiest smoking 
category), for the Netherlands, base year 2010 
 
Finally, effects on health care spending are shown in Figure 4.19. The figure shows the 
difference (as a percentage of 2014 health care expenditure) in health spending for an 
intervention scenario compared to a scenario that is extrapolating spending based on 
2014 prevalence. In the intervention scenarios a lower smoking prevalence results in 
different levels of spending (and less smoking-related diseases). The figure shows the 
effects on total spending and on the costs of smoking-related disease and all other 
diseases separately. The costs of care for smoking related diseases decline, and the 
costs of all other diseases increase. It can be seen that initial savings peak about 5 
years after the reference year, while a break-even point would be obtained in 21 
years. Over the entire period, health care expenditures increase with 7.4% in the 
intervention scenario compared to the reference scenario. The latter difference was 
calculated by adding undiscounted spending over the entire time horizon, weighing 
costs in each period equally. Figure 4.20 shows the difference in health spending for a 
cohort of 50-years old in euros rather than percentages. In this cohort of elder people, 
savings are more pronounced than in the total population and the break-even point is 
further into the future.  
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Figure 4.19: Changes in health spending when everyone quits smoking in current population 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.20: Changes in health spending when everyone quits smoking in current elderly 
population 
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For BMI, the pattern is more or less similar, but the effect on the total population 
numbers is smaller, resulting in less pronounced increases in diseases unrelated to 
BMI. Please note that in the figures below disease prevalence is expressed as a 
percentage, rather than in absolute numbers.  
 
 
  
Figure 4.22: The total population in the reference scenario (lifestyle prevalence as observed), scenario 1 
(“best of all for BMI”), and scenario 2 (100% in healthiest BMI category) 
Figure 4.21 Effects of two scenarios concerning BMI (scenario 1, best of all and scenario 2, all in most 
healthy BMI category) on prevalence of ischemic heart disease, for the Netherlands, baseyear 2010. 
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Figure 4.23: Effects of two scenarios concerning BMI (scenario 1, best of all and scenario 2, all 
in most healthy BMI category) on prevalence of diabetes, for the Netherlands, baseyear 2010. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.24: Effects of two scenarios concerning BMI (scenario 1, best of all and scenario 2, all 
in most healthy BMI category) on prevalence of colorectal cancer, for the Netherlands, baseyear 
2010. 
 
For lung cancer, in scenarios with improved BMI prevalence rises because of an older 
population.  
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Figure 4.25: Effects of two scenarios concerning BMI (scenario 1, best of all and scenario 2, all 
in most healthy BMI category) on prevalence of lung cancer, for the Netherlands, baseyear 
2010. 
 
The net effect on health spending of an improved BMI in the population over time 
reflects first net savings and then increased costs. The latter are due to the population 
getting a longer life expectancy as a result of a healthier lifestyle which comes with an 
increase in diseases related to old age.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.26 Changes in health spending “All positive” scenario compared to current practice, 
entire population, scenario concerning better BMI. 
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For alcohol use, the risks were smallest and as a result, effects on total population 
numbers from the scenarios were hardly perceptible. (Figure 4.31) The net effect on 
total spending showed savings for the entire time horizon. Hence, for alcohol the 
effects on life expectancy are too small to imply an increase in spending from costs in 
life years gained.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 4.27: Effects of two alcohol use scenarios (scenario 1, best of all and scenario 2, all in 
most healthy alcohol use category) on total population numbers, for the Netherlands, baseyear 
2010.  
Figure 4.28: Effects of two alcohol use scenarios (scenario 1, best of all and scenario 2, 
all in most healthy alcohol use category) on prevalence of ischemic heart disease, for the 
Netherlands, baseyear 2010. 
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Figure 4.30: Effects of two alcohol use scenarios (scenario 1, best of all and scenario 2, all in 
most healthy alcohol use category) on prevalence of oesophagus cancer, for the Netherlands, 
baseyear 2010. 
 
 
Figure 4.31: Effects of two alcohol use scenarios (scenario 1, best of all and scenario 2, all in 
most healthy alcohol use category) on prevalence of colorectal cancer, for the Netherlands, 
baseyear 2010. 
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Figure 4.32: Effects of two alcohol use scenarios (scenario 1, best of all and scenario 2, all in 
most healthy alcohol use category) on prevalence of diabetes, for the Netherlands, baseyear 
2010. 
 
 
 
Figure 4.33:  Changes in health spending “All positive” scenario compared to current practice, 
entire population, scenario concerning alcohol use.  
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Table 4.8 demonstrates the estimated years in which the savings in risk factor related 
disease costs equal the costs of all other diseases. For smoking this equals 2030 
(assuming immediate risk reduction) or 2023 (assuming graduate risk reduction). For 
BMI this break-even point occurs later, because it has a smaller effect on mortality. 
Consequently, cost increases related to the greater use of care in longer lives are 
smaller. For alcohol small net savings result over the entire time horizon. 
  
Table 4.8: Cost results of dynamic life table analysis 
 
Table 4.9: Overview of results for disease specific scenarios on health spending  
 BMI Alcohol Smoking  
(immediate risk 
reduction)  
Smoking  
(gradual risk 
reduction)  
“Best of all” scenario compared to current 
practice scenario 
    
%  Costs 0.5 -0.1 1.8 4.0 
Year in which savings in costs of risk factor related 
diseases equal additional costs of ‘other diseases’  
2036 NA* 2030 2023 
Year in which cumulative savings in risk factor 
related diseases are outweighed by additional costs 
of ‘other diseases’  
2047 NA* 2039 2027 
“All positive” scenario  compared to current 
practice 
    
% Costs 1.4 -0.6 3.3 7.4 
Year in which savings in additional costs of risk 
factor related diseases equal costs of ‘other 
diseases’  
2038 NA* 2027 2024 
Year in which cumulative savings in risk factor 
related diseases are outweighed by additional costs 
of ‘other diseases’  
2049 NA* 2035 2029 
*Savings in health care costs of alcohol related diseases outweigh the additional costs caused by other 
diseases in life years gained. No discounting was applied on future costs.  
 
 
Conclusions concerning disease specific analyses  
These additional analyses reinforce the notion that a healthier lifestyle (less smoking, 
a lower BMI or more sensible use of alcohol) will pay off in terms of substantial health 
benefits. Regarding health spending results are less clear-cut. Initially savings are 
obtained from a reduction in lifestyle related diseases. When the population then lives 
longer as a result of the healthier lifestyle, health spending may rise from increased 
spending on age related diseases. It depends both on the lifestyle and demography of 
the population as well as on methodological choices such as time horizon and possible 
discounting of future costs what is the overall net effect on spending.   
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5. Results in perspective, qualitative aspects 
 
Analysing health system efficiency is complicated: the inputs and outputs / outcomes 
can be quantified in many different ways and the high number of variables that affect 
outcomes form a cluster of interacting factors related to individuals, their living 
environment and the health system at regional and national level.   
The MACELI-study contributes to the knowledge on health systems efficiency and, 
more specifically, sheds a light on the interaction between life style, inputs and 
outcomes. The current chapter puts these results in perspective. It contains reflections 
on how the project outcomes fit in the overall complex picture of health system 
efficiency. Furthermore, we discuss some methodological problems and their 
consequences for the interpretation of the results.  
5.1 What is health system efficiency?  
Several definitions and types of efficiency are found in the literature, such as 
technical, productive and allocative efficiency (Palmer and Torgerson, 1999). Most 
definitions refer to ‘value for money’ or, more generally, can be traced back to the 
result of: 
 
 𝑜𝑢𝑡𝑐𝑜𝑚𝑒𝑠 𝑖𝑛𝑝𝑢𝑡𝑠⁄  
 
These rather theoretical concepts raise questions about what this means in real life 
and for real health policy. First, we will focus on the numerator: what should health 
systems produce? Is production the only relevant objective of a health system? 
 
What health systems produce (outputs) 
Most European countries are facing challenges concerning health such as rising 
expenditures, aging populations, an increasing prevalence of chronic illnesses and 
economic recession. These challenges have accelerated the interest for the 
performance of the “health system”.  They have contributed to the perception of the 
national organization of everything related to health and healthcare as a ‘system’. 
Many European countries made system reforms, and others are still in the middle of 
such reforms. Monitoring the functioning of health systems and evaluating the results 
of system reforms require an explication of goals or objectives of the system: what 
should the system produce? An obvious answer to that question is ‘health’. However, 
this concept contains several dimensions and its definition is heavily debated. 
Moreover, health is not the only relevant output of health systems.    
 
WHO, being one of the first explicitly conceptualizing the objectives of health systems 
distinguished the following key objectives (WHO, 2000):  
- the level of population health,  
- inequality in the distribution of health,  
- the level of health system responsiveness,  
- inequality in the distribution of responsiveness,  
- fairness in financial contributions    
CIHI uses a comparable concept for health system outcomes: “the improvement of the 
level and distribution of health in the population, the health system’s responsiveness 
to the needs and demands of Canadians and value for money to ensure health system 
sustainability” (CIHI, 2013). 
OECD defines outcomes of the system as health status ”how healthy are the citizens of 
the OECD member states?”. Health status is further operationalized as health 
conditions, human function and quality of life, life expectancy and well-being and 
mortality”.  
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In contrast to these positively formulated outcomes, Donabedian (1980) distinguished 
five undesired outcomes in his standard work on quality of care, the 5ds: 
Dissatisfaction, Discomfort, Disability, Disease, Death.    
Many other (slightly) different definitions can be found in the literature; however, 
providing an exhaustive overview is unnecessary to conclude that what health systems 
should produce covers several dimensions and that not only the mean value counts, 
but also the distribution of the outcomes over the population. For practical reasons, 
only a few outcomes of health systems were used in the MACELI-study: life 
expectancy, Healthy Life Years and life expectancy in good self-perceived health. 
Other relevant outcomes, such as disparities, responsiveness or financial protection 
were not incorporated.  
   
What we put into the system (Inputs) 
Measuring inputs seems more straightforward than measuring outputs. In the pathway 
from inputs to outputs, financial inputs form the first step. However, money first 
needs to be spend on inputs that can really be used to ‘produce’ healthcare or to 
create the conditions for this. Such inputs are for instance human resources, medical 
education, pharmaceuticals, materials, buildings, equipment, guidelines and 
information systems (Massoud et al. 2001). The system of health accounts provides 
an international definition and enables to compare countries with regard to their 
expenses on healthcare. This definition only include goods and services that are used 
up during the accounting period (year) and not capital goods. Including the latter one 
would complicate the comparison between countries.   
 
Confounding variables 
Although health systems contribute to the health of the population, it is important to 
keep in mind that besides the inputs and output that we discussed above many other 
(confounding) factors exist. A major share of the variation in health both within and 
between countries is determined by factors outside the health system. Such factors 
can roughly be grouped into biological (genetic) factors, economic, social, cultural and 
contextual factors. Some of these factors may have a direct effect on health (e.g. air 
pollution, traffic safety, drinking water facilities) while others affect health via behavior 
(cultural differences in eating and drinking habits, unemployment). Other factors, such 
as educational attainment have both direct and indirect effects. The economic 
situation of a country determines the amount of money that can be devoted to for 
example health, education and social security. Investments in other sectors than 
prevention and health care may contribute to the health of the population: for 
instance investments in housing, traffic, education and labor conditions. For our study, 
this means that an effect of confounding variables cannot be ruled out. Educational 
level and national income were included in our models. The results, as presented in 
4.1, pointed out that their effects could not be ignored. Therefore, these variables 
were also included in the efficiency models. 
5.2 The boundaries of the health system  
When comparing health systems, an essential problem that needs to be solved is 
determining where the boundaries of health systems lie. Obviously, hospital care will 
be part of the health system in all reasonable definitions. However, a health system 
can be defined very broadly or very narrowly. A very narrow definition may just cover 
curative healthcare while a very broad definition may also include regulation of the 
use of seatbelts, water treatment and realization of bicycle tracks to promote physical 
exercise (Murray and Frank, 2000). Papanicolas and Smith (2012) stated that there is 
no right answer to the question where the boundaries of a health system lie in 
general, as “there are sound reasons for promoting the use of both wider and 
narrower boundaries. Narrow boundaries are better suited to holding stakeholders 
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accountable, while broader boundaries are better for a more holistic understanding of 
determinants”. Figure 5.1 summarizes advantages and disadvantages of broad and 
narrow definitions.   
  
 
Figure 5.1: Performance measurement implications of setting health system boundaries 
(source: Papanicolas and Smith, 2012) 
   
In our study, a relatively narrow definition was used. We focused on investments in 
curative care (hospital care, ambulatory care and outpatient medication, see 2.2) as 
input variable. Lifestyle behaviour was considered an exogenous variable in the model. 
The idea behind that approach is that the outcomes of health systems may differ 
because in one system suppliers have to deal with a population with an unhealthier 
lifestyle. Lifestyle behaviour is considered a factor beyond the reach of the health 
system. Difference in lifestyle may confound the relation between health care 
spending and health outcomes.  
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From a methodological point of view, this simplification of reality is practical and the 
only way to compare systems controlling for life style and necessary to model 
scenarios in which people would have a healthier life style. Nevertheless, from a public 
health policy perspective, it is very plausible to look at life style as an intermediary 
variable, rather than a confounder. In other words: one of the aims or instrumental 
goals of health systems is promoting a healthy life style. Not only public health 
workers, but also doctors work on prevention and may motivate their patients for 
instance, to stop smoking. Investments in prevention may contribute to better health 
outcomes.  See Figure 5.3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Earlier (in 5.1) we discussed that health is influenced by much more factors than 
factors belonging to the health system. The same is true for spending. It seems logical 
that a higher need for care among the population results in a higher demand and so 
will generate more supply that needs to be financed. Although this is partly true, a 
quick look at health budgets of countries shows that the countries with the highest 
spending are not the countries with the most unhealthy population but rather the most 
wealthy countries (e.g. Norway, Switzerland). Like in other markets, demand will rise 
with supply as long as people can afford it. We will further discuss this in the next 
section.        
 
Although the possibilities to influence life style could not be incorporated in the 
models, this topic is addressed in chapter 6, in which we provide an overview of 
options to effectively and efficiently influence life style. 
 
5.3 Diminishing returns? 
The relation between spending and health outcomes has often been characterized as 
one of diminishing marginal returns. This means that beyond a certain point, 
additional inputs produce lower returns. A typical example of such a relation is shown 
in figure 4 which was also shown in chapter 2. The figure shows a clear difference in 
outcomes between countries that spend 1000 euro per capita or less and those that 
Outcomes Spending Health care 
(curative care) 
Lifestyle 
Spending 
Healthcare,  
curative care, 
secondary 
prevention,  
health promotion 
 
 
Lifestyle 
Outcomes 
Figure 5.2: Schematic representation of the relations between spending, healthcare, life style 
and outcomes, using narrow definition of health system.   
Figure 5.3: Schematic representation of the relations between spending, healthcare, 
prevention, life style and outcomes, using a broader definition of health system 
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spend 1500 euro or more. Above 1500 euro, however, extra euros invested do seem 
to be much less worth in terms of generating better outcomes. Norway for instance, 
shows a slightly lower life expectancy than Spain, while spending almost 50% more. 
Note that this figure is for life expectancy, for quality adjusted life expectancy (HLY 
and LEPGPH) the relations are less extreme but similar.     
 
 
 
Figure 5.4:  the association between curative spending and life expectancy 
 
Also in relatively rich and wealthy countries, debates about cost containment are 
omnipresent. The ‘law of diminishing returns’ can be helpful in rationalizing 
discussions about prioritization, cost containment and, for instance, coverage of health 
insurance packages. Since every euro can only be spent once, in the policy debates 
questions arise like: “how much are we prepared to pay for a new treatment that adds 
two months to the life of a patient suffering from cancer?” Or, should interventions 
that add relatively little in terms of life years or quality of life be included in the basic 
health insurance package? Even when interventions and technologies already are very 
effective, both professions and industry will continue to innovate. Beyond a certain 
point, further improvement requires a larger and larger investment (Learmonth, 2006; 
Mold et al., 2010). Innovation in medical treatment and technology is essential, but 
also one of the main drivers of rising expenditures.  
 
On the other hand, as discussed above, health systems have several aims. Some of 
these aims are important and do have a societal impact, but may not directly pay off 
in terms of life years or preventing disability. They offer for instance a reduction of 
dissatisfaction and discomfort. It seems plausible that a shift in focus of health policy 
will take place when the system is relatively well-functioning. A certain ‘hierarchy of 
needs’ not only applies to individuals but also to health systems: fighting infectious 
diseases and neonatal mortality pays off significantly in terms of life years. When such 
basic factors are relatively well organized, policy makers will start investing in 
responsiveness, patient experiences, privacy, better financial protection, etc. Although 
such things may not generate returns in terms of life years, they fulfil the expectations 
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of tax payers and insured and they may contribute to well-being and satisfaction. In 
relation to figure 4, this means that countries that spend more than 1500 euros per 
capita are not necessarily wasting their money. Another possible explanation could be 
that a single “health production function” does not exist and countries are actually on 
different curves.  
 
To summarize, the overall position in figures as displayed here provides little concrete 
indication for improving health policy but it may be a starting point to reflect on large 
budgetary posts and how this relates to the needs of the population.  
5.4 Time lags. 
Time lags exist between health spending and health outcomes, which means that 
current health may have been affected by past investments. The fact that our 
analyses are mainly based on cross sectional correlations is a methodological 
limitation that is discussed in chapter 7. 
Especially when looking at developments of health systems efficiency over time, it is 
important to pay attention to the economic recession that started in 2008 and affected 
almost all European countries, although some more than others. A recent analysis of 
the OECD showed that until 2008, health expenditures rose in all European countries. 
After 20008, this changed dramatically: approximately one third of the countries had 
decreasing expenditures, another third still had increasing expenditures but this 
increase levelled off. Morgan and Astolfi (2014) suggested that for many countries, 
these decreasing expenditures resulted from drastic cut-backs in prevention. This 
conclusion might be criticized given the relatively low part of prevention expenditure 
related to lifestyle and the relatively low part of total expenditure related to 
prevention. Given these small budgets to start with, the overall impact of the 
recession on lifestyle prevention should not be exaggerated. Nevertheless when 
already small budgets are put under further pressure, effective policy may be seriously 
hampered.   
In terms of the fraction outcomes/inputs as shown in 1.2, reductions in health 
expenditure result in a seemingly steep rise in health system efficiency. However, 
health expenditures respond much quicker to economic developments than e.g. life 
expectancy and cut-backs on prevention or other important parts of the system, may 
generate their adverse effects in the future.     
5.5 Choice of outcome measures.  
In this study, three outcome mesures were used: life expectancy, Healthy Life Years 
and life expectancy in good poor self-perceived health. As was mentioned under 5.1, 
this means that we only cover a part of the possible outputs of health systems. Partly, 
this was done for practical reasons: it would not be feasible to cover the full range of 
outcomes. Moreover, some outcomes show more variations in defintions and are more 
difficult to measure in a standardized way. In the terminology of Donabedian, our 
measures mainly refer to death, disease and disability. In terms of healthcare, the 
outcome measures represent results of curative care rather than long term and social 
care. Long term care focusses primarily on living with illness and/or disability rather 
than curing diseases and rather aims to contribute to quality of life and wellbeing 
rather than prolonging life.   
5.6 Lifestyle clustering.  
In the models presented in this study and in many epidemiological studies, BMI, 
smoking and alcohol are treated as independent risk factors. Such factors are not 
randomly spread over the population but often cluster within people and families 
(Schuit et al, 2002; Conry et al., 2011).  
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A study in England showed that the part of the population that engaged in multiple 
unhealthy behaviors decreased over time but this was mainly due to a decrease 
among the higher socio-economic groups and the higher educated. People with no 
qualifications were over five times as likely to engage in at least four unhealthy 
behaviours (smoking, excessive alcohol use, poor diet, and low levels of physical 
activity) (Buck and Frosini, 2012).   
The Kings fund concluded that interventions to promote a healthy life style should 
adopt a more holistic approach, moving beyond policies in which the focus is on  
individual lifestyle risks one at a time, as this ignores how behaviours are actually 
distributed in the population (Buck and Frosini, 2012).  
5.7 Conclusion.  
The MACELI-study contributes to the knowledge about efficiency of health systems 
and the importance of life style in this relation. One main conclusion is that a healthy 
lifestyle clearly contributes to better health outcomes. The effect of lifestyle on health 
spending is less clear and seems to disappear when overall wealth (GDP per capita) is 
taken into account.  
The study is a step in improving the comparison of efficiency between health systems. 
However, it should be kept in mind that the results only cover a limited part of 
relevant aims of health systems and that we did not touch upon major issues as 
responsiveness and disparities. Investments in the health system may generate 
valuable returns also when these cannot be expressed in terms of e.g. life expectancy. 
In this study, life style was treated as a factor to control for when comparing health 
systems. This was a pragmatic choice that enables us to compare efficiency taking into 
account intrinsic differences in population conditions between countries. The models 
contribute to existing knowledge by separating factors that can be more directly 
influenced by health services from public health factors.  
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6. Results in perspective, lifestyle and options for 
healthy lifestyle 
6.1 Lifestyle behaviour in European countries.  
We compiled data regarding alcohol consumption, smoking and overweight/obesity for 
each country, consisting of self-reported lifestyle behaviour. Figure 2.1 to Figure 2.3 
summarize the information on lifestyle prevalence. Figure 2.1 shows the differences 
between countries in terms of BMI. We also considered differences between males and 
female. The percentage non-overweight (BMI<25) was lowest for females in Malta and 
Eastern European countries such as Croatia, Latvia, Lithuania and Hungary. For males, 
similar countries appeared at the bottom, except for Latvia. Much greater between-
country variation was found for smoking.(Figure 2.3)  The percentage never smoked 
varied between around 25% for males in Latvia and more than 75% for females in 
Portugal and the Czech Republic.  
With regard to alcohol consumption (Figure 2.2), the data show large differences 
between males and females in most countries. The percentage of the population 
reporting heavy drinking was rather small. This is most probably, at least partly, due 
to underreporting. Since the data sources used to calculate Odds Ratios use similar 
questions based on self-reporting, the estimated prevalence is consistent with the 
Odds Ratios used for standardization.    
The prevalences for each lifestyle variable and category were combined into 36 
categories5 indicating the prevalence of combined smoking, drinking and overweight.  
 
6.2 Results literature review.  
The literature review was performed to gain insight into the (cost)-effectiveness of 
interventions aimed at lifestyle improvement, which may provide lessons how to 
achieve lifestyle changes as hypothesized in the scenario analyses. The searches 
resulted in 69, 121 and 83 cost-effectiveness studies on interventions aiming at more 
healthy use of alcohol, at tobacco control and at a more healthy weight respectively. 
The studies were sorted on country and outcome measure, this could be done for 63 
(alcohol), 112 (tobacco) and 75 studies (weight). For alcohol, 25 studies were 
performed in the US, while 14 were performed in other countries outside Europe and 2 
were reviews. The European studies consisted of 11 studies presenting costs per 
QALY, DALY or life year gained, 2 cost studies and 9 presenting varying alcohol related 
outcomes, like number of drinks. For smoking 47 studies were performed in the US, 
while 14 were performed in other countries outside Europe and 3 were reviews. The 
European studies consisted of 38 studies presenting costs per QALY, DALY, or life year 
gained and 11 presenting costs per quitter. For overweight, 16 studies were 
performed in the US, while 18 were performed in other countries outside Europe and 6 
were reviews. The European studies or reviews consisted of 20 studies presenting 
costs per QALY, DALY, or life year gained and 6 presenting costs per weight related 
outcome, like kg weight loss, or change in BMI.  
 
All non-European studies were excluded, since organization and costs of interventions 
can be highly variable throughout different countries, due to differences in health care 
system.  
Considering type of policy interventions, the majority concerned interventions aiming 
at individuals. These consisted of some form of counseling or a pharmacotherapeutical 
                                           
5 Combining 4 categories for alcohol use, 3 BMI categories and 3 categories for 
smoking generate 4*3*3=36 combination categories.  
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intervention or a combination of these. For smoking these were 33 studies. The 
remaining 16 studies consisted of evaluations of prevention (trying to prevent young 
people form starting to smoke), taxation, reimbursement of cessation help, smoking 
bans and mass media campaigns.  
For overweight, all studies could be classified as evaluating individual based 
interventions, either medication (11 studies) or counseling (13 studies) or a 
combination of both (2 studies). 4 Studies aimed at children using counseling and 
could be considered preventive.   
 
6.3 Spending on prevention.  
Figure 6.4 and 6.5 underneath show expenditures on prevention and public health 
services across European countries, both in absolute terms and as a percentage of 
GDP. According to the definitions of the System of Health Accounts, the figures 
comprise services designed to enhance the health status of the population as distinct 
from the curative services, which repair health dysfunction (OECD, 2011). Typical 
services are vaccination campaigns and programmes. The following six functions are 
distinguished: 
 Maternal and child health; family planning and counselling 
 School health services 
 Prevention of communicable diseases 
 Prevention of non-communicable diseases 
 Occupational health care 
 All other miscellaneous public health services 
  
Using the SHA definitions implies that care should be taken in interpreting these 
numbers, because several preventive services will be attributed to services under 
curative care. Differences in the definition and organization of prevention programmes 
between countries may affect these figures. Given that prevention aiming at a 
healthier lifestyle will only comprise a small percentage of these outlays, it is not really 
possible to link the numbers in the figures below to lifestyle outcomes for the different 
countries. To dive further into the issue, we tried to find information for each lifestyle 
factor separately.  
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Figure 6.1: Expenditures on prevention and public health services per inhabitant in Purchasing 
Power Standard, 2010 or nearest year available (Source: Eurostat). 
 
 
Figure 6.2: Expenditures on prevention and public health services as percentage of total health 
expenditures, 2010 or nearest year available (Source: Eurostat). 
 
Tobacco 
Information on tobacco policy can be found in reports by Joossens and Raw (Joossens 
2006; Joossens 2014). These authors regularly investigated all policy regarding 
tobacco control in the EU member states and scored the stringency of these policies, 
using an elaborate score function. In total 100 points may be obtained for a country 
that applies all policy options considered in their most stringent form. The tables  
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below list the scores as obtained in 2013, together with information on budgets for 
tobacco control in the various countries (both based on Joossens 2014) and their 
smoking prevalence as obtained from the Eurobarometer data. By ordering and 
grouping countries according to policy score, budget for tobacco control, and smoking 
prevalence, it can be seen that some countries have low prevalence despite relatively 
mild policies (PT, NL), while others have stringent policies and low prevalence (ICE, 
NO). Information was not available for all countries. It must be stressed that 
estimating budgets in a consistent way was probably a very hard job. Also some 
countries with low prevalence are those for which we could not use the 
EuroBarometer, and had to rely on alternative sources.   
In summary, these figures do given an indication, but in general no direct link exists 
between current spending and current smoking prevalence. What would be required to 
investigate this further would be a time series of budgets and a time series of 
prevalence, to see whether stringent policy pays off over time in terms of prevalence 
reductions.  
 
Table 6.1: Countries ordered by policy score (source Joossens 2014, Eurobarometer 2012) 
 
 country Score (100 max) Budget ppp € 2012 Prevalence % 15+ former smokers 
UK 74 0,35 27 26 
IE 70 0,14 29 19 
Ice 66 1,63 13,9 32 
NO 61 0,45 16   
FR 57 0,12 28 24 
ES 56 0,1 33 22 
MT 56   27 17 
FI 55 0,36 25 22 
SE 48 0,06 13 30 
HU 48 0,008 32 15 
NL 47 0,09 24 31 
BE 47 0,23 27 20 
IT 46 0,21 24 13 
DK 46 0,23 26 31 
BG 46 na 36 16 
RO 44 0,04 30 12 
SI 43 0,06 28 19 
EE 43 0,05 26 21 
PL 43 0,01 32 20 
LV 41 0,002 36 16 
PT 41 na 23 15 
HR 40 0,007     
SK 39 na 23 22 
LU 37 0,06 27 22 
LT 35 0,007 30 15 
EL 35 na 40 16 
CZ 34 na 29 17 
DE 32 na 26 26 
AT 31 0,06 33 20 
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Table 6.2: countries ordered by budget (source Joossens 2014, Eurobarometer 2012) 
 
country Score (max 100) Budget ppp € 2012 Current Smokers (% 15+) former smokers 
Ice 66 1,63 13,9 32 
NO 61 0,45 16   
FI 55 0,36 25 22 
UK 74 0,35 27 26 
BE 47 0,23 27 20 
DK 46 0,23 26 31 
IT 46 0,21 24 13 
IE 70 0,14 29 19 
FR 57 0,12 28 24 
ES 56 0,1 33 22 
NL 47 0,09 24 31 
SE 48 0,06 13 30 
SI 43 0,06 28 19 
LU 37 0,06 27 22 
AT 31 0,06 33 20 
EE 43 0,05 26 21 
RO 44 0,04 30 12 
PL 43 0,01 32 20 
HU 48 0,008 32 15 
HR 40 0,007     
LT 35 0,007 30 15 
LV 41 0,002 36 16 
MT 56 
 
27 17 
BG 46 na 36 16 
PT 41 na 23 15 
SK 39 na 23 22 
EL 35 na 40 16 
CZ 34 na 29 17 
DE 32 na 26 26 
 
 
Table 6.3: countries ordered by smoking prevalence (source Joossens 2014, Eurobarometer 
2012) 
 
country Score (max100) Budget ppp € 2012 Current Smokers (% 15+) former smokers 
SE 48 0,06 13 30 
Ice 66 1,63 13,9 32 
NO 61 0,45 16   
PT 41 na 23 15 
SK 39 na 23 22 
NL 47 0,09 24 31 
IT 46 0,21 24 13 
FI 55 0,36 25 22 
DK 46 0,23 26 31 
EE 43 0,05 26 21 
DE 32 na 26 26 
UK 74 0,35 27 26 
MT 56   27 17 
BE 47 0,23 27 20 
LU 37 0,06 27 22 
FR 57 0,12 28 24 
SI 43 0,06 28 19 
IE 70 0,14 29 19 
CZ 34 na 29 17 
RO 44 0,04 30 12 
LT 35 0,007 30 15 
HU 48 0,008 32 15 
PL 43 0,01 32 20 
ES 56 0,1 33 22 
AT 31 0,06 33 20 
BG 46 na 36 16 
LV 41 0,002 36 16 
EL 35 na 40 16 
HR 40 0,007 
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Alcohol  
For alcohol, GISAH from the WHO provides the most comprehensive overview of policy 
levels, while also at the EU level policy stringency is compared in several reports. 
Elaborate information may also be found on the site of EUROCARE. Three publications 
were found that did attach overall scores to rate policy stringency and completeness. 
The last of these was published in 2007 (Brand 2007) and covers 30 countries, among 
which several European. For EUROCARE, the original scale from the ECAS study was 
re-applied in 2005 and was calculated for a range of EU member states. Finally, as 
part of the Bridging the Gap project, a report on the same scale was published, 
presenting scores for 2005 for 30 European countries. (Karlsson & Österberg 2006, cf 
Eurocare.org or Karlsson and Osterberg 2007). This one seems most relevant for the 
current project. Its outcomes are presented in graphs in the publication and in 
separate factsheets for each country. Recent information on budgets for alcohol policy 
could not be discovered. Similar tables as for tobacco for this reason could not be 
constructed. 
Overweight and obesity 
For overweight and obesity, to the best of our knowledge neither a single policy 
stringency score for a sufficiently large range of countries, nor information on budgets 
was available. Similar tables as for tobacco for this reason could not be constructed. 
 
Conclusions  
Based on the limited information available, no firm conclusions can be drawn. The 
exception is tobacco policy, where the research by Joossen et al. has been performed 
for a range of years. While some countries seem to indicate success of a stringent 
policy (e.g. CIeland and Norway), others do not. What would be required to 
investigate this further would be a time series of budgets and a time series of 
prevalence, to see whether stringent policy pays off over time in terms of prevalence 
reductions. 
Spending on prevention and public health contains multiple preventive policies and 
policy aiming at a healthier lifestyle is only a small part of these budgets. Especially in 
countries with smaller health care budgets, the majority of prevention budgets will be 
aiming at infectious diseases. This implies that adding such prevention spending in our 
main analyses would have confused rather than improved the analysis. To complicate 
matters further, many types of lifestyle policy will bring costs outside the prevention 
budget, e.g. when general practitioners advise their patients concerning lifestyle. Also, 
several types of policy are even outside the health care system, for example school 
programs, taxation and other types of regulation. This implies that several policy 
options have a financial burden that may quite often fall outside the definitions of the 
SHA. Given these difficulties, the approach taken in the current project, taking lifestyle 
as an exogenous variable and standardize for its possible impact on health care 
systems is a pragmatic solution. Using this approach, the most logic spending 
component to consider are curative care spending as we did, since these bear most 
direct relation to the health outcomes included in our analyses.  
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7. Discussion and policy implications  
 
The previous two chapters already covered a large part of the discussion by putting 
our results into perspective and relating them to other literature regarding health 
system efficiency and research regarding a healthy lifestyle prevalence and its effects 
on health outcomes and health care spending. The current chapter adds to this and 
aims to summarize those smaller or larger methodological issues brought up during 
the expert panel validation phase and in discussions with our expert committee, which 
were not included in the two previous chapters. Furthermore it discusses possible 
policy implications, keeping in mind that the results should be interpreted with due 
caution.  
Methodology  
Health care efficiency in the literature 
The efficiency of health systems concerns the relationship between the resources 
invested in health systems and the output produced by it. Commonly, population 
health is used as main output measure, because improving population health is 
considered the main goal of health services and health systems. Various studies have 
used international aggregated data to analyze the average relationship between health 
spending and population health across countries (e.g. Hitiris and Posnett, 1992; 
Cremieux et al., 1999; Berger and Messer, 2002; WHO, 2000; Or et al., 2005; Nixon 
and Ullman, 2006; Joumard et al., 2008; Heijink et al., 2013). These studies may 
clarify whether – on average - investments in health systems have an impact on 
population health at country level. Most studies found a positive association between 
health spending and population health (Van Baal et al., 2013). Few studies aimed to 
analyse the efficiency of health systems, which requires an additional step. Efficiency 
analyses are much more common in the organizational literature, for example to 
compare the efficiency of hospitals in a specific country (Jacobs et al., 2006; 
Hollingsworth, 2008). These studies are usually performed at the level of specific 
sectors (hospital care) rather than the entire health system. The goal of an efficiency 
analysis at system level would be to investigate whether individual countries reach the 
maximum level of population health they could achieve, given their level of health 
spending (Retzlaff-Roberts et al., 2004; Afonso and Aubyn, 2006; Joumard et al., 
2008). It focuses on the part of the variation in health outcomes that cannot be 
explained by measures of health spending (and other confounders). Efficiency analysis 
involves several conceptual and analytical issues, as described below. 
 
Methodological issues  
Previous studies mostly used so-called health production functions representing the 
relationship between health outcomes and several input variables (determinants of 
health). Commonly, aggregate input measures and health outcome measures at 
country level were used. At first, the production function determines the average 
relation between health spending and health while controlling for potential 
confounders. Secondly, it can be used to estimate the efficiency of individual 
countries. To that purpose, (part of) the variation in health outcomes that cannot be 
explained by input variables, is attributed to inefficiency as explained below.  
Methods to estimate efficiency of (health care) systems can be divided into two 
categories: parametric methods and non-parametric methods (for an overview see 
Jacobs et al., 2006; or for examples see Afonso and Aubyn, 2006 and Joumard, 
2008). Both methods were used in this study. 
Parametric methods use econometric techniques to estimate the parameters of the 
(production) function. The regression model generates estimates of the average 
relationship between health spending and health. Following, the residual, or: the 
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deviation of the observed data from the model prediction, is used as measure of 
efficiency. Some studies attributed the entire residual to inefficiency (equal to the 
Corrected Ordinary Least Squares (COLS) procedure). Others split the residual into 
two components: random error and inefficiency (Stochastic Frontier Analysis). 
Previous studies involving parametric methods most often used panel data models, 
because it creates more power in comparison to cross-sectional data. 
Non-parametric methods do not impose any conditions on the functional form, but let 
the observed data determine the shape of the function. Data Envelopment Analysis 
(DEA) is the most widely used non-parametric technique. DEA considers the 
observations with the highest output/input ratio as efficient. It constructs an efficiency 
frontier through the efficient observations using linear programming (‘enveloping the 
observations’ in the dataset). The distance between the frontier and data points below 
the frontier is entirely attributed to inefficiency. One of the main disadvantages of the 
DEA approach is that it is sensible to outliers and may produce less reliable results for 
those countries with little peers (particularly relevant for small datasets). However, it 
does not rely on distributional assumptions as parametric models do.   
 
Conceptual issues 
As mentioned in the introduction, the conceptual issues refer to defining the inputs 
and outputs of the health system, defining the boundaries of the health system and 
identifying the external factors and time lags that affect the input-output relationship. 
Often, the output of health systems has been measured using (summary) measures of 
population health such as life expectancy, healthy life expectancy or infant mortality. 
Clearly, these output measures are affected by factors beyond the control of health 
systems such as the general wealth of the population, environmental factors, lifestyle, 
and demographics. In order to take this into account, most previous studies added 
these variables as covariates to their models (at aggregate level) (see e.g. Nixon and 
Ulmann, 2006; Joumard et al., 2008 and Van Baal et al., 2013).  
A second issue is the ‘unit of analysis’ which should be identified in order to set the 
boundaries of the efficiency analysis (Jacobs et al., 2006). The unit of analysis should 
be able to convert resources into outputs and be comparable across the sample. In 
other words, the services included in the definition of the health system should be able 
to influence the population health measure that is used. In this study, our unit of 
analysis is the health system, based on the definitions of the System of Health 
Accounts framework. Using the SHA improves the comparability across countries, 
because the main aim of the SHA is to reach comparable definitions. However, this 
has not been reached yet for all services included in the accounts, for example 
regarding long-term care (OECD, 2012). 
Finally, time plays an important role. Health outcomes may be affected both by 
current health care, but also by care in the past. Current spending will affect future 
health as well as current health. Similarly, past lifestyle behaviour may affect current 
levels of health and health spending. In a sensitivity analysis this was further 
investigated for smoking, the lifestyle factor for which the epidemiological evidence 
concerning risks of past behaviour is most elaborate (cf Apppendix 29.3).   
Though authors have aimed to tackle the issues mentioned in the previous paragraph, 
no study using country level data was able to address all issues (Van Baal et al., 
2013). 
Methodological issues of the current study 
Though the methods and data used in this report have been used in previous studies 
as described above, several specific issues need to mentioned.  
 
First, the lifestyle data we used were self-reported and are likely to be subject to 
response heterogeneity (across populations), which may affect the lifestyle estimates. 
Furthermore, the Eurobarometer survey only irregularly contained lifestyle questions. 
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As a result, the reference year of the lifestyle data varied to some extent. This survey 
contained about 1500 observations per country, which is smaller than most national 
surveys (Bogdanovica et al., 2011). However, our pooling methods used the entire 
sample with country dummies, while allowing age patterns to differ across countries. 
By using such pooling techniques rather than stratified analyses for each country 
separately, we tried to account for the relatively small samples sizes in each country. 
Notwithstanding the comments that could be made regarding the sampling method 
and especially the relatively small sample size of the Eurobarometer, it is the only 
survey that is both freely available at the level of individual data and contains 
information from all 28 EU member states. Once new and better data sources become 
available on all countries, a re-analysis is advisable.  
 
Second, changes in health outcomes and health spending were based on individual 
level data. Previous studies showed that the level of health spending and changes in 
health spending at country level may be determined by factors that cannot be 
measured at individual level (Getzen, 2006). As a result, the impact of lifestyle 
measured at individual level may be outweighed by other factors at macro level. Such 
factors were discussed in the qualitative chapter. This project however aimed to 
analyse the effect of lifestyle factors and this could be done best by considering 
individual level data, since lifestyle does affect health mainly through individuals, with 
maybe the exception of alcohol use, which also has strong external effects. 
The effect of the three different lifestyles was assumed to be multiplicative, in line with 
our estimates of odds ratios which were corrected for the other lifestyles. Prevalence 
was also assumed to be independent. It would have been better to account for 
clustering, using individual data. However, we could not do so, since we had to rely on 
separate survey rounds for the different lifestyle factors. To reliably estimate 
clustering would require a single survey covering all lifestyles investigated in the same 
questionnaire and with sufficient sample sizes.    
Another problem with our estimates of odds ratios for smoking and overweight could 
be the limited age range covered by SHARE, which starts at age 50. However, younger 
people also have less disability, implying that possible overestimations of odds ratios 
for these groups contribute relatively little to the total standardized outcomes. We 
have added sensitivity analyses with a 50+ population for some scenarios.  The 
SHARE survey data did not include all countries used in the entire study. In addition, a 
French survey was used for estimating odds ratios related to alcohol consumption. 
These showed better face validity than the odds ratios based on the original multi-
country survey.  
As opposed to spending, other variables could have been chosen for the measure of 
health care use. Literature shows examples using volumes, which avoids the price 
effect. We corrected for price differences by using purchasing power parities.  
Our additional analyses are evaluating scenarios at the disease level. This highlights 
that disease specific information is worthwhile next to the aggregate outcome 
measures in our main analyses. Note however, that these analyses use a different 
type of scenarios. The standardization in the main analysis aims to correct for the 
possible disturbing effect of lifestyle on health system efficiency estimates. In 
contrast, the additional analyses evaluate hypothetical lifestyle scenarios to evaluate 
the potential future effects of changes in lifestyle. In combination with information on 
costs and effects of interventions, such analyses may support lifestyle policy by 
evaluating more realistic policy scenarios and informing about long term health gains, 
effects on health care spending and cost-effectiveness. In theory, one could perform 
the main analysis also by using a disease specific model. However, this would require 
data on prevalence of chronic diseases, on disease related quality of life, and on 
health care spending specific to diseases for all countries. Such data is not yet 
available.  
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Another point of critique may regard the amount of standardization. One could argue 
that countries should be made more comparable by also standardizing for the 
demographic distribution (age and gender distribution in the populations). This 
particularly refers to the health spending data, since the summary measures of 
population health take into account the population distribution. Health spending was 
standardized for differences in disability and life expectancy between countries. 
Unfortunately, more detailed age-specific health spending data, which would enable a 
more elaborate standardization, are unavailable at this moment. 
The DYNAMO HIA model used for the standardization was developed as part of a EU 
FP7 grant and publicly available. Its development was carefully documented and 
published in peer reviewed journals. The conceptual model was validated through an 
expert committee, while the code and implementation were tested. A limitation is that 
the model version used for the current report was not independently validated. Since 
the main structure of the model was not altered, this is not of major concern. An 
important further validation effort would be to compare model results to external data 
concerning the EHIS health outcomes in different lifestyle categories. For instance we 
could compare the model predictions regarding perceived quality of life and life 
expectancy for smoking, overweight, moderate drinkers in Germany to an external 
data source with the same information. This is a research project in itself, and it is 
expected that such data are not readily available.     
The research aimed to include information on all 29 countries. The Eurobarometer 
however did not contain information on Iceland, Norway and Croatia, while some of 
our other data sources covered smaller subsets of countries. This is shown in tables. 
While in the analyses, we used proxy countries to impute for missing data, still we had 
too little information to reliably estimate health spending corrected for lifestyle in 
about 9 countries. Croatia, Norway and Iceland were included in the calculations, but 
not included in the figures, since the lifestyle information was based on different 
sources and hence the results were considered to be less well comparable to those of 
the other countries. 
Changes in lifestyle translate into health benefits. Part of these benefits only occur 
after quite some time, since lifestyle related diseases later in life may be prevented by 
a healthy lifestyle at young age. The current cross sectional analyses directly related 
current lifestyle to current health outcomes, which is inherent in cross sectional 
research, but a clear limitation. It partly explains that some of the odds ratios found 
may appear low, especially for alcohol use. Nevertheless, for most alcohol related 
diseases it is current and not past exposure that has the strongest relation to current 
health outcomes.  
Smoking behaviour 20 years ago may affect current health outcomes. Partly this is 
accounted for by including former smoking as a separate category in the analyses. For 
overweight and alcohol however, such a category could not be distinguished. The 
extent to which old lifestyle behaviour for alcohol and overweight would influence the 
health spending-health relationship at macro-level, and cross-country differences 
therein, is unclear. Also, the literature does not provide any evidence on this. The 
additional analyses showed that changing the assumptions about the timing of 
smoking cessation in the most extreme case could create a difference of about 3 years 
in terms of smoking standardized life expectancy. 
Time lags also exist between health spending and health outcomes, which means that 
current health may have been affected by past investments. Our panel data allow 
going back to 2004, but not further, given important changes in data definitions in 
that year. 
It might be argued that countries with a long history of healthy lifestyle should 
perform better than countries which just shifted, and that our analyses cannot 
distinguish between these two types of countries. So some of the countries that show 
relatively poor health outcomes given their level of expenditure could be countries 
with unhealthy lifestyles in the past, which were not sufficiently corrected for by our 
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current standardization methods. Note that this only is a problem when trends do 
differ a lot among the different countries. Further research into this issue would need 
comparable historic lifestyle data, and additional sources for estimating odds ratios. 
The SHARE data base might provide the latter type of data, since it contains now 4 
waves now.   
 
Recommendations  
Given these discussion points, the main implication that arises from the current 
research is that better data concerning lifestyle and its effects on quality of life would 
be highly desirable. For the type of research as currently undertaken international 
comparability and easy access is highly relevant. The EHIS initiative in this respect is 
very important.  
In the meantime, new Eurobarometers surveys covering several lifestyle factors in one 
survey would enable to investigate clustering. If the survey would also include some 
quality of life outcomes that would be even better, providing an additional source, 
next to SHARE for investigating the relation between lifestyle and aggregate self-
reported health outcomes. Such outcomes could be the two EHIS items, self-reported 
health and disability, or could cover a short quality of life questionnaire, like the SF12, 
or EQ5D. While larger sample sizes and more elaborate surveys are of course 
preferred, added value in the currently existing surveys is also worthwhile.  
In addition, regarding data, the ongoing initiatives to provide more consistent and 
complete information on health care spending are very worthwhile. Having spending 
information at the level of conditions would be very interesting and enable disease 
specific modeling which is useful for the evaluation of policy scenarios.   
 
Policy implications 
The finding that a better lifestyle does improve health outcomes considerably is not 
new, but worthwhile stressing once more. Also, the results of the review regarding 
cost-effectiveness underline the potential value of investing in primary prevention. Our 
analyses suggest that improved lifestyles do not strongly influence the demand for 
health care, with small consequences of better lifestyle behaviour on health spending 
in the long run, while health benefits might be substantial. However, these results 
were obtained in a cross sectional analysis. The additional analyses with a dynamic 
model show that for some lifestyles, especially smoking, the positive effect on life 
expectancy could rise the average age of the population, which contributes to health 
care spending. Definite conclusions would require such analyses in more than a single 
country and use of more realistic intervention scenarios. Given that upfront 
investments are needed to implement cost effective interventions, further research 
could investigate ways to incentive these investments. 
The relatively small impact of lifestyle on countries relative efficiency indicates that 
probably the three factors investigated are not of major influence regarding countries’ 
relative health system efficiency. Still, a more elaborate analysis with data on very 
long time periods would be needed to support more definite conclusions. The data 
requirements of such a study are large however and we question whether the foreseen 
additional insights are worth the efforts required. A more fruitful approach in terms of 
policy support would be to support countries in their lifestyle policy strategy. Scenarios 
as in our additional analyses and especially more realistic policy scenarios on concrete 
interventions and regulations may inform countries about the foreseen health gains 
from lifestyle policy in relation to short term and long term effects on health care 
spending, in line with the Australian ACE project.    
Our modelling analyses further show that improvements in lifestyles have a bigger 
impact on healthy life expectancy than on life expectancy: people not only live longer 
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but also longer in good health. This may have implications for the policy debate on the 
statutory retirement age in EU age as living longer in good health might also facilitate 
longer working lives.  
   
Conclusion 
This report presents the findings of the MACELI study on health spending and health 
outcomes across European countries. The study shows substantial variation in 
(curative) health spending and population health between European countries. On 
average, countries that spend more on health care also have a healthier population. In 
addition, the efficiency analysis shows some variation between countries in terms of 
the “health spending-health” ratio (cost-effectiveness). These results are similar to 
Joumard et al. (2008) who presented figures for life expectancy using panel data. 
However, given the strong association between GDP per capita and health spending, 
the effect of health spending disappears after adjusting for GDP per capita and it 
becomes unclear whether health spending has an independent effect on health 
outcomes. As a result, the current cross-sectional data do not allow drawing far-
reaching conclusions.  
 
We also found observable differences in lifestyle prevalence between countries. 
Individual level data analysis shows an effect of lifestyle behaviour on self-reported 
health. Furthermore, unhealthy lifestyles are associated with greater mortality risk, 
which is included in the DYNAMO-HIA simulations. That is, differences in lifestyle 
potentially affect countries health system efficiency scores through several pathways.  
The modelling results reflect these relationships and hypothetical healthier scenarios 
(through changes in lifestyle) generated higher healthy life expectancy at country 
level. At the same time, differences in health spending remained largely unchanged in 
all scenarios. This implies, within the limits of our study design, that lifestyle is not an 
important confounder when one wants to estimate the impact of health spending on 
population health.   
As a result, the average “health spending-health” ratio improved as a result in the 
scenarios with a healthier lifestyle. However, the differences in efficiency between 
countries did not change substantially after adjustment for lifestyle. 
The scenarios ignored the costs and difficulties of obtaining the improved lifestyle. This 
precludes current firm policy implications. Our literature review underlines that 
potentially cost-effective policy options are available and the clear potential for 
efficient prevention policy.   
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9. Appendix  
 
9.1 Health system cost effectiveness results with total health 
spending  
 
This Appendix includes results of the unadjusted analyses including total health 
spending instead of curative care spending (so similar to section 4.1).  
 
Table 9.1: Elasticity of population health to total health spending, GDP per capita and 
education 
 LE HLY LEGPH 
Basic model (t=2010) 
   Total health 
spending 
0.042* -0.068 0.047 
   GDP per capita 0.011 0.166 0.059 
   Education -0.037 -0.093 0.030 
   Ni 29 29 29 
   R-squared 0.80 0.28 0.60 
    
Panel data model (t=2004-2011) 
   Total health 
spending 
0.036*** -0.042 0.094*** 
   GDP per capita -0.035*** 0.019 -0.065*** 
   Education 0.118*** 0.207*** 0.192*** 
   Nit 231 208 208 
P-value of null hypothesis of no effect. *p<0.10; **p<0.05; ***p<0.01 
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Figure 9.1: The association between total health spending and population health 
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Figure 9.2: Output oriented-technical efficiency estimated by parametric analyses using total 
health spending 
 
 
Figure 9.3: Output oriented technical efficiency estimated by DEA using total health spending 
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9.2 Baseline values for health spending and population health 
 
 
Country LE LEGPH HLY THCE (€) 
Austria 80.45 58.33 59.60 2339.46 
Belgium 80.05 60.53 62.94 2201.44 
Bulgaria 73.81 54.95 64.76 545.69 
Croatia 76.65 58.37 58.37 893.62 
Cyprus 81.15 59.73 64.79 1347.31 
Czech Republic 77.57 53.44 62.69 1152.76 
Denmark 79.24 58.30 60.74 2553.83 
Estonia 75.98 46.11 55.61 713.23 
Finland 80.01 58.11 57.08 1886.45 
France 81.34 56.91 62.17 2344.18 
Germany 80.49 56.25 61.98 2460.08 
Greece 80.50 62.65 66.65 1512.03 
Hungary 74.54 47.35 56.93 875.28 
Iceland 81.92 67.68 67.68 1420.94 
Ireland 80.81 67.12 65.96 1979.02 
Italy 82.13 58.16 67.33 1825.51 
Latvia 72.90 41.63 54.19 382.25 
Lithuania 73.16 45.15 59.63 722.84 
Malta 80.71 56.10 70.49 1358.14 
Netherlands 80.77 64.30 60.40 2229.57 
Norway 81.03 68.47 68.47 2769.94 
Poland 76.30 48.32 59.76 793.41 
Portugal 79.93 43.83 57.23 1739.92 
Romania 73.77 54.96 57.08 436.00 
Slovakia 75.46 50.57 51.68 1243.42 
Slovenia 79.52 50.30 52.81 1351.82 
Spain 82.04 59.97 63.59 1743.38 
Sweden 81.52 66.71 70.80 2004.78 
United Kingdom 80.40 65.07 64.50 1802.92 
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9.3 Additional scenarios with different odds ratios for former 
smokers  
 
Figure 9.4 shows the level of health spending and life expectancy at country level in 
two additional scenarios using our cross sectional main analysis, but with different 
odds ratios for former smokers. In a first variant, all former smokers in a country are 
assumed to be long-term quitters. This assumes the healthiest starting situation in 
each country. For such already very healthy countries (all former smokers quit long 
ago) less room exists for improvement when moving to a scenario with a healthier 
lifestyle (in this case scenario 1, “best of all”). So, the increase in life expectancy in 
this variant is smaller than in the main analysis. In a second variant, all former 
smokers are assumed to be recent stoppers. This assumes the least healthy starting 
situation in each country. For these not so healthy countries (all former smokers just 
quitted) more room exists for improvement when moving to a scenario with a 
healthier lifestyle (in this case scenario 1). So, the increase in life expectancy in this 
variant is larger than in the main analysis. These variants serve to investigate further 
the possible effects of differences between countries in their lifestyle history. The 
figure shows that changing the assumptions about the timing of smoking cessation in 
the most extreme case can create a difference of about 3 years in terms of smoking 
standardized life expectancy. Keeping in mind that especially the blue line reflects an 
unrealistic and extreme situation in which all former smokers have just quitted very 
recently, this is of the same order of magnitude as the actual effect sizes in our main 
analyses. 
The actual results for scenario 1 show a line that lies in between these two extremes. 
In the actual results, the relative risks used for former smoker are the same for all 
countries and in between those of current and never smokers. Thus, we implicitly 
assume that the average time since cessation in former smokers as included in these 
relative risks properly reflects that in all countries included in the analyses. Note, 
however, that the current analyses do use age specific data on percentages of current 
and former smokers as well as age specific risks. This partly helps to distinguish 
between countries which made a recent transition towards less smoking and countries 
that have always had a low smoking prevalence. The latter will be characterized by 
relatively few former smokers at all ages, while the former will have large numbers of 
former smokers in the age groups that used to smoke until recently. Using more 
detailed information would of course be preferable. However, as can be seen from the 
current figure, while countries do move upward (life expectancy differs about 3 years 
in terms of life expectancy) changes on the x-axis are much smaller. A more detailed 
analysis would not only require detailed information on time since cessation of former 
smokers in all countries, but also disease specific information, since risks of former 
smokers and how these change with time since cessation vary per disease. 
(Hoogenveen et al. 2008) This would complicate the analysis considerably.  
Similar analyses for alcohol and overweight were not possible, because risks were only 
estimated for current lifestyles, in contrast to smoking. Also, existing epidemiological 
studies do not provide much information on the magnitude of time-lag effects for 
these risk factors. 
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Figure 9.4: The association between curative care spending and life expectancy in the additional 
scenario with different odds ratios for former smokers 
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9.4 Details on data analysis for lifestyle  
 
Survey questions BMI 
For overweight, the questions used were obtained from Eurobarometer survey no.64.3 
from November-December 2005 (http://www.gesis.org/).  
 
We used the following questions to calculate BMI: 
- Q.D5 How tall are you (in cm) without shoes? 
- Q.D6 How much do you weigh (in kg) without shoes and clothes? 
 
BMI was calculated using the basic formula (BMI=weight (in kg)/height (in m)²). 
Following, three BMI classes were distinguished:  
- BMI<25 
- BMI>=25 & BMI<30 (overweight) 
- BMI>=30 (obesity)  
 
Survey questions tobacco 
For tobacco, the question used were from Eurobarometer survey no 77.1 from 
February-March 2012 (http://www.gesis.org/). 
 
The question used was:  
- EB72.3 QD1: “Regarding smoking cigarettes, cigars or a pipe, which of the following 
applies to you?” (READ OUT – ONE ANSWER ONLY) 
 
The following answer categories were available: You currently smoke (M); You used to 
smoke but you have stopped; You have never smoked; DK (do not know/no answer). 
Category DK was left out for the final pooled analysis, but is presented in the raw 
data. It was assumed these were proportionally distributed over the other three 
categories. Finally, three categories remained:  
- never smokers  
- former smokers  
- current smokers  
 
Survey questions alcohol 
For alcohol, we used the questions from the Eurobarometer survey no 72.3, which was 
conducted in October 2009 (http://www.gesis.org/). 
 
Questions used were:  
- QC1a: During the past 12 months, did you drink any alcoholic beverage (beer, wine, 
sprits, cider or other local beverages)? 
Answers: Yes; No; DK/Refusal 
- QC1c: Did you drink any alcoholic beverages (beer, wine, spirits, cider or other local 
beverages) in the last 30 days? 
Answers: Yes; No; DK/Refusal. 
- QC2: In the last 30 days, how many times did you drink any alcoholic beverages? 
Answers: Daily; 4 – 5 times a week; 2 – 3 times a week; Once a week 2 – 3 
times a month; Once; Don’t remember\ Refusal (Spontaneous) 
- QC3: On a day when you drink alcoholic beverages, how much do you usually drink?  
Answers: 1-2 drinks; 3-4 drinks; 5-6 drinks; 7-9 drinks; 10 drinks or more; It 
depends (Spontaneous); DK\ Refusal 
 
These questions were combined to calculate the average daily amounts consumed in 
grammes. The mid-points of the answer categories from QC3 were multiplied with the 
assumed average 12 grammes of alcohol per drink: 1.5*12 g; 3.5*12g; 5.5*12g;  
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8*12g; 10*12g. These results were then multiplied with the frequencies from QC2 to 
obtain total weekly and average daily intake. Persons answering yes to either QC1a or 
QC1c, but having a NA on questions QC2 and/or QC3 were categorized as drinking 
rarely, that is, 0-0.025 g daily.  
 
Following, four alcohol consumption categories were distinguished, using the cut-off 
points of the WHO (see table below). The two highest WHO categories were combined 
into a single highest category. Also the categories lifetime abstainer and former 
drinker were combined, and people indicating very small annual intake were added to 
this category of “not to rare drinkers”.  
 
Men 0-
0.025 
0.025-40 40-60 60+ 
Women 0.025-20 20-40 40+ 
 
This resulted in three datasets with individual data containing information on country, 
age and gender, as well as lifestyle category (either overweight 3 categories, smoking 
habit 3 categories, or drinking habit 4 categories).   
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9.5 Overview of cost-effectiveness studies on lifestyle interventions 
in a European setting  
Table 1: Alcohol  
Study Country Outcome  
1. Angus C, Scafato E, Ghirini S, Torbica A, Ferre F, Struzzo P, Purshouse 
R, Brennan A. Cost-effectiveness of a programme of screening and brief 
interventions for alcohol in primary care in Italy. BMC Fam Pract2014; 
15(1): 26  
Italy QALY 
2. Barrett B, Byford S, Crawford MJ, Patton R, Drummond C, Henry JA, 
Touquet R. Cost-effectiveness of screening and referral to an alcohol 
health worker in alcohol misusing patients attending an accident and 
emergency department: a decision-making approach. Drug Alcohol 
Depend2006; 81(1): 47-54 
England Level of 
drinking 
3. Berg M van den, Baal PH van, Tariq L, Schuit AJ, Wit GA de, Hoogeveen 
RT. The cost-effectiveness of increasing alcohol taxes: a modelling study. 
BMC Med2008; 6(1): 36. 
Netherlands  QALY 
4. Blankers M, Nabitz U, Smit F, Koeter MWJ, Schippers GM. Economic 
evaluation of internet-based interventions for harmful alcohol use 
alongside a pragmatic randomized controlled trial. Journal of Medical 
Internet Research2012; 14(5) 
Netherlands  QALY 
5. Coulton S, Drummond C, James D, Godfrey C, Bland JM, Parrott S, 
Peters T. Opportunistic screening for alcohol use disorders in primary 
care: comparative study. Bmj2006; 332(7540): 511-7 
England Costs per true 
positive  
6. Drummond C, Coulton S, James D, Godfrey C, Parrott S, Baxter J, Ford 
D, Lervy B, Rollnick S, Russell I, Peters T. Effectiveness and cost-
effectiveness of a stepped care intervention for alcohol use disorders in 
primary care: pilot study. Br J Psychiatry2009; 195(5): 448-56 
England Alcohol 
consumption 
7. Holm AL, Veerman L, Cobiac L, Ekholm O, Diderichsen F. Cost-
effectiveness of changes in alcohol taxation in Denmark: a modelling 
study. Cost Eff Resour Alloc2014a; 12(1): 1 
Denmark DALY 
8. Holm AL, Veerman L, Cobiac L, Ekholm O, Diderichsen F. Cost-
effectiveness of preventive interventions to reduce alcohol consumption in 
denmark. PLoS One2014b; 9(2): e88041 
Denmark DALY 
9. Kaner E, Lock C, Heather N, McNamee P, Bond S. Promoting brief 
alcohol intervention by nurses in primary care: a cluster randomised 
controlled trial. Patient Educ Couns2003; 51(3): 277-84 
England Correctly 
treated patient  
10. Lai T, Habicht J, Reinap M, Chisholm D, Baltussen R. Costs, health 
effects and cost-effectiveness of alcohol and tobacco control strategies in 
Estonia. Health Policy2007. 
Estonia DALY 
11. Long CG, Williams M, Hollin CR. Treating alcohol problems: a study of 
programme effectiveness and cost effectiveness according to length and 
delivery of treatment. Addiction1998; 93(4): 561-71 
England Days without 
use, drinking 
intensity 
12. Mansdotter AM, Rydberg MK, Wallin E, Lindholm LA, Andreasson S. A 
cost-effectiveness analysis of alcohol prevention targeting licensed 
premises. Eur J Public Health2007. 
Sweden QALY 
13. Palmer AJ, Neeser K, Weiss C, Brandt A, Comte S, Fox M. The long-
term cost-effectiveness of improving alcohol abstinence with adjuvant 
acamprosate. Alcohol and Alcoholism, 2000;35:478-92. 
Germany Abstainers  
14. Parrott S, Godfrey C, Heather N, Clark J, Ryan T. Cost and outcome 
analysis of two detoxification services. Alcohol and Alcoholism, 
2006;41:84-91. 
England Unit reduction 
alcohol 
consumption 
15. Purshouse RC, Brennan A, Rafia R, Latimer NR, Archer RJ, Angus CR, 
Preston LR, Meier PS. Modelling the Cost-Effectiveness of Alcohol 
Screening and Brief Interventions in Primary Care in England. Alcohol 
Alcohol2012. 
England QALY 
16. Purshouse RC, Meier PS, Brennan A, Taylor KB, Rafia R. Estimated 
effect of alcohol pricing policies on health and health economic outcomes 
in England: an epidemiological model. Lancet2010. 
England Various  
17. Smit F, Lokkerbol J, Riper H, Majo MC, Boon B, Blankers M. Modeling 
the Cost-Effectiveness of Health Care Systems for Alcohol Use Disorders: 
How Implementation of eHealth Interventions Improves Cost-
Effectiveness. J Med Internet Res2011; 13(3): e56 
Netherlands DALY 
18. Tariq L, van den Berg M, Hoogenveen RT, van Baal PH. Cost-
effectiveness of an opportunistic screening programme and brief 
intervention for excessive alcohol use in primary care. PLoS One2009a; 
4(5): e5696 
Netherlands QALY 
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19. UKATT. Cost effectiveness of treatment for alcohol problems: findings 
of the randomised UK alcohol treatment trial (UKATT). Bmj2005; 
331(7516): 544 
England QALY, 
criminality, 
drinks per day 
20.Watson J, Crosby H, Dale V, Tober G, Wu Q, Lang J, McGovern R, 
Newbury-Birch D, Parrott S, Bland J, Drummond C, Godfrey C, Kaner E, 
Coulton S. AESOPS: a randomised controlled trial of the clinical 
effectiveness and cost-effectiveness of opportunistic screening and 
stepped care interventions for older hazardous alcohol users in primary 
care. Health Technol Assess2013; 17(25): 1-158 
England QALY, alcohol 
related 
problems  
   
 
 
Table 2: Overweight and Obesitas  
 
Study Country Outcome 
1. Ara R, Brennan A. The cost-effectiveness of sibutramine in non-
diabetic obese patients: evidence from four Western countries. Obes 
Rev2007; 8(4): 363-71 
4 countries  diabetes 
2. Bemelmans W, van Baal P, Wendel-Vos W, Schuit J, Feskens E, Ament 
A, Hoogenveen R. The costs, effects and cost-effectiveness of 
counteracting overweight on a population level. A scientific base for 
policy targets for the Dutch national plan for action. Prev Med2008b; 
46(2): 127-32 
Netherlands  QALY 
3. Brennan A, Ara R, Sterz R, Matiba B, Bergemann R. Assessment of 
clinical and economic benefits of weight management with sibutramine in 
general practice in Germany. Eur J Health Econ2006; 7(4): 276-84 
Germany  QALY 
4. Foxcroft DR. Orlistat for the treatment of obesity: cost utility model. 
Obes Rev2005; 6(4): 323-8 
England QALY 
5. Fuller NR, Colagiuri S, Schofield D, Olson AD, Shrestha R, Holzapfel C, 
Wolfenstetter SB, Holle R, Ahern AL, Hauner H, Jebb SA, Caterson ID. A 
within-trial cost-effectiveness analysis of primary care referral to a 
commercial provider for weight loss treatment, relative to standard care--
an international randomised controlled trial. Int J Obes (Lond)2013b; 
37(6): 828-34 
Australia, 
England, 
Germany 
QALY 
6. Galani C, Schneider H, Rutten FF. Modelling the lifetime costs and 
health effects of lifestyle intervention in the prevention and treatment of 
obesity in Switzerland. Int J Public Health2007b; 52(6): 372-82 
Switzerland QALY 
7. Gusi N, Reyes MC, Gonzalez-Guerrero JL, Herrera E, Garcia JM. Cost-
utility of a walking programme for moderately depressed, obese, or 
overweight elderly women in primary care: a randomised controlled trial. 
BMC Public Health2008; 8: 231 
Spain QALY 
8. Hertzman P. The cost effectiveness of orlistat in a 1-year weight-
management programme for treating overweight and obese patients in 
Sweden: a treatment responder approach. Pharmacoeconomics2005; 
23(10): 1007-20 
Sweden QALY 
9. Hollinghurst S, Hunt LP, Banks J, Sharp DJ, Shield JP. Cost and 
effectiveness of treatment options for childhood obesity. Pediatr 
Obes2013. 
England BMI 
10. Hollingworth W, Hawkins J, Lawlor DA, Brown M, Marsh T, Kipping 
RR. Economic evaluation of lifestyle interventions to treat overweight or 
obesity in children. Int J Obes (Lond)2012. 
UK Life years 
gained 
11. Iannazzo S, Zaniolo O, Pradelli L. Economic evaluation of treatment 
with orlistat in Italian obese patients. Curr Med Res Opin2008; 24(1): 63-
74 
Italy QALY 
12. Kalavainen M, Karjalainen S, Martikainen J, Korppi M, Linnosmaa I, 
Nuutinen O. Cost-effectiveness of routine and group programs for 
treatment of obese children. Pediatr Int2009. 
Finland BMI 
13. Kesztyus D, Schreiber A, Wirt T, Wiedom M, Dreyhaupt J, 
Brandstetter S, Koch B, Wartha O, Muche R, Wabitsch M, Kilian R, 
Steinacker JM. Economic evaluation of URMEL-ICE, a school-based 
overweight prevention programme comprising metabolism, exercise and 
lifestyle intervention in children. Eur J Health Econ2011. 
Germany Waist 
circumference 
14. Lacey LA, Wolf A, O'Shea D, Erny S, Ruof J. Cost-effectiveness of 
orlistat for the treatment of overweight and obese patients in Ireland. Int 
J Obes (Lond)2005; 29(8): 975-82 
Ireland QALY 
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15. McConnon A, Kirk SF, Cockroft JE, Harvey EL, Greenwood DC, 
Thomas JD, Ransley JK, Bojke L. The Internet for weight control in an 
obese sample: results of a randomised controlled trial. BMC Health Serv 
Res2007; 7: 206 
England QALY 
16. Miners A, Harris J, Felix L, Murray E, Michie S, Edwards P. An 
economic evaluation of adaptive e-learning devices to promote weight 
loss via dietary change for people with obesity. BMC Health Serv 
Res2012; 12(1): 190 
England QALY 
17. Olsen J, Willaing I, Ladelund S, Jorgensen T, Gundgaard J, Sorensen 
J. Cost-effectiveness of nutritional counseling for obese patients and 
patients at risk of ischemic heart disease. International Journal of 
Technology Assessment in Health Care, 2005;21:194-202 
Denmark Life years 
gained  
18. Siggaard R, Raben A, Astrup A. Weight loss during 12 week's ad 
libitum carbohydrate-rich diet in overweight and normal-weight subjects 
at a Danish work site. Obes Res1996; 4(4): 347-56 
Denmark Weight  
19. Trueman P, Haynes SM, Felicity Lyons G, Louise McCombie E, 
McQuigg MS, Mongia S, Noble PA, Quinn MF, Ross HM, Thompson F, 
Broom JI, Laws RA, Reckless JP, Kumar S, Lean ME, Frost GS, Finer N, 
Haslam DW, Morrison D, Sloan B. Long-term cost-effectiveness of weight 
management in primary care. Int J Clin Pract2010. 
England  Weight  
20. van Baal PH, van den Berg M, Hoogenveen RT, Vijgen SM, Engelfriet 
PM. Cost-Effectiveness of a Low-Calorie Diet and Orlistat for Obese 
Persons: Modeling Long-Term Health Gains through Prevention of 
Obesity-Related Chronic Diseases. Value Health2008a. 
Netherlands  QALY 
21. Warren E, Brennan A, Akehurst R. Cost-effectiveness of sibutramine 
in the treatment of obesity. Med Decis Making2004; 24(1): 9-19 
England QALY 
 
 
Table 3: Smoking 
 
Study Country Outcome 
1. Annemans L, Nackaerts K, Bartsch P, Prignot J, Marbaix S. Cost 
effectiveness of varenicline in Belgium, compared with bupropion, nicotine 
replacement therapy, brief counselling and unaided smoking cessation: a 
BENESCO Markov cost-effectiveness analysis. Clin Drug Investig2009b; 
29(10): 655-65 
Belgium QALY 
2. Athanasakis K, Igoumenidis M, Karampli E, Vitsou E, Sykara G, 
Kyriopoulos J. Cost-Effectiveness of Varenicline Versus Bupropion, Nicotine-
Replacement Therapy, and Unaided Cessation in Greece. Clinical 
Therapeutics2012b; 34(8): 1803-1814 
Greece Quitter 
3.    Bauld L, Boyd KA, Briggs AH, Chesterman J, Ferguson J, Judge K, 
Hiscock R. One-Year Outcomes and a Cost-Effectiveness Analysis for 
Smokers Accessing Group-Based and Pharmacy-Led Cessation Services. 
Nicotine Tob Res201113 (2): 135-45 
England QALY 
4. Bolin K, Lindgren B, Willers S. The cost utility of bupropion in smoking 
cessation health programs: simulation model results for Sweden. 
Chest2006; 129(3): 651-60 
Sweden QALY 
5. Bolin K, Mork AC, Willers S, Lindgren B. Varenicline as compared to 
bupropion in smoking-cessation therapy--cost-utility results for Sweden 
2003. Respir Med2008; 102(5): 699-710 
Sweden QALY 
6. Bolin K, Mork AC, Wilson K. Smoking-cessation therapy using varenicline: 
the cost-utility of an additional 12-week course of varenicline for the 
maintenance of smoking abstinence. J Eval Clin Pract2009a; 15(3): 478-85 
Sweden QALY 
7. Bolin K, Wilson K, Benhaddi H, de Nigris E, Marbaix S, Mork AC, Aubin 
HJ. Cost-effectiveness of varenicline compared with nicotine patches for 
smoking cessation--results from four European countries. Eur J Public 
Health2009b; 19(6): 650-4 
BE, FRA, SW 
and England 
QALY 
8. Boyd KA, Briggs AH. Cost-effectiveness of pharmacy and group 
behavioural support smoking cessation services in Glasgow. Addiction2009; 
104(2): 317-325. 
Schotland QALY 
9.    Brown J, Kotz D, Michie S, Stapleton J, Walmsley M, West R. How 
effective and cost-effective was the national mass media smoking cessation 
campaign 'Stoptober'?. Drug Alcohol Depend20141; 135: 52-8 
England Life years  
10. Chevreul K, Cadier B, Durand-Zaleski I, Chan E, Thomas D. Cost 
effectiveness of full coverage of the medical management of smoking 
France Life years  
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cessation in France. Tob Control2012. 
11. Coleman T, Agboola S, Leonardi-Bee J, Taylor M, McEwen A, McNeill A. 
Relapse prevention in UK Stop Smoking Services: current practice, 
systematic reviews of effectiveness and cost-effectiveness analysis. Health 
Technology Assessment, 2010;14:1-152. 
England QALY 
12. Cornuz J, Gilbert A, Pinget C, McDonald P, Slama K, Salto E, Paccaud F. 
Cost-effectiveness of pharmacotherapies for nicotine dependence in primary 
care settings: a multinational comparison. Tob Control2006; 15(3): 152-9 
6 countries Life years  
13. Cornuz J, Pinget C, Gilbert A, Paccaud F. Cost-effectiveness analysis of 
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9.6 Validation phases: Study design and expert workshop.  
 
Study design, form and summary of results.  
 
Study Design for review purposes  
 
 
“Life Table Analysis: health system cost-effectiveness 
assessments across Europe” 
 
Tender n° EAHC/2013/Health/05 
 
 
Contract notice 2013/S 043143 of 27/03/2013  
 
 
 
 
 
 
 
by 
National Institute for Public Health and the Environment 
(RIVM), in cooperation with ErasmusMC and Erasmus 
University.  
 
 
 
 
Bilthoven, The Netherlands, January, 2014. 
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1. Questions for reviewers 
This document describes our study design. While aiming to keep it readable and short, 
we have added some tables and appendices with additional detail. Of course, if you 
have any further questions, you could contact us: Talitha.Feenstra@rivm.nl, or 
Richard.Heijink@rivm.nl.  
 
Our question to you as a reviewer is to comment on the study design, focusing on 
those parts that concern your expertise. To enable finding these parts, we have made 
ample use of subheadings throughout the text. That is, we do not expect you to 
comment on the entire text, although you may of course feel free to do so.  
The text starts with our main objective. Then in sections 3, 5, 6 and 7 our approach is 
described, while section 4 gives the data sources and definitions we plan to use. 
Finally section 8 shortly overviews the timelines of the project. The appendices give an 
overview of the organization of the project, a list of country abbreviations, data 
sources considered for lifestyle factors and a reference list. 
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Please give us your reaction to the following questions:  
1. Do you agree with the approach (data sources/output measures) proposed?  
2. What could be advantages of the current approach? 
3. What could be important limitations?  
4. What are caveats to be aware of? E.g. risks of bias to take into account. 
5. Do you have suggestions regarding references or experts to consult? 
6. Did we miss important data sources?  
 
It is important to keep in mind that the current research project will have a limited 
budget and time horizon of 12 months. Nevertheless, the results have to be 
sufficiently reliable and enable sound interpretation.    
 
For your reaction you may apply the form attached, or just use your own preferred 
format. Please indicate your area(s) of expertise, your answer to the 6 questions 
above and any further comments you wish to make.  
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2. Main Objective  
The main objective of this project is to assess the comparative cost-effectiveness of 31 
European health systems, while correcting for the impact of three lifestyle factors 
(tobacco, alcohol, and overweight) on both health spending and outcomes.  
Life-table analyses will link lifestyle to outcomes. Subsequently, regression analysis on 
standardized estimates of total spending and health outcomes will produce lifestyle 
adjusted cost-effectiveness frontiers. Based on these, further quantitative and 
qualitative analysis of the relative performance of health systems across Europe will 
be done.  
The countries involved are the EU28 plus Norway, Iceland and Liechtenstein (see 
appendix for a full list), as commissioned by the Executive Agency for Health and 
Consumers (EAHC). Missing data will be approximated, consulting country–experts for 
validity.  
 
 
3. Health system cost-effectiveness analysis  
 
3.1 Visualizing cost-effectiveness  
The analysis will start with simple scatter plots of the relationship between health 
spending and health, plotting country-level health spending on the x-axis and country-
level health outcomes on the y-axis. Information on definitions is given below and in 
section 4 on data sources used.  
 
 Health expenditures 3.1.1
Previous studies often used total health expenditure, as defined in the System of 
Health Accounts (SHA) (e.g. Nixon and Ulmann, 2006; Joumard et al., 2010; Heijink 
et al., 2013). We will use this as a starting point. Besides, we will apply a more strict 
definition of health expenditures, only including SHA-categories that are expected to 
have an impact on the health outcomes measured. Using the provider dimension, we 
will include hospitals, ambulatory care and providers of medical goods (table 1). Using 
the functional dimension, we will include curative and rehabilitative care, ancillary 
services to health care and medical goods (table 1). 
  
 Health outcomes  3.1.2
As a measure of health benefits, we will use three measures that are all official 
European Community Health Indicators (ECHI), chosen by the ECHI Monitoring 
(ECHIM) project (Tuomi-Nikula et al. 2012): Life Expectancy (LE), Healthy Life Years 
(HLY) i.e. Life expectancy without disability, and Life expectancy in good perceived 
health (LEGHP).  
 
3.2 Uncorrected cost-effectiveness curves.  
Regression analyses (using health outcomes as dependent variable and health 
expenditure as independent variable) on country level data will estimate health 
system efficiency of individual countries. We will apply corrected ordinary least 
squares (c-OLS), that is all unexplained variation in health outcomes between 
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countries will be attributed to inefficiency. For comparison, also other interpretations 
of the unexplained variation will be analyzed (for an overview of approaches, see 
Hollingsworth, 2003; Jacobs et al., 2006).     
 
3.3  Cost-effectiveness graphs and curves corrected for lifestyle.  
The main objective of the current project is to adjust health system cost-effectiveness 
for the impact of lifestyle factors. Therefore, both health spending and health 
outcomes will be standardized using the methods proposed in section 4. Following, 
adjusted scatter plots will be produced, using the lifestyle standardized outcomes. 
Moreover, these standardized outcomes will be used to re-estimate the regression 
models and health system efficiency of individual countries. 
An important difference to other approaches (as in e.g. Nixon and Ulmann, 2006; 
Joumard et al., 2010; Heijink et al., 2013) is that we standardize both spending and 
health outcomes for lifestyle, rather than including lifestyle as a covariate in the 
regression model. This enables to produce easy to interpret graphical representations.  
 
3.4 Further analyses: covariates and time lags.  
In a third step, additional covariates will be added, using those that came out as 
significant in other studies, namely educational level, per capita gross domestic 
product (GDP), and health system typology.  
Finally, attention will be paid to possible time lags between health spending and its 
effects on health outcomes. These analyses will concentrate on a subset of countries, 
for which we have panel data on both health spending, health outcomes and macro-
level lifestyle indicators. Lifestyle corrections in these time series will necessarily be 
more straightforward than the elaborate corrections in the main analyses.   
      
 
4. Data selection for quantitative analysis 
The data sources for information on health spending, health outcomes, lifestyle 
factors, and demographic data are given below. Our choice was guided by three 
principles. First, we aimed to be consistent with the recommendations of the ECHIM-
Joint Action final report (Tuomi-Nikula et al. 2012). Second, we aimed for data that 
were comparable across countries, hence preferably from large multi country surveys, 
or from sources that had paid attention to comparability. Third, we needed data 
specific to age and gender. Liechtenstein (37,000 inhabitants) is unavailable in most 
databases. We will approach by using neighboring countries and national statistics. 
Our data will refer to adults aged 15 years and over. For lifestyle variables, the 
appendix provides an overview of data sources evaluated and their status in the study 
design (primary source, additional source, or not used). 
 
4.1 Data on health expenditure.  
The World Health Organization (WHO), Organisation for Economic Co-operation and 
Development (OECD) and Eurostat jointly collect data on health spending from 
national agencies according to the System of Health Accounts (SHA) framework. The 
framework distinguishes three dimensions (see table 1). 
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Financing Provider Function 
General government 
(general and social 
security funds) 
Hospitals Curative and rehabilitative care 
Private sector 
(private insurance, 
out-of-pocket, other) 
Nursing and residential 
care facilities 
Long-term nursing care 
Rest of the world Ambulatory care Ancillary services to health 
care (laboratory, diagnostic 
imaging, patient transport) 
 Providers of medical 
goods 
Medical goods 
(pharmaceuticals and 
appliances) 
 Public health programs Prevention and public health 
services 
 General health 
administration and 
insurance 
Health administration and 
health insurance 
 Other industries Not specified by kind 
 Rest of the world  
  Total current health 
expenditure 
  Capital formation 
Total health 
expenditure 
Total health 
expenditure 
Total health expenditure 
Table 4.1: Different dimensions in the SHA.  
 
4.2 Data on health outcomes.  
The Eurostat database[2] and Eurohex[3] databases contain data on self-reported 
health and disability (Global Activity Limitation Indicator, GALI). These indicators will 
be used to calculate Healthy Life Years (HLY) and Life expectancy in good perceived 
health (LEGHP) in addition to life expectancy. These life and health expectancies are 
published on an annual basis for all EU member states, Norway, and Iceland.  
 
4.3 Data on Lifestyle Factors.  
 
 Smoking 4.3.1
For smoking, we propose as our main data source the Eurobarometer, a multi-country 
survey in the entire EU with its most recent round in 2012. (TNS NIPO 2012, [12]) 
This recent survey contains the % of regular daily smokers (ECHI 44), as well as the 
% of former smokers. For countries with missing information, a mapping is to be 
developed that links %s of smokers to Eurostat data on total sales of cigarettes. For 
additional sources see appendix. The choice is conditional on getting access to 
Eurobarometer data.  
 
 Alcohol  4.3.2
For alcohol, the ECHI indicators are: total adult (age 15+) per capita consumption 
(liters of pure alcohol, ECHI 46) and hazardous use (ECHI 47). WHO and EU cooperate 
to provide information through EUSAH (part of GISAH) [10]. Liters per capita are 
available for recent years (2010-2012) for 30 countries, through the EU HEIDI tool 
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[13]. Preferably, we will add information on average consumption level per country, 
according to the EMA/WHO categorization (table 2). This categorization is very 
detailed enabling to combine categories when necessary for data availability or 
modeling, since surveys vary in their categorizations. Rehm et al. (2012) present a 
method to use country-specific data on total consumption (liters per capita) along with 
global information on distributions to calculate country specific divisions into 
categories of consumption level. They present this information for 2009 for 30 
countries (not LT). The most recent Eurobarometer survey on alcohol was performed 
in 2009, covers the EU27 and categorizes in terms of drinks per day.(TNS NIPO 2010) 
We will compare these data and the approach from Rehm et al. to find age and gender 
specific distributions over categories of alcohol consumption. 
 
Men Lifetime 
abstainer 
Former 
drinker 
0-40 40-60 60-100 100+ 
Women 0-20 20-40 40-60 60+ 
Table 4.2: WHO/EMA categorization of alcohol consumption in grams of alcohol (on average) 
 Overweight 4.3.3
The ECHI includes BMI as indicator of overweight (ECHI 42). It distinguishes normal 
weight, overweight or moderate obesity (defined as a BMI between 25 and 29.9), and 
severe obesity (defined as a BMI of 30 and over). For the prevalence of obesity, WHO 
data will be used with reference year 2008.[14] In addition, a recent 
IASO(international Association for the study of Obesity) publication on overweight and 
obesity in the EU27 contains results from national surveys with varying reference 
years ranging from 2003 to 2012 [11].  
 
4.4 Demographic data.  
The Eurostat data are highly standardized in order to secure international 
comparability.  We use the Eurohex database [3] for population data and death counts 
for all EU27 countries, Croatia, Norway, and Iceland. For Liechtenstein national data 
will be used. 
 
4.5  Data linking lifestyle to health outcomes.  
Odds ratios linking risk factor exposure to health outcomes (GALI and self-perceived 
health) will be obtained from the SHARE (Survey of Health and Retirement in Europe, 
[8]). Odds ratios will be assumed constant over all countries and regions. These ratios 
will link current lifestyle to current health outcomes. For smoking, ratios for former 
smokers will also be estimated. For alcohol and overweight, the main health effects 
are linked to current behavior. For alcohol, the main exception to this rule is cancer, 
with total lifetime exposure being the main explanatory factor. However, “on an 
epidemiological level, most of the burden may be related to current drinking.” (Rehm 
et al. 2012) ECHIM also proposes current alcohol use to calculate attributable 
mortality, while including current and former smokers.(Tuomi-Nikula et al. 2012) 
Relative risks of lifestyle for all-cause mortality will be taken from literature.  
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5. Standardizing health and health spending for 
lifestyle 
We will apply the existing DYNAMO-HIA (DYNamic MOdeling for Health Impact 
Assessment) Model to calculate lifestyle standardized outcomes.(Boshuizen et al. 
2012) The 31 countries and many scenarios involved make it more practical and less 
error prone to use this dedicated software. DYNAMO-HIA includes checks of the input 
data (e.g. total prevalence of risk factor equals 100%) and has data storage 
capacities. 
We will run DYNAMO-HIA with lifestyle risk factors directly linked to general health 
outcomes. This avoids the use of less comparable and often unavailable country 
specific disease prevalence, incidence and mortality data, as well as disease and 
country specific cost data that will be impossible to obtain for all 31 countries included.  
 
5.1 Model extension.  
The output of DYNAMO-HIA will be mortality probabilities, prevalence of self-rated 
health/disability by age, gender and country and life and health expectancy (HLY, 
LEGHP) in various scenarios in which risk factor levels are varied.  
In order to also calculate health spending in these various scenarios we will need 
estimates of health spending stratified by age, gender, country/region and preferably 
also self-rated health/disability, mortality risk and/or risk factor level. We will estimate 
the relation between age, risk factors, mortality risk, self-rated health/disability and 
health spending. We will try several model specifications based on the scientific 
literature. The results will be validated using literature on the topic and our own earlier 
work for the Netherlands. Preferably, these estimates are to be performed at least 
region (Nordic, North-West, East and South Europe) specific, since differences in unit 
costs will affect the relations found. The resulting regression models explaining health 
spending will be used to correct aggregate country level health spending as described 
in the previous section for lifestyle changes assumed in the different scenarios (section 
5.2 below).  
The current version of DYNAMO-HIA allows to model one risk factor per scenario. An 
important extension that will be made to the model as part of the proposed project is 
to allow for multiple risk factors so that in scenario analyses all three risk factors can 
be changed simultaneously and a non-smoking, normal weight, normal drinking 
population can be compared to e.g. a smoking, normal weight, normal drinking 
population (benchmarking).  
 
5.2 Scenario analysis-standardization.  
The below scenarios were included in the tender call for the standardization of lifestyle 
factor prevalence across countries (that is, 31 countries, and the EU-27 as a whole): 
A. All prevalences of unhealthy behavior set to 0%, 
B. All prevalences set – stepwise by 10% increases - to 100% for each lifestyle 
factor 
C. All prevalences set to observed (cross-country) minimal prevalences 
D. All prevalences set to observed (cross-country) maximal prevalences 
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E. All prevalences set to those of the country that presents the median 
observation across countries in terms of health outcome 
F. All prevalences set to those of the country that presents the median 
observation across countries in terms of health expenditure. 
All 5 separate scenarios (A and C to F) will be calculated. We will use multifactorial 
design combined with meta-modelling/interpolation to calculate the results for the 
stepwise increases in scenarios B.  
  
5.3 Time lags 
Since we use the model to standardize both health outcomes and health care 
spending, we apply current lifestyle factors to standardize current results. Of course, 
current outcomes and current spending are affected also by previous lifestyle. For 
smoking, former smokers are explicitly included to reflect the strong risks they still 
run compared to never smokers. However, delays in the effects of lifestyle on health 
outcomes are different for each disease and lifestyle factor, therefore fully including 
these relations would require very complex modeling. Our main approach involves 
standardizing both sides of the regression equation for current lifestyle in a similar 
way. By using age-specific data, further effects of time lags should be relatively small. 
Countries with different histories regarding lifestyle will show different age profiles in 
lifestyle and hence the results of standardization will be different.  
 
5.4 Validation.  
To test the robustness of the proposed approach that links risk factors directly to 
health outcomes, and to analyze the effects of time lags in more detail, we will work 
through the complete DYNAMO-HIA model with explicit modeling of diseases for The 
Netherlands and if possible also for Germany. These two countries have detailed cost 
data available. [1,5] Comparing both approaches for these countries provides further 
insight into the robustness of results.  
 
 
6. Incremental cost effectiveness of changes in 
lifestyle 
The comparison of the scenarios with the baseline (starting from the non-standardized 
"as is" situation) will be used to calculate incremental cost-effectiveness outcomes in 
terms of extra € spent or saved per added unit of health outcome (Life expectancy, 
HLY, Life expectancy in good perceived health). Since (the cost of) specific 
interventions are not included, these incremental cost effectiveness outcomes are not 
true cost-effectiveness ratios as usually applied.(E.G. Vos et al. 2010) They rather 
express how country-specific costs and health outcomes may change according to 
hypothetical lifestyle factor prevalence changes.  
Note that this is something else than comparing different countries’ position against 
the estimated (standardized) regression curves. The latter provides insight into the 
potential efficiency gains by moving further towards the curve, e.g. by system 
changes. 
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From our literature review, we will compose an overview of lifestyle interventions 
addressing the three lifestyle factors at stake (smoking, alcohol and 
overweight/obesity) and their cost-effectiveness. Combining information from 
literature with our own scenario analyses will then provide a first underpinning of the 
magnitude of health gains to be gained with additional investments in lifestyle 
interventions in the difference geographical entities.  
 
7.  Qualitative analysis for further interpretation of the 
results  
In a qualitative analysis, we will take a broader view on the topic and analyze possible 
explanations and implications of the results, using the health system frameworks 
developed in the RIVM Public Health Forecasting.  
The qualitative analysis includes discussing the role of other important lifestyle factors 
such as physical activity level. Health systems may generate benefits or outputs in 
addition to better average health, and not included in the cost-effectiveness ratio. 
Furthermore, the chapter will discuss the role of determinants of health such as social 
conditions and the general economic situation. The chapter will also pay attention to 
aspects related to health policy and tentatively come with recommendations. Our 
outcomes will be compared with results from studies on the cost-effectiveness of 
interventions aiming at lifestyle factors. 
We will finally focus on the proportionality between investment in health promotion 
and disease prevention, and expenditure on disease treatment in the long term and 
differences between countries. This will be performed conditional on data availability 
and with due attention to consistency over countries.  
 
8. Planning  
After the current review round, the study design will be finalized. The quantitative 
analyses will start, and an interim report is due at the end of June 2014. During 
summer, the qualitative analyses will be performed. All study findings will be 
presented to external experts (not the current reviewers) in a workshop in autumn 
2014. To enhance a lively discussion, a draft report will be sent to the experts 
involved ahead of this meeting, so that they can prepare themselves. The discussion 
then takes place based on discussion questions.  
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Appendix  
 
Project members 
RIVM: Dr GA de Wit, Dr TL Feenstra, Dr R Heijink, Dr M van den Berg, and Prof dr H 
Boshuizen. 
iMTA, Erasmus University:  Dr PHM van Baal, Dr C de Meijer.  
University Medical Center Rotterdam: Dr W Nusselder, Drs. D Wapperom  
 
Expert committee  
Prof J Polder, Prof J Mackenbach, Dr A Wong, Dr W Bemelmans and Prof W Brouwer.  
 
Table 3: time schedule of activities,  
Time (month) Activities 
M2 Written study design for review by experts 
M3-M6 i Health system c/e 
Quantitative analyses using DYNAMO HIA and regression analyses. 
M6 Interim report 
M7-M9 Qualitative analysis and discussion 
Workshop with experts. M9 
M10  Processing comments 
M11-M12 Additional deliverables and finetuning of final study 
 
 
Table 4: List of deliverables and tasks. 
Deliverable (D)/Task (T) Type of output 
T1. Literature review Contribution to study design and report 
D1. Inception report Report 
T2. Study Design Study Design  
T3. Validity assessment of study 
design  
Final study design in report 
T4. Health System cost effectiveness Contents of report, graphs and tables  
D2. Interim Report Report 
T5. Discussion Contents of report 
T6. Qualitative analysis of 
implications 
Contents of report 
T7. Validity Assessment Improvement of final study 
D3. Final Study Report 
D4. Electronic data file Data file 
D5. Report on validation Added to report 
D6. Executive summary Included in report 
D7. Abstract Included in report 
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List of countries and their abbreviations. 
 
AT 
BE 
BG 
HR 
CY 
CZ 
DK 
EE 
FI 
FR 
DE 
EL 
HU 
IS 
IE 
IT 
LV 
LI 
LT 
LU 
MT 
NL 
NO 
PL 
PT 
RO 
SK 
SI 
ES 
SE 
UK 
 
 
AUSTRIA 
BELGIUM 
BULGARIA 
CROATIA  
CYPRUS 
CZECH REPUBLIC 
DENMARK 
ESTONIA 
FINLAND 
FRANCE 
GERMANY 
GREECE 
HUNGARY 
ICELAND 
IRELAND 
ITALY 
LATVIA 
LIECHTENSTEIN 
LITHUANIA 
LUXEMBOURG 
MALTA 
NETHERLANDS 
NORWAY 
POLAND 
PORTUGAL 
ROMANIA 
SLOVAKIA (Slovak 
Republic) 
SLOVENIA 
SPAIN 
SWEDEN 
UNITED KINGDOM 
 
EU27=all countries above except HR, IS,NO,LT. EU28=all countries except NO,IS, LT. 
 
Impact of lifestyle on macro cost-effectiveness  
Using regression models, the efficiency of individual countries can be estimated in 
different ways: attributing all remaining variation, besides what is explained by 
covariates, to inefficiency. This is called corrected ordinary least squares, and implies 
a shift of the OLS function to a frontier combining the most efficient countries; or 
attributing part of the deviation to inefficiency and part to random noise. This method 
is called stochastic frontier analysis.  
 
Data sources for lifestyle factors   
A EAHC requirement is that all data are at least from 2005 or onwards. This 
disqualifies a number of older surveys, among which the data from the Eurothines 
project, which were applied in a previous DYNAMO HIA application.  
 
The following tables contain an overview of more recent data sources evaluated for  
each of the three lifestyle factors.  
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Table 5 Overview of datasources available for the different lifestyle variables needed. Tobacco 
Source Variable Year 
(most 
recent) 
Countries  
 
Comments   
Eurostat [2] % of 
current, 
former, 
never 
smokers 
2009 EU27+NO   
EHIS [2] % daily 
smokers  
2006-2010 Limited6 2nd wave in 
2014 
By gender 
and age (8 
cats) 
Eurobarometer 
[12] 
% current, 
former, 
never 
smokers 
2012 EU27 
(Misses HR, 
NO,ICE) 
About 1000 
respondents 
per country 
By gender 
and age, 
but small 
numbers 
WHO GHO 
[14] 
Adult 
smoking, 
daily and 
current 
smoking % 
Varies, EU28, NO, 
ICE 
National 
surveys. 
Metadata 
and 
estimates 
for 2008 
and 2010. 
WHO Infobase % daily 
smokers 
OLD Worldwide Seems often 
older than 
2005. 
By age and 
gender 
WHO HFA DB 
[9] 
% daily 
smokers 
2008-2011 EU, not PO  Based on 
national 
surveys 
Only by age 
by 
reference to 
national 
surveys. 
OECD Health 
data [7] 
% daily 
smokers.  
2009-2012 Limited  Incomplete 
regarding 
countries 
Not by age? 
By gender 
 
Further notes concerning smoking 
Sources mainly found by direct consultation of online databases. 
 
Comparability affected by cigarette smokers (or smokers in general), definition of 
current smoker (frequency and amount). 
 
                                           
6 The first wave of the EHIS was implemented during the period 2006-2009 under a gentlemen's 
agreement. Nineteen countries have carried it out in the following years. 2006: AT, EE; 2007: 
SI, CH; 2008: BE, BG, CZ, CY, FR, LV, MT, RO, TR; 2009: DE, EL, ES, HU, PL, SK.  
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Table 6 Overview of datasources available for the different lifestyle variables needed. Alcohol 
Source Variable Year 
(most 
recent
) 
Countrie
s  
 
Comment
s  
 
Eurostat [2]      
EHIS [2] ECHI46 and 
47 
2006-
2010 
Limited1 2nd wave in 
2014 
By 
gender 
and age 
(8 cats) 
Eurobarometer [12] Liters per 
capita, 
adults, 
15+, 
categories 
of average 
daily 
consumptio
n 
2009 EU27 
(Misses 
HR, 
NO,ICE) 
About 1000 
respondent
s per 
country 
By 
gender 
and age, 
but 
small 
numbers 
WHO Global Alcohol 
database  
Liters per 
capita, 
adults, 
15+. 
Varies EU28, 
NO, ICE 
Trends 
1990-
2010: 
Status 
report 
2013. 
 
EUSAH/EISAH/GISAH 
WHO+EU [10] 
(http://who.int/gho/eisah
). 
Liters per 
capita, 
adults, 
15+. 
2008, 
2011, 
2012. 
Worldwid
e 
 By age 
and 
gender 
WHO HFA DB [9] Liters per 
capita. 
Adults 15+. 
2005 Worldwid
e 
Based on 
national 
surveys, 
first source 
for 
Anderson 
and 
Blaumberg 
Only by 
age by 
referenc
e to 
national 
surveys. 
OECD Health data [7]  2009-
2012 
Limited  Incomplete 
regarding 
countries 
Not by 
age? 
By 
gender 
CAMH report (Rehm et al. 
2012)  
Liters per 
capita, 
adults, 15+ 
and 
average 
daily 
consumptio
n in 
categories 
2009 EU27 
+NO+ICL 
-HR-Lie.  
Not clear 
about 
actual 
reference 
year of 
data, own 
calculations 
added to 
data 
Must be 
by age 
and 
gender. 
 
Further notes concerning Alcohol 
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Reports consulted: Committee, EU 2010, Anderson and Blaumberg 2006, Anderson et 
al. 2012, Horlings and Scoggins (2006), Rehm et al. (2012), WHO 2013, Tuomi-Nikula 
et al. 2012. Eurobarometer 331, 2010. In addition online databases were directly 
consulted.    
 
“The best indicator for overall volume of alcohol consumption is adult (age 15+ years) 
per capita consumption (Gmel & Rehm, 2004), as it avoids the various biases 
introduced by current surveys of the general population (for example, Groves, 2004; 
Shield & Rehm, 2012).” (from WHO 2012).  
 
Non-drinkers are to be split into never drinkers and former drinkers. Occasional 
drinkers (Allemani 2001) may differ per culture.   
 
Underreporting up to 60% (Bloomberg 2003). Assume this to be constant over 
countries.  
 
 
Table 7 Overview of datasources available for the different lifestyle variables needed. 
Overweight 
Source Variable Year 
(most 
recent) 
Countries  
 
Comments   
Eurostat 
[2] 
     
EHIS [2] ECHI42 2006-
2010 
Limited1  2nd wave in 
2014 
By gender 
and age (8 
cats) 
WHO 
GHO [14] 
Overweight, 
Obesity, Mean 
BMI 
2008 EU28+NO,IS. 
Not LI  
  
IASO 
report 
[12] 
BMI 
categories 
2008  Limited Calculated 
data based on 
national 
surveys 
Reference 
years may 
vary.  
Not clear 
about age 
categories. 
OECD 
Health 
data [7] 
 2009-
2012 
Limited  Incomplete 
regarding 
countries 
Not by age? 
By gender 
 
Further notes concerning overweight 
Reports consulted for overweight. OECD 2012, Sassi 2010, IASO 2012 [12]. In 
addition online databased were consulted.  
 
Important distinction between self-reported and measured BMI. Most surveys use self-
reported BMI, IASO data repository provides a distinction, but is incomplete. 
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Study Design for review purposes, reply 
form  
 
 
“Life Table Analysis: health system cost-effectiveness 
assessments across Europe” 
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Reply form  
 
Our question to you as a reviewer is to comment on the study design, focusing on 
those parts that concern your expertise. To enable finding these parts, we have made 
ample use of subheadings throughout the text. That is, we do not expect you to 
comment on the entire text, although you may of course feel free to do so.  
 
It is important to keep in mind that the current research project will have a limited 
budget and time horizon of 12 months. Nevertheless, the results have to be 
sufficiently reliable and enable sound interpretation.    
 
Contact: Talitha.Feenstra@rivm.nl, or Richard.Heijink@rivm.nl.  
 
 
Your area(s) of expertise:  
 
 
 
Do you agree with the approach proposed? Please comment your answer.  
  
 
 
 
 
Do you agree with the data sources proposed? Please comment your answer.  
Did we miss important data sources?  
 
 
 
 
 
Do you agree with the output measures proposed? Please comment your answer.  
 
 
 
 
 
What could be advantages of the current approach? 
 
 
 
 
 
What could be important limitations?  
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What are caveats to be aware of? E.g. risks of bias to take into account. 
 
 
 
 
 
Do you have suggestions regarding references or experts to consult? 
 
 
 
 
 
 
Any further comments or remarks?  
 
 
 
 
 
 
 
Thank your for your efforts.  
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“Life Table Analysis: health system cost-effectiveness 
assessments across Europe” (MACELI)  
Contract 20136303 Call for tenders EAHC/2013/Health/05 
Results of expert review of study design. 
 
List of experts consulted and responses.  
 
In total 19 experts were approached, of which 10 confirmed their participation in 
December. From 7 of these, we received a timely and complete review. One of them 
withdrew in second instance, one could not make it in time due to problems of 
receiving the design to the right address and one did not respond. In addition we 
approached our advisory board with an open opportunity to comment, resulting in one 
further review.  
Areas of expertise covered were using experts’ own wordings:  Public health 
technology assessment, Economic evaluation, Outcome measurement, Obesity 
epidemiology, Public health, Life table modeling, Demography, Health economics, 
Macroeconomics, Health care at macro level, Efficiency analysis, Global health, Medical 
demography, and Social epidemiology.     
 
Table 3: Overview of experts involved in review of study design 
Experts approached Participation 
confirmed 
Review received 
Name Affiliation 10 7 
Prof A Street University of York, UK   
Prof M McKee LSHTM, UK Replacement 
proposed 
 
Prof U Hakkinen National Institute for Health and 
Welfare, Finland 
  
Dr E Nolte RAND Europe, UK 1 Problem with email on 
our side 
Prof A Ludbrook University of Aberdeen, UK   
Dr S Cnossen CPB, Netherlands 1 Withdrawn 
Prof J Seidell VU University Amsterdam, Netherlands   
Dr A Peeters Monash University, Australia   1 1 
Dr C van Ewijk CPB, Netherlands 1 1 
Prof Dr T Vos IHME, University of Washington, USA 1 1 
Prof F Willekens RUG/NIDI, Netherlands 1 1 
Dr J Lauer WHO 1  
Prof S Evers Maastricht University, Netherlands 1 1 
Prof M Lindenboom University of Amsterdam, Netherlands Replacement 
proposed 
 
Prof J Barendregt University of Queensland, Australia   
Anton Kunst University of Amsterdam, Netherlands 1 1 
Dan Chisholm WHO   
Franco Sassi OECD   
Adriana Castelli University of York, UK 1 1 
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Summary of comments  
 
The complete overview of all comments can be found in a separate excel document. 
From these we extracted the following main comments. 
 
Several reviewers asked more clarification on the approach to standardizing for 
lifestyle differences on both health outcomes and health care spending. In addition, 
some reviewers critiqued this double standardization approach, while others 
considered this as of great value, especially the use of DYNAMO-HIA. Thus opinions 
were mixed on this topic. 
   
More general comments on the study approach were suggestions to include explicit 
uncertainty analyses by several reviewers, to remove Liechtenstein, to add a 
discussion of strengths and limitations, to reconsider using the RIVM framework in the 
qualitative analyses and to change the order of the qualitative and quantitative 
analysis.  
  
Two more specific comments on the definition of lifestyle scenarios were given. A 
reviewer asks what would be the healthy reference category in alcohol and 
overweight. Another point is the definition of scenarios with stepwise increases on 
multiple categories.  
 
Regarding the regression analyses, several reviewers suggested use of spending per 
capita or spending adjusted with PPP. Three reviewers had problems with the 
regressions as such, but for varying reasons. Caution in the interpretation was also 
suggested. 
More specifically, 5 reviewers suggested adding other covariates, while one warned 
against over controlling and suggested using country specific dummies. 
 
The validation by a full analysis on NL and DE was critiqued by 4 reviewers as not 
helpful for the main objective.  
 
Almost all reviewers expressed concerns for consistency in the data used and 
comparability across countries of the various variables. It was suggested to use 
statistical methods rather than expert opinion to correct for missing values. It was 
also suggested to show international patters in the raw data before proceeding with 
the analyses. Some comments concerned terminology and reporting of alcohol and 
overweight. One pointed at existing controversies in the value of relative risks for 
overweight.  
 
Four reviewers underlined that the results of the project cannot be interpreted as cost-
effectiveness ratios, since no interventions and costs of these are included. A reviewer 
thought life expectancy was a less appropriate measure to reflect the effect of health 
care spending, while the other two were better.  
       
Some reviewers did not fully understand the objective of the project or commented it 
seemed like two objectives in one.  
Several reviewers asked for more explanation on the use of DYNAMO HIA.  
 
No alternatives for our data sources were mentioned, except the site of the IHME, 
which are the GBD data. 
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List of proposed adaptations in response to comments 
 
 
Regarding comments on overall objective and the approach towards standardizing for 
lifestyle differences we propose that more clarification is the best way forward.  
In addition, we consider a sensitivity analysis using a more common way to control for 
differences in life style, that is, by including covariates in the regression analyses, see 
below on the contents of the sensitivity analyses.   
 
In addition, more elaborate uncertainty analyses would also be preferable, however, 
this would require time and probably the interim analyses will contain limited 
uncertainty analyses, to be followed by more elaborate ones in the final report. 
We will consider removing Liechtenstein. Very few data will be available and this 
country deviates from the others, for its very open system. That is, many citizens will 
go to neighboring countries for part of their health care.  
We will add strengths and limitations, as we planned to do, in the discussion chapter. 
 
Regarding the definition of lifestyle scenarios, the reviewer is right that the category of 
non-use in alcohol and very low BMI in overweight are a mixture of abstainers and 
former drinkers. However, by using similar categories in SHARE when estimating odds 
ratios, risks in these categories will reflect the mixed populations.  
Regarding scenarios, we will define these in terms of shifts towards a more healthy 
distribution over categories. We would however prefer to focus on the scenarios that 
are of interest to policy, like the most healthy country, the EU28 average, and the 
least healthy country. 
 
Regarding the sensitivity analyses, we thought this over in reaction to the reviewer 
comments. Given the importance of consistency in data, we propose to replace the full 
evaluations of NL and DE by elaborate sensitivity analyses on the following points:  
- Different way of accounting for lifestyle in the regressions: not by double 
standardization, but in the more common way by including it as a covariate.  
- Use of a different set of input data on lifestyle, that is, the GBD data.  
- For a limited set of countries, use of panel data in addition to the standard analyses.  
 
Regarding the regression analyses, the reviewers opinions were mixed. We propose to 
better explain our approach and indeed use sufficient caution in the interpretation of 
the results. This concerns causality claims and interpretation as a cost-effectiveness 
ratio. However, we will review interventions and provide information on their costs and 
benefits.  
 
Given that no substantial comments on our choice of data sources were given, we do 
not propose any changes here. However, we will remain aware of the consistency 
issues. We did not see very critical comments concerning time lags in lifestyle 
variables specifically, though the standardization and regression approach was 
commented (see above) and hence we will proceed as proposed in the study design by 
using the double standardization with age and gender specific data, as much as 
possible.  
 
For the use of DYNAMO-HIA, more explanation will be added in the methods of the 
report, given the questions raised by the reviewers.   
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Conclusions  
 
The main changes to the study design in response to the reviewer comments concern 
replacing the sensitivity analyses by those required for by the reviewers and being 
careful in the definition of the scenarios to be evaluated with DYNAMO-HIA.  
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Expert workshop, program, summary of results, and list of discussion points 
 
The effect of lifestyle on health system efficiency. 
Methodological and policy issues. 
Invitational Workshop as part of the EAHC tendered project: Macro Cost Effectiveness 
corrected for Lifestyle (MACELI).  
Contract 20136303 Call for tenders EAHC/2013/Health/05 “Life Table Analysis: health 
system cost-effectiveness assessments across Europe”.  Funded by the European 
Union in the frame of the EU Health Programme (2008-2013) 
 
LOCATION: Park Inn Radisson Brussels Midi 
TIME: 11h00-16h00 
 
Draft Program 
10h30-11h00  Coffee. 
 
11h00-11h15  Start of the workshop   Dr TL Feenstra 
11h15-11h35  Introduction of participants  
11h35-11h40  Background of the EAHC call Representative DG Sanco: Dr 
A Carvalho 
11h40-12h20  MACELI main interim results  Dr PHM van Baal 
12h20-13h00  Guest speaker    Prof M St Aubyn 
13h00-14h00   LUNCH 
 
14h00-15h00  sub sessions 
Each sub session will consist of two presentations of 15 minutes each explaining 
methods applied in the MACELI project in more detail. This is followed by extensive 
time for discussion.  
 
1. Use scenarios to standardize countries for differences in lifestyle 
This sub session will address consistent prevalence estimates of lifestyle behavior, 
estimating and interpreting Odds Ratios for health outcomes related to lifestyle and the 
use of life table modeling to relate lifestyle scenarios to health outcomes. Special 
attention will go to having a look at the observed actual lifestyle results for all countries 
and the calculated odds ratios and their interpretation. The role of time lags will be 
addressed.  
Keywords: alcohol use, smoking, overweight, cross-country comparisons, odds ratios, 
self-reported health outcomes, life table modeling. 
 
2. Interpreting outcomes of efficiency frontiers 
What is the best way to correct for differences in lifestyle when assessing the efficiency 
of health care systems? This subsession will cover in more detail the topics addressed in 
the morning. Different approaches to assessing health system efficiency and their 
(dis)advantages will be discussed. Furthermore, we will discuss the interpretation and 
usability of country-level comparisons and rankings of health system performance and 
the role of lifestyle and other environmental factors.  
Keywords: Regressions, DEA, covariates, stratification. 
 
15h00-15h15  Tea break 
 
15h15-15h45  Plenary discussion  Prof Dr HM Boshuizen  
 
15h45   Closure and drinks 
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The effect of lifestyle on health system efficiency. 
Methodological and policy issues. 
 
Invitational Workshop as part of the EAHC tendered project: Macro Cost Effectiveness 
corrected for Lifestyle (MACELI).  
Contract 20136303 Call for tenders EAHC/2013/Health/05 “Life Table Analysis: health 
system cost-effectiveness assessments across Europe”.  Funded by the European 
Union in the frame of the EU Health Programme (2008-2013) 
 
LOCATION: Park Inn Radisson Brussels Midi 
TIME: 11h00-16h00 
Summary of Results and action points 
Organizers present 
Pieter van Baal   Erasmus University   
Michael van den Berg RIVM(National Institute of public health and the environment) 
Hendriek Boshuizen RIVM(National Institute of public health and the environment) 
Talitha Feenstra  RIVM (National Institute of public health and the environment) 
Koen Fussenich  RIVM(National Institute of public health and the environment) 
Richard Heijink  RIVM(National Institute of public health and the environment) 
Petra Hoogerhuis  RIVM(National Institute of public health and the environment) 
Wilma Nusselder  Erasmus Medical Centre 
Ardine de Wit  RIVM(National Institute of public health and the environment) 
 
Participants present and subsession attended.  
  
Sub 
session 1 
Sub 
session 2 
Henrik Brønnum-Hansen University of Copenhagen 1  
Guy d' Argent   EAHC (Executive Agency for Health and Consumers) 1  
Arthur Carvalho DG Sanco 1  
Marion Devaux OECD (The Organisation for Economic Co-operation 
and Development) 
1  
Gabriela Flores University of Lausanne  1 
Ulrich Frick University of Zurich 1  
Eileen Kaner Newcastle University 1  
Tim Lobstein IASO  (The International Association for the Study of 
Obesity) 
  
Pascal Meeus INAMI  (Belgian Health Insurance system)  1 
Cor van Mosseveld CBS (Statistics Netherlands)  1 
Ivo Rakovac World Health Organisation 1  
Francoise Renard Scientific Institute of Public Health 1  
Jean-Marie Robine French National Institute of Health and Medical 
Research 
1  
Markus Schneider Basys (Applied Systems Research Consulting 
Corporation Ltd) 
 1 
Miguel St. Aubyn UECE-ISEG, University of Lisbon  1 
Dirk van der Steen  DG Sanco  1 
Michael Stolpe Kiel Institute for the World Economy  1 
Tommy Visscher Windesheim University of Applied Sciences   
Matthias Vogl Helmholtz Zentrum München 1  
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Summary of morning session.  
 
11h00-11h15  Start of the workshop   Dr TL Feenstra 
11h15-11h35  Introduction of participants  
11h35-11h40  Background of the EAHC call Representative DG Sanco: Dr A 
Carvalho 
11h40-12h20  MACELI main interim results  Dr PHM van Baal 
12h20-13h00  Guest speaker    Prof M St Aubyn 
 
All presentations were received with a lively discussion in the audience.  
Afternoon session.  
14h00-15h00  sub sessions 
15h00-15h15  Tea break 
15h15-15h45  Plenary discussion 
 
Both sub sessions were well attended, with slightly more participants in the first sub 
session. From the subsessions, two lists of suggestions and points for discussion 
result. Additionally in the plenary discussion two points brought up were:  
- Pay attention to relations between BMI/Smoking/Alcohol in the discussion. 
- Message of costly, but cost-effective results quite hard to explain for a wide audience.  
May use disease-specific modeling to explain this better.  
 Action points for the MACELI Team 
- Adjust policy setting to new EU policy documents as presented by A. Carvalho.  
- Use discussion of DEA approach by St Aubyn in chapter on methods, when explaining 
the different approaches towards assessing health system efficiency.  
- Use points on lists of suggestions to improve the discussion and as input for the 
qualitative chapter. Put interim results into their appropriate perspective. 
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 Long list of discussion points workshop. 
 
- Health care spending is chosen as dependent variable, alternative would have been use 
of health services 
- Baseline scenario to be understood as current level of interventions available to prevent 
and treat diseases related to unhealthy lifestyle, not as a baseline scenario as used by 
WHO.  
- Impact of clustering of smoking and BMI. Correction for clustering of smoking and BMI, 
we did not do that, but data were robust enough not to expect large impact of 
clustering. 
- Limitation that SHARE concerns only 50+ persons, overestimation of effects because 
data from older people are used.  
- delay between health behavior and its consequences.  
- use EHIS health interview survey for sensitivity analysis?  
- differences in OR as used from international literature, may especially be influential for 
the disability estimates. Reduced OR for younger people?  
- Separate scenarios for smoking and obesity and impact on cost estimates, explain and 
discuss finding that reduction in risky behavior results in higher health care costs. 
Expectation that separate analysis for obesity would reduce healthcsre spending instead 
of augmenting it 
- Discuss the notion of differences between demand or need for health care? Self 
perceived health how does that relate to needs? If you are rich, more demand. 
- Preference for use of data on occurrence of chronic diseases, rather than perceived 
health. Possibility to use European harmonized data on occurrence of chronic diseases?  
- DALY could have been an interesting outcome  
- discuss the difference between current use of data on curative health expenditure 
instead of data on preventive health expenditure?  
- It may take time to see effects of lower spending in le  
- What is best performer spending..? Om prevention?  
- Explain standardisation 
- Share 50+ 
- Compare model results to observed results? In addition to cau observed vs scenario 
outcomes.  
- Period not cohort  
- Le at birth vs share with age 50+, suggestion use model for 50+ as a SA  
- For disability, lit uses different outcomes.  
- Wat is er voor verschil tussen de 2 plaatjes in % verschil in le?  
- Outcome, considered DALYs, more layers. This is just a one period outcome.  
- Zit op de le vs volume punt van Peter Achterberg 
- Why no within countrry comparisons  
- Volumes  vs expenditure. Price is an outcome of the health system.  
- Alcohol results based in limitations of dataset?  
 
 Suggestions from subsession 1.  
Main points for policy implications and discussion:  
- Drinking patterns are important 
- The causal pathway for alcohol in relation to health care use is sometimes unexpected, 
due to care avoidance and rationing.  
- Pay attention to model validation and uncertainty of outcomes.  
- A trade-off exists between high quality data and including a large range of countries. 
Main points for methodology and further research:  
- Better prevalence data on alcohol could be interesting, but have to match with self 
reported data used to find ORs.  
- Compare the results assuming a fixed age pattern with those obtained now.  
- Consider the possibility to restrict the analyses to the age group of 50+. 
- Try using cross tabulation to get information on patterns for alcohol use from EB data.  
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- Consider applying SHARE waves to get insight into time effects of lifestyle variables.  
- Evaluate an additional scenario that results in 2 more HLY in 2020, since that is a EU 
goal.  
- Use disease free life expectancy as an outcome (ECHO) in further research.  
Other points discussed.  
- Take the US and Australian literature on interventions and k/e into account. Check the 
recent OECD literature review on alcohol interventions. Focus on interventions at a 
system level, rather than interventions targeting individuals.  
- Use the 2010 paper by Lim et al. to justify the choice of lifestyle risk factors.  
- Include a thorough explanation of choices made concerning alcohol data and how these 
were used in the analyses.  
- Use the findings from the project for recommendations concerning new data gathering: 
what deserves special attention in a next Eurobarometer? What are recommendations 
for other data gathering efforts ongoing with EU support? 
- Discuss choices concerning ORs. Alternative choices could have been made.  
- For further research, an approach using disease specific data could use ECHO data . 
  
 Suggestions from subsession 2.  
Main points for policy implications and discussion:  
- If system performance improves, GDP rises.  
- Within country variations 
- Many returns of spending not measured/not included in the outcomes.  
- Is healthy life style an intermediating variable or an exogenous variable.  
Main points for methodology and further research 
- Time lags 
- Other input measures such as number of doctors, beds, etc., not only expenditure 
- Correct for wage level differences 
- Correct for population density 
- Include capital investment? 
- Interaction between age and BMI 
- Correct for public health activities?  
- Health expenditure not broken down by spending per age group 
- Interactions between age and BMI not taken into account 
- Year 2009 GDP data different? Exclude 2009 or other recession years? 
 
 General discussion 
- Pay attention to relations between BMI/SMOK/Alc in the discussion. 
- Message of costly, but cost-effective results too hard for wide audience? Use disease-
specific modeling to explain this better. Showing effects on competing diseases will 
make results less counterintuitive 
- Can we use data of Health Matrix (risk factors)? Use GBD data as a justification for our 
choice of lifestyle behaviors 
- Group interventions in review in individual and collective interventions. System policy 
level interventions will also be helpful, now not included in review. Literature review 
should be extended to Australia and Canada 
- Other points brought forward, to be discussed in final report: 
o Those who stop smoking will step into other addictions, less room for change 
than suggested 
o Behaviors not isolated, cumulative effects, model assumes multiplicative effects 
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9.7   Selected results for the EU-28 Member States  
 
This appendix contains a selection of the graphs and tables from Chapter 4 for the EU-
28 Member States.  
 
Results of unadjusted analyses.  
 
 
Figure 9.5: The association between curative care spending and life expectancy 
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Figure 9.6: The association between curative care spending and healthy life years 
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Figure 9.7: The association between curative care spending and life expectancy in good 
perceived health. 
  
 
 
Table 9.2: Elasticity of population health to curative care spending, GDP per capita and 
education 
 LE HLY LEGPH 
Basic model (2010)    
   Curative care spending 0.055*** -0.076 0.053 
   GDP per capita 0.000 0.180 0.055 
   Education -0.022 -0.031 0.018 
   N 21 21 21 
   R-squared 0.76 0.30 0.58 
    
Panel data model (2004-2011)    
   Curative care spending 0.031*** -0.174*** 0.103*** 
   GDP per capita -0.022** 0.097** -0.059*** 
   Education 0.131*** 0.311** 0.252*** 
   N 179 164 164 
P-value of null hypothesis of no effect. *p<0.10; **p<0.05; ***p<0.01 
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Figure 9.8: Health system efficiency estimated by parametric analysis (actual-predicted 
population health in years)  
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Figure 9.9:  Health system efficiency estimated by Data Envelopment analysis (efficiency score 
between 0 and 1).  
 
The same figure has also been split into three separate figures, one for each health 
outcome and with countries ordered by efficiency.  
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Figure 9.10: Health system efficiency estimated by Data Envelopment analysis (efficiency score 
between 0 and 1), using Life Expectancy as health outcome.  
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Figure 9.11: Health system efficiency estimated by Data Envelopment analysis (efficiency score 
between 0 and 1), using Healthy Life Years as health outcome.  
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Figure 9.12: Health system efficiency estimated by Data Envelopment analysis (efficiency score 
between 0 and 1), using Life Expectancy in Good Perceived Health as health outcome.  
 
 
  
.8
5
.9
.9
5
1
E
ffi
c
ie
n
c
y
 s
c
o
re
SK HR LT SI HUPL CZ AT DKBE CY EE EL LU DE FI FR NO IT ES UK NL SE BG IE IS LV MT PT RO
    Final report MACELI 
 
 
December, 2014  
 150 
Results of scenario analyses.  
 
Table 9.3: Baseline values for health spending and population health  
Country LE LEGPH HLY THCE (€) 
Austria 80.45 58.33 59.60 2339.46 
Belgium 80.05 60.53 62.94 2201.44 
Bulgaria 73.81 54.95 64.76 545.69 
Croatia 76.65 58.37 58.37 893.62 
Cyprus 81.15 59.73 64.79 1347.31 
Czech Republic 77.57 53.44 62.69 1152.76 
Denmark 79.24 58.30 60.74 2553.83 
Estonia 75.98 46.11 55.61 713.23 
Finland 80.01 58.11 57.08 1886.45 
France 81.34 56.91 62.17 2344.18 
Germany 80.49 56.25 61.98 2460.08 
Greece 80.50 62.65 66.65 1512.03 
Hungary 74.54 47.35 56.93 875.28 
Ireland 80.81 67.12 65.96 1979.02 
Italy 82.13 58.16 67.33 1825.51 
Latvia 72.90 41.63 54.19 382.25 
Lithuania 73.16 45.15 59.63 722.84 
Luxembourg 80.45 61.46 64.89 2821.36 
Malta 80.71 56.10 70.49 1358.14 
Netherlands 80.77 64.30 60.40 2229.57 
Poland 76.30 48.32 59.76 793.41 
Portugal 79.93 43.83 57.23 1739.92 
Romania 73.77 54.96 57.08 436.00 
Slovakia 75.46 50.57 51.68 1243.42 
Slovenia 79.52 50.30 52.81 1351.82 
Spain 82.04 59.97 63.59 1743.38 
Sweden 81.52 66.71 70.80 2004.78 
United Kingdom 80.40 65.07 64.50 1802.92 
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Table 9.4: Changes in health and health expenditures in scenario 1 compared to the base case 
scenario 
 
Difference between scenario 1 and base case scenario 
Country LE (years) LEGPH (years) HLY (years) TCHE* (€) 
Austria 0.95 2.98 2.18 38 
Belgium 1.11 3.21 2.21 31 
Bulgaria 1.31 2.77 2.19 10 
Croatia 1.65 3.77 4.91 30 
Cyprus 1.21 3.90 2.90 23 
Czech Republic 1.21 3.90 2.90 21 
Denmark 1.41 2.67 2.00 60 
Estonia 1.66 3.79 2.99 19 
Finland 0.85 3.16 2.86 15 
France 1.05 2.73 1.69 39 
Germany 1.15 3.46 2.34 35 
Greece 1.80 3.73 2.71 33 
Hungary 1.67 4.14 3.26 19 
Ireland 0.63 2.93 2.15 21 
Italy 0.36 2.59 1.58 14 
Latvia 2.25 4.87 3.99 13 
Lithuania 1.89 3.58 3.23 21 
Luxembourg 1.14 3.32 2.37 50 
Malta 1.26 4.95 3.00 13 
Netherlands 1.38 2.68 2.14 52 
Norway 2.14 3.66 3.07 95 
Poland 1.86 3.74 3.36 22 
Portugal 0.65 3.75 2.73 12 
Romania 1.38 2.75 2.46 11 
Slovakia 1.30 2.79 2.30 20 
Slovenia 1.20 3.42 2.79 24 
Spain 1.21 4.38 3.25 29 
Sweden 0.66 1.25 0.92 26 
United Kingdom 0.99 3.22 2.42 21 
*Total curative care spending (€ per capita, price level 2010) 
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Table 9.5: Changes in Life Expectancy (years) by country and scenario 
 Scenario no7 2a 2b 2c 2d 3a 3b 3c 3d 
Austria 3.09 1.79 1.24 0.07 -6.27 -3.75 -3.13 -0.04 
Belgium 3.30 1.95 1.27 0.09 -6.29 -3.78 -3.15 0.01 
Bulgaria 3.74 2.16 1.57 0.02 -6.07 -3.67 -3.19 0.01 
Croatia 4.03 2.11 1.79 0.06 -5.64 -3.70 -2.60 0.07 
Cyprus 3.18 1.80 1.32 0.03 -5.44 -3.38 -2.58 -0.01 
Czech Republic 3.42 1.77 1.59 0.04 -6.26 -3.96 -2.97 -0.02 
Denmark 3.65 2.37 1.20 0.12 -6.08 -3.51 -3.34 0.02 
Estonia 4.31 2.43 1.77 0.03 -6.35 -3.82 -3.42 0.03 
Finland 3.07 1.62 1.41 0.04 -6.52 -4.10 -3.12 0.00 
France 3.34 1.94 1.32 0.09 -6.66 -3.99 -3.37 0.00 
Germany 3.83 2.33 1.32 0.07 -6.51 -3.95 -3.33 -0.06 
Greece 3.95 2.26 1.63 0.05 -5.34 -3.29 -2.69 0.03 
Hungary 4.43 2.37 1.97 0.00 -6.36 -4.07 -2.99 0.03 
Iceland 3.98 2.02 1.77 0.15 -4.82 -3.21 -2.26 0.18 
Ireland 2.73 1.44 1.19 0.09 -6.55 -4.14 -3.03 0.01 
Italy 2.42 1.33 0.99 0.10 -6.65 -4.07 -3.02 -0.08 
Latvia 5.05 2.97 1.98 -0.01 -6.04 -3.55 -3.30 0.06 
Lithuania 4.70 2.51 2.11 0.00 -6.50 -4.04 -3.45 0.12 
Luxembourg 3.08 1.75 1.34 0.04 -5.87 -3.60 -2.81 0.01 
Malta 3.29 1.38 1.79 0.02 -5.62 -3.95 -2.16 0.05 
Netherlands 3.47 2.12 1.21 0.15 -5.79 -3.43 -3.00 0.04 
Norway 4.23 2.25 1.75 0.17 -5.14 -3.31 -2.55 0.19 
Poland 4.46 2.71 1.67 0.03 -6.12 -3.59 -3.23 0.00 
Portugal 2.89 1.40 1.38 0.07 -6.78 -4.32 -2.99 0.00 
Romania 4.19 2.27 1.71 0.10 -6.60 -4.09 -3.36 0.07 
Slovakia 3.83 2.09 1.64 0.03 -6.29 -3.91 -3.03 -0.02 
Slovenia 3.47 1.62 1.77 0.05 -6.13 -4.06 -2.67 0.02 
Spain 3.34 1.78 1.45 0.07 -5.97 -3.79 -2.65 0.00 
Sweden 2.71 1.63 1.02 0.05 -6.43 -3.83 -3.14 -0.07 
UK 3.16 1.79 1.26 0.13 -6.38 -3.96 -3.09 0.04 
 
  
                                           
7 Scenario definitions were 2a: 100% healthy; 2b: 100% no smoking; 2c: 100% best BMI; 2d: 100% in 
healthiest category for alcohol consumption; 3a: 100% unhealthy; 3b: 100% smoking; 3c: 100% worst 
BMI; 3d: 100% most unhealthy category for alcohol consumption  
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Table 9.6: Changes in Healthy Life Years (years) by country and scenario8 
  2a 2b 2c 2d 3a 3b 3c 3d 
Austria 6.57 2.30 2.49 1.78 -14.78 -2.79 -7.53 -3.63 
Belgium 6.48 2.20 2.66 1.74 -14.84 -3.18 -7.37 -3.39 
Bulgaria 5.60 2.13 2.36 1.15 -9.82 -2.73 -5.23 -1.78 
Croatia 7.84 2.36 3.43 2.12 -10.61 -2.49 -5.58 -2.43 
Cyprus 6.55 2.01 2.82 1.80 -11.42 -2.44 -5.63 -2.67 
Czech Republic 6.23 1.95 2.83 1.40 -12.96 -3.05 -6.15 -2.90 
Denmark 7.02 3.20 2.81 1.18 -19.27 -4.02 -8.90 -4.89 
Estonia 7.20 2.39 2.82 1.84 -12.66 -2.41 -6.37 -2.93 
Finland 7.62 2.23 3.33 2.12 -16.37 -3.55 -7.85 -3.98 
France 5.95 2.16 2.42 1.47 -15.35 -2.97 -7.70 -3.85 
Germany 6.68 2.31 2.57 1.82 -14.43 -2.94 -7.28 -3.34 
Greece 5.81 1.81 2.53 1.39 -8.19 -1.77 -4.39 -1.97 
Hungary 7.21 2.09 3.03 2.02 -10.69 -2.56 -5.66 -2.16 
Iceland 7.31 2.49 3.94 0.97 -14.99 -3.32 -6.12 -3.94 
Ireland 6.26 1.78 2.46 2.09 -14.05 -3.59 -6.83 -2.61 
Italy 5.22 1.37 1.76 2.13 -12.34 -2.99 -6.71 -2.08 
Latvia 8.06 2.73 3.21 1.96 -11.27 -2.06 -5.92 -2.43 
Lithuania 7.00 2.21 3.01 1.62 -9.88 -2.45 -5.30 -1.82 
Luxembourg 6.56 2.27 2.99 1.49 -14.69 -3.31 -7.10 -3.51 
Malta 6.20 1.44 3.16 1.55 -8.78 -2.96 -4.10 -1.55 
Netherlands 6.70 2.50 2.77 1.48 -16.39 -3.07 -7.82 -4.34 
Norway 7.28 2.91 3.70 0.75 -15.62 -3.53 -6.34 -4.00 
Poland 7.45 2.48 2.75 2.07 -11.62 -2.47 -6.23 -2.23 
Portugal 6.81 1.71 2.68 2.44 -13.12 -2.90 -7.07 -2.61 
Romania 6.35 1.95 2.43 1.82 -10.51 -2.46 -5.81 -2.10 
Slovakia 5.99 1.88 2.40 1.68 -11.92 -2.19 -5.75 -2.90 
Slovenia 7.65 2.20 3.42 1.96 -16.07 -3.36 -7.53 -4.24 
Spain 7.33 2.08 2.91 2.29 -12.72 -2.65 -6.56 -2.62 
Sweden 4.83 1.82 2.08 1.01 -15.88 -4.06 -7.27 -3.13 
UK 6.68 2.16 2.74 1.96 -14.72 -3.48 -7.22 -3.22 
 
  
                                           
8 Scenario definitions were 2a: 100% healthy; 2b: 100% no smoking; 2c: 100% best BMI; 2d: 100% in 
healthiest category for alcohol consumption; 3a: 100% unhealthy; 3b: 100% smoking; 3c: 100% worst 
BMI; 3d: 100% most unhealthy category for alcohol consumption  
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Table 9.7: Changes in Life Expectancy in Good Perceived Health (years) by country and 
scenario9 
 
2a 2b 2c 2d 3a 3b 3c 3d 
Austria 8.40 3.04 2.90 2.52 -19.31 -4.54 -11.16 -3.59 
Belgium 8.69 3.04 3.44 2.40 -19.94 -5.22 -10.64 -1.89 
Bulgaria 6.51 2.37 2.51 1.70 -11.96 -2.82 -6.86 7.66 
Croatia 9.80 3.11 4.14 2.73 -14.14 -4.22 -7.59 -2.95 
Cyprus 8.29 2.56 3.42 2.38 -14.12 -3.68 -7.37 2.00 
Czech Republic 7.17 2.36 2.79 1.89 -15.91 -3.86 -8.92 5.41 
Denmark 9.03 3.90 3.63 1.73 -24.53 -6.19 -13.52 -3.99 
Estonia 9.14 3.11 3.07 2.55 -16.92 -4.17 -10.34 5.65 
Finland 8.19 2.50 3.49 2.29 -17.77 -4.76 -9.44 -6.19 
France 8.39 3.09 3.17 2.28 -20.86 -5.03 -11.88 0.30 
Germany 9.31 3.21 3.38 2.68 -19.81 -5.12 -11.23 1.42 
Greece 7.53 2.51 3.20 1.91 -11.49 -2.78 -6.05 1.67 
Hungary 8.56 2.64 2.97 2.74 -13.05 -3.48 -7.77 6.94 
Iceland 8.79 3.12 4.81 1.21 -20.34 -5.30 -9.09 -5.07 
Ireland 7.77 2.39 3.08 2.66 -19.12 -5.67 -9.73 -4.45 
Italy 7.41 2.05 2.20 3.20 -17.49 -4.60 -9.79 6.58 
Latvia 9.94 3.59 3.12 2.69 -14.54 -3.31 -9.41 9.35 
Lithuania 7.82 2.68 2.82 2.04 -13.30 -3.11 -8.15 12.10 
Luxembourg 8.50 2.87 3.80 2.10 -18.79 -5.00 -9.74 -4.58 
Malta 9.83 2.39 4.46 2.92 -15.62 -4.53 9.41 12.58 
Netherlands 7.98 3.08 3.31 1.80 -21.23 -5.22 -15.83 -9.66 
Norway 8.70 3.44 4.55 0.98 -21.20 -5.54 -9.59 -5.14 
Poland 8.36 2.88 2.57 2.56 -14.48 -3.39 2.52 8.57 
Portugal 8.81 2.59 2.57 3.53 -16.27 -4.65 3.54 10.04 
Romania 6.79 2.18 2.48 2.03 -11.65 -3.22 -6.64 -0.62 
Slovakia 7.22 2.30 2.67 2.07 -14.57 -3.76 -8.19 -2.73 
Slovenia 9.20 2.83 3.73 2.46 -19.03 -5.07 -9.74 -3.26 
Spain 9.47 2.79 3.54 3.15 -16.67 -4.28 -5.69 0.35 
Sweden 6.56 2.13 2.84 1.70 -23.57 -6.42 -6.14 -0.01 
UK 8.22 2.80 3.47 2.35 -19.22 -5.45 -10.47 -4.63 
 
 
  
                                           
9 Scenario definitions were 2a: 100% healthy; 2b: 100% no smoking; 2c: 100% best BMI; 2d: 100% in 
healthiest category for alcohol consumption; 3a: 100% unhealthy; 3b: 100% smoking; 3c: 100% worst 
BMI; 3d: 100% most unhealthy category for alcohol consumption 
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Table 9.8: Changes in curative care spending per capita (€) by country and scenario9 
Country 2a 2b 2c 2d 3a 3b 3c 3d 
Austria 112 74 33 3 47 -6 24 -2 
Belgium 89 67 16 3 38 -19 30 0 
Bulgaria 28 26 1 0 28 -7 25 0 
Croatia 51 41 5 1 37 -12 34 1 
Cyprus 57 39 15 1 39 2 24 0 
Czech Republic 57 38 16 1 24 -10 17 0 
Denmark 156 107 40 5 38 12 -10 1 
Estonia 51 35 13 0 19 -5 11 0 
Finland 296 152 145 1 -226 -120 -124 0 
France 116 80 29 4 44 -19 31 0 
Germany 111 89 10 3 45 -32 42 -2 
Greece 74 55 15 1 44 2 25 1 
Hungary 54 49 1 0 41 -28 53 1 
Iceland 82 49 25 4 47 8 21 4 
Ireland 99 55 37 3 14 -10 -2 1 
Italy 70 39 26 3 18 -2 5 -2 
Latvia 30 24 5 0 14 -3 10 1 
Lithuania 55 38 13 0 16 -14 13 2 
Luxembourg 114 78 34 2 46 -4 21 0 
Malta 47 30 13 0 30 -12 28 1 
Netherlands 133 81 42 6 42 26 -10 2 
Norway 172 102 54 8 71 18 17 9 
Poland 50 39 8 0 27 -7 22 0 
Portugal 59 40 14 2 24 -31 34 0 
Romania 34 22 8 1 15 -6 12 1 
Slovakia 55 53 -3 1 64 -35 78 -1 
Slovenia 72 48 19 1 39 -27 45 1 
Spain 80 52 21 2 40 -7 30 0 
Sweden 103 64 34 2 25 6 -4 -3 
UK 73 55 12 4 33 -17 26 1 
 
 
 
 
Figure 9.13: The association between curative care spending and life expectancy, unadjusted 
and adjusted for lifestyle behaviour (scenario 1) 
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